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1 
CHAPTER I 
 
INTRODUCTION TO AUTISM: HISTORY, EPIDEMIOLOGY, AND GENETICS 
 
 
Overview 
Classically defined, autism (OMIM 209850) is a neurodevelopmental 
disorder characterized by deficits in language and reciprocal social interaction, as 
well as repetitive, restricted behaviors and interests. Narrowly defined autism or 
autistic disorder is a specific diagnosis in DSM-IV category termed Pervasive 
Developmental Disorders (PDDs). PDDs include autism, Asperger syndrome, 
Rett syndrome, PDD not otherwise specified (PDD-NOS), and the very rare 
childhood disintegrative disorder. Autistic disorder, PDD-NOS, and Asperger 
syndrome are collectively termed autism spectrum disorders or ASDs, though 
“autism” is often used interchangeably to describe those with all of these ASDs 
and not necessarily narrowly defined autism. Autism has a prevalence of about 1 
in 150 individuals, with males affected at four times the rate of females [1]. ASDs 
typically manifest before the age of three, and span the life of the individual. 
While autism is typically a devastating disorder, a spectrum of functioning exists 
ranging from high functioning individuals with normal IQ to those with severe 
cognitive impairment requiring permanent institutional care. The estimated 
lifetime cost of care for a person with autism is estimated at $3.2 million dollars, 
and the total cost to society in the United States is upwards of $35 billion dollars 
a year [2].  Despite the evidence for strong heritability in autism and the 
2 
consensus that its etiology is primarily genetic, the nature of that underlying 
genetic etiology of the majority of cases remains elusive [3]. 
 
A Brief History of Autism 
Swiss psychiatrist Eugen Bleuler, originally coined the term “autism” 
around 1912 to refer to “an escape from reality” [4].  Hans Asperger first used the 
term in a psychiatric context to describe “autistic psychopaths” in 1938  [5]. 
Asperger described a milder syndrome (now called Asperger syndrome) 
resembling autism, but that leaves language intact. In his original patients, he 
noticed a lack of empathy, little interest in forming friendships, one-sided 
conversations, and often clumsy movements. He also noted that these children 
frequently showed highly circumscribed interests and thus he termed them “little 
professors”.  
In 1943, a contemporary of Asperger’s, Leo Kanner, published “Autistic 
Disturbances of Affective Contact” in the journal Nervous Child. Kanner adapted 
this term to describe children he believed to be afflicted with a syndrome not 
previously described, labeling it infantile autism that was sometimes referred to 
as Kanner’s syndrome. Kanner noted that affected individuals lacked the typical 
enjoyment of social interactions, frequently preferring solitude instead. His 
patients had specific features that included this autistic aloneness and the desire 
for the maintenance of sameness. His original cohort also exhibited abnormal 
speech with echolalia, pronominal reversal, literalness and inability to use 
language for communication; these are language deficits frequently noted in 
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autism as it is described today. Kanner suggests that any intrusion into the outer 
or inner world of these children often caused extreme distress often presenting in 
temper-tantrums [6,7]. Kanner anecdotally noted that these children were 
virtually all  the offspring of university faculty and that, among the parents, there 
were very few “warmhearted fathers and mothers”.  He further noted that the 
parents and grandparents were often “preoccupied with abstractions of literary, 
scientific, or artistic nature,” and showed limited interest in socializing with others 
[6]. The observations of subclinical ASD traits in these family members, later 
termed the “broader autism phenotype,” would prove to be valuable in studying 
the genetics of the disorder.  
From Kanner’s time and through the 1970s, the bias in psychiatry 
attempted to explain psychiatric disorders as a result of poor parenting, leading 
society to believe this was the cause of autism. So called “refrigerator mothers” 
were claimed to lack maternal warmth or emotion were blamed for autism. This 
view persisted as late as 1976 as exhibited in a review by Hanson and 
Gottesman entitled “The genetics, if any, of infantile autism and childhood 
schizophrenia,” in which they concluded that that no strong evidence exists 
implicating genetics [8].  The first  twin study by Rutter and Folstein in 1977 was 
extremely influential in moving the field to understand that autism had a 
significantly genetic etiology [9,10]. The current concept of autism as a 
biomedical disorder was driven largely by these and other twin and family studies 
that document its heritability and association with a variety of genetic syndromes 
4 
[9,11,12,13]. Today, the definition of autism, understanding of its epidemiology 
and genetics, have all been greatly refined. 
 
The Autism Phenotype 
In the 65 years since Kanner’s description, the concept and diagnosis of 
autism has changed dramatically. As the understanding and definition of autism 
has evolved, autism is now placed under the heading of pervasive developmental 
disorder (PDD) with Asperger syndrome, Rett syndrome, and pervasive 
developmental disorder not otherwise specified (PDD-NOS) in the Diagnostic 
and Statistical Manual of Mental Disorders IV [14].  
As a phenotype, what is termed “autism” is often meant to include not just 
autism in a classical sense, but also autism spectrum disorders (ASDs). Autism 
is characterized by problems in three domains: (1) deficits in language and 
communication, (2) difficulties with social interaction and reciprocity, and (3) 
patterns of stereotypic behaviors and restricted interests [14]. The presentation of 
autism can vary dramatically from mild to severe onset is typically before three 
years of age [14]. If threshold deficits in these core domains are met, the 
diagnosis of autistic disorder, sometimes termed “classical autism” is given. If 
criteria for autism are not met, one may be diagnosed with one of two other 
Autism Spectrum Disorders (ASDs), Asperger syndrome or PDD-NOS. PDD-
NOS makes up the majority of diagnosed ASDs. The disturbance must not be 
better accounted for by Rett syndrome or the very rare childhood disintegrative 
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disorder. The ICD-10 uses essentially the same definition and criteria [15]. The 
domains affected in each of the three major ASDs are shown below in Table 1-1. 
 
Table 1-1 Domains of impairment in the major ASDs1. 
Domain Autistic 
disorder Asperger PDD-NOS All ASDs 
Social communication All All All  
language All - Variable  
Repetitive and 
restrictive behaviors 
All All Variable  
Sensory abnormalities >90% 80% Variable 94% 
Developmental 
regression 2 
15%-40% ? ? 15%-40% 
Motor signs 3 60%-80% 60% 60% 60%-80% 
Sleep disturbance 55% 5%-10% 40% 50% 
Gastrointestinal 
abnormalities 4 
45% 4% 50% 4%-50% 
Epilepsy 5 10%-60% 0%-5% 5%-40% 6%-60% 
Comorbid psychiatric 
diagnosis 6 
70% 60% >25% 25%-70% 
Cognitive impairment 
(IQ<70) 
70% - >70% 70% 
1 If required for all diagnosis, this is indicated by the word “All”; if not observed, a 
– is used. Estimates used are from references cited [16,17,18,19,20,21,22,23]. 
The far right column gives the estimate of frequency in all common ASDs. 2 
Reduction of abilities in language and social skills. 3 Hypotonia, gait problems, 
toe walking, apraxia. 4 Six months or more of diarrhea, constipation, reflux, or 
bloating. 5 Range of epilepsy estimates reflects presence of other comorbid 
features, such as intellectual disability and CP, which may dramatically increase 
epilepsy risk. 6 Mood and conduct disorders, aggression, ADHD. 
 
In addition, a number of comorbidities are common in autism and include 
sensory abnormalities, developmental regression, motor signs and symptoms,  
sleep disorders, seizures/epilepsy, gastrointestinal abnormalities, and comorbid 
psychiatric diagnoses [16,17,18,19,20,21,23,24]. Approximately 70% of those 
with autism also meet criteria for mental retardation, now termed intellectual 
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disability [16]. The frequency of the comorbidities is also estimated for the three 
major ASDs in table 1-1. Comorbidity of ASDs with other neuropsychiatric 
disorder (such as anxiety, depression, ADHD) further underscores the need to 
accurately parse quantitative endophenotypes that may shed light on pathways 
common to comorbid diseases. 
Diagnosis and measurement of ASDs core components and comorbidities 
has improved dramatically with the development of a number of diagnostic 
instruments. The Autism Diagnostic Interview current revision (ADI-R) along with 
the Autism Diagnostic Interview (ADOS) are the two most commonly used 
research instruments for the careful measurement of the core and co-morbid 
features of autism [25,26,27,28].  
The ADI-R is an interview given to the child’s primary caregiver or 
caregivers and consists of 93 questions assessing these features [27]. The 
ADOS is an age-adjusted interactive interview with the child which consists of 
four modules that gauge responses to tasks or activities [26,28]. Each of these 
tests measures deficits in categories of language and social skills and patterns of 
repetitive and restrictive behavior.  Using these instruments, the extent of autistic 
impairment and other co-morbidities may be indexed in a semi-quantitative 
manner. If scoring thresholds are met for domains in a given diagnostic 
instrument, a child may meet criteria for autism. Sub-threshold measurements in 
any one category may still earn the subject a label of autism spectrum disorder. 
These tools, along with a clinician’s best judgment, can thus help to distinguish 
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autism from other Pervasive Developmental Disorders (PDDs), including 
Asperger syndrome, and PDD not otherwise specified (PDD-NOS) [29].  
The clinical heterogeneity of the disorder across the core domains makes 
ASDs challenging to analyze. Children may differ widely in intellectual ability. 
Two patients with a diagnosis of autism may present quite differently: one may 
have above average IQ, the other with severe intellectual disability, which is 
common in 30%-70% of those with autism [1,16]. The developmental trajectory of 
those with ASDs can often vary widely with some showing dramatic improvement 
over time and others making little or no improvements, though higher IQ appears 
to be associated with more favorable outcomes [30].  Since ASDs are not 
thought to be single conditions based on pathophysiology or etiology, they are 
considered rather to be clinical syndromes. Some recent progress in genetics 
has permitted the identification of subsets of ASDs based on etiology.  
 
Autism Epidemiology and Risk Factors 
ASDs, as defined above, affect 1.5 million Americans of all ancestral, 
socioeconomic, and geographic backgrounds and carries a prevalence rate of 
approximately 1 in 150, though classic autism (i.e. autistic disorder) afflicts just 1 
in 500 [1,31,32]. This means that ASDs are more prevalent than many other 
“common” childhood disorders [3].  
Advanced maternal and paternal ages have emerged as replicable risk 
factors for ASDs [33,34,35].  It has been postulated that this might be due to (1) 
increased risk for chromosomal non-disjunction or non-alleleic homologous 
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recombination during maternal oogenesis, (2) increased mutation burden in older 
sperm, and (3) parents with features of the broader phenotype often marry later  
[35,36]. However the extent to which pathogenic CNVs and point mutations arise 
maternally or paternally and the true risk that advanced maternal and paternal 
age is a risk factor in autism has yet to be determined.  
A few of other events appear to be correlated with increased risk of 
autism. These include a family history of psychiatric conditions (such as 
schizophrenia), multiple births, cerebral palsy, and cognitive impairment. 
While the number of diagnosed cases of autism has increased several fold 
in the past decade, the rapid increase appears to be most critically driven by 
awareness of the disorder, the changing definition of autism, increased diagnosis 
by physicians, and the availability of diagnostic tools [14,37,38].  
Further, since educational and other resources, medical coverage, and 
reduced stigma may be associated with a diagnosis of autism compared to 
“mental retardation” (now called intellectual disability), a number of cases of 
diagnostic substitution appear to have played a role in the increased prevalence 
of autism [39]. States or regions which offer greater resources to those with 
autism as a diagnosis instead of alternative diagnoses will therefore have higher 
rates of autism ascribed, though such diagnoses may not be accurate. Therefore, 
there has been a marked decrease in the number of diagnosed cases of mental 
retardation and a concordant increase in the number of diagnoses of ASDs 
[40,41].  
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The Genetics of Autism Spectrum Disorders 
Twin and family studies and large epidemiological studies have shown 
that autism is primarily a genetic condition.  It is now widely appreciated that 
ASDs are genetic disorders and that the genetics of these disorders is complex 
and confounded by locus and allelic heterogeneity and potentially by oligogenic 
inheritance, epigenetics, gene-gene interactions [23,24].  
Twin and family studies indicate that autism is a primarily genetic disorder 
with about 90% of the disorder explainable by genetics (i.e. broad sense 
heritability of about 0.9) and a concordance ranging from 60%-92% for 
monozygotic twins (MZ) and 0%-10% for dizygotic twins (DZ) depending on the 
phenotypic definition [42,43]. Males are affected four times as frequently as 
females, and epidemiological studies indicate a sibling risk ratio (sibling 
recurrence risk / population prevalence) in the range of 25-67 [44,45]. This 
makes autism the most heritable of psychiatric disorders.  
The search for autism susceptibility alleles has included linkage studies, 
CNV studies, and genome-wide association and candidate gene studies, each 
briefly reviewed below. It will be shown how these lines of evidence, while each 
contributing to our understanding of autism, complement one another and 
support the proposed aims of the thesis. 
Family studies indicate that family members of those with idiopathic 
autism often show subclinical traits of autism, collectively called the broader 
autism phenotype, and it is thought that autism may manifest through the 
accumulation of genes that increase the degree to which these traits are 
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expressed [46,47]. Studies of families with a history of ASDs have shown that 
first-degree relatives (i.e. parents and siblings) have higher frequency of 
characteristics common to ASD phenotypes (e.g. language deficits, social 
responsiveness differences, and presence of repetitive or restrictive behaviors) 
than in non-autism family controls and the general population [48,49,50,51].  
Thus, it seems reasonable that a measurable proportion of the genetic liability to 
ASDs in some cases might take the form of risk alleles that increase risk for 
some or all of the component traits of autism (i.e. the broader autism phenotype).  
Also clear is that the genetic architecture of autism is complex since, aside 
from a growing number of copy number variations (e.g. 15q11-q13, 16p11.2, 
22q11.2) that can carry with them a frequently clear diagnosis of autism, the 
majority of cases appear to be spontaneous and likely polygenic in nature [52]. 
Approximately 10% of individuals presenting clinically with autistic features can 
be can be diagnosed with common single-gene disorders with an etiologically 
distinct cause. These include fragile X syndrome (OMIM #300624), tuberous 
sclerosis complex (OMIM #191100) [24,53], Angelman syndrome (OMIM 
#105830) [54] and Rett syndrome (OMIM #312750), [55] and others [3].  
Twin- and family-based studies suggest that for most idiopathic cases, the 
most parsimonious model involves multiple genes and potential epistasis that 
collectively give rise to ASD phenotypes [56]. Given the high heritability, it was 
thought that identifying autism genes would be a relatively straightforward; 
however it is currently only possible to identify the etiological cause of a 
approximately 10-20% of all cases [57,58,59]. Genetic abnormalities known to be 
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associated with autism include a number of copy number variants (CNVs), gene 
mutations (MECP2, SHANK3, NLGN3, NLGN4X), and cytogenetic abnormalities 
[60,61,62]. The majority of cases, however, have no apparent etiology.   
Given the former findings of increased rates of the broader autism 
phenotype in some families without obvious molecular etiology in combination 
with the 10-20% of cases which have an identifiable etiology, a model emerges 
that may accommodate both of these observations. This model may involve the 
applied force of CNVs, point mutations, and common variation with epistatic 
forces to account for the phenotypic variation seen in autism and the finding of 
subclinical BAP traits in family members. It is apparent that there are two 
emergent themes in recent analysis of the data: a case for highly penetrant rare 
variants that dramatically increase risk, and a case for more common variants 
that collectively increase risk for presentation of each of the core phenotypic 
domains. 
The genes selected for study, namely UBE3A and GABRB3 of the 15q11-
q13 region, were selected not just because of mechanism, but because of 
multiple convergent lines of evidence supporting their selection. The evolution of 
 
Molecular and Statistical Genetics: Linkage Analysis  
Genetic linkage analysis in human populations is used to analyze 
multiplex family pedigrees for linkage between a chromosomal region and a trait. 
The statistic most frequently used is the logarithm of the odds (LOD) score or 
some variant thereof. In brief, the LOD and its related linkage statistics measure 
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the likelihood that affected family members share a chromosomal region more 
often than would be expected by chance alone [63]. The power of linkage is that 
it does not presuppose a common disease-common variant model of a given 
disease. Rather, linkage should be able to detect both highly penetrant rare 
variants and, to lesser extent, variants of more modest effect sizes.  
Despite the benefits of linkage, in the search for autism susceptibility loci, 
linkage signals have appeared on every chromosome, reflecting significant locus 
heterogeneity [64]. The reasons for this are incompletely understood. It may be 
that sampling variation or ascertainment biases do not identify comparable 
samples. This may be due in part to the ‘winner’s curse’ that may result in 
association and linkage for the reporting of a first instance to reach a suggestive 
or significant LOD score or P-value [65]. As a result, few replication studies find 
the same effects in independent data sets. Replication studies may need to be 
far larger than initial studies to detect loci conferring minor effects [66].  From 
recent reviews [64,67] and search of Pubmed, it appears nearly 20 genome-wide 
linkage studies have been conducted to date. The few replicated findings 
common between are studies are reviewed in Table 1-2.  
 
Table 1-2 Chromosomal regions showing linkage in more than one study. 
Region Candidate genes References 
2q24-q31 SLC25A12, CENTG2 [68,69,70] 
5p13-p14 - [45,71] 
7q22-q32 RELN, MET, CADPS2 [70,72,73,74] 
7q34-q36 CNTNAP2, EN2 [72,75,76] 
9q33-q34 TSC1 [45,77] 
15q11-q13 GABRB3, UBE3A [78,79,80] 
17q11-q21 SLC6A4, ITGB3 [71,81,82,83] 
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Some of the findings above may result from regions containing multiple 
genes that could increase risk for autism which would make detection and 
replication easier for the above regions. 
One noteworthy point from review of linkage studies is that many of the 
significant findings (as well as part of the reason for failure to replicate) have 
come from not analyzing autism as a categorical trait, but rather analyzing the 
individual components of autism such as measures of language. In fact, methods 
such as ordered subset analysis (OSA), and quantitative trait linkage (QTL) 
mapping have shown greater promise for identifying genes with alleles that 
increase severity of language deficits or rigid compulsive behaviors, as examples 
[75,84]. Several studies showed by QTL mapping for “age of first word” that a 
language locus existed on 7q34-q36 [75,76,85].  Thus restricting analysis to the 
component traits in autism (see Table 1-1), there may be greater sensitivity to 
detect loci through use of linkage studies.  
These results seem to support an oligogenic model, in which ASDs may 
result from perturbations of many different genes. There is some evidence that 
single deleterious mutations in such genes are sufficient to cause autism, but 
also evidence that many such genes may contribute in some manner to the 
deficits characteristic of the autism phenotype. These results support the view 
that multiple risk alleles may act independently or together through additive or 
epistatic mechanisms to modulate risk for autism [86].  
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Some loci, such as 17q11.2, which harbors the serotonin transporter gene 
(SLC6A4), show linkage in families with only affected males, but little or no 
linkage in families with affected females [82]. Sex-chromosome linkage analysis, 
too, has been disappointing despite the 4:1 difference in male:female prevalence, 
with most studies assessing linkage of the X chromosome not yielding significant 
results [87].  This could be explained in part by reduced power to analyze allele 
sharing on the X chromosome in a collection of autism families. The absence of 
consistent linkage signals on the X chromosome may be due to rare or de novo 
variants in multiple X chromosome loci are too numerous. There may be simply 
too many X chromosome genes which when upset by mutation in hemizygous 
males can result in cognitive impairment or autism. It is also possible that skewed 
X chromosome inactivation in females could provide a challenge to identifying 
risk loci or the presence of two X chromosomes could buffer females from the 
higher frequency of ASDs. Another possibility is that autosomal loci show 
differential penetrance in males compared to females as the results of male-only 
family analysis on chromosome 17q11.2 and other studies seem to suggest 
[82,88,89]. 
Locus heterogeneity, allelic heterogeneity, phenotypic heterogeneity and 
epistatic interactions may also confound the ability to replicate linkage signals.  
Despite these difficulties, several genes showing evidence for linkage replicated 
across two or more linkage studies have indicated the involvement of rare and/or 
common variants with ASDs [88,90,91,92,93,94].  
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Molecular Genetics: Candidate Gene Studies  
A number of candidate genes, some underlying linkage peaks and others 
not, have been studied for the presence of rare or common variation. Candidate 
gene studies have most typically taken the form of resequencing of exons in 
candidate genes or association studies. The former seeks to identify rare variants 
that result in rare coding changes that impact the resultant protein. The latter 
seeks to identify common variants and alleles that are over-transmitted to 
affected individuals.  
Mutation in a number of single genes can result in syndromes that present 
with features of autism, but are clinically distinct. Examples include Angelman 
syndrome (UBE3A), Fragile X syndrome (FMR1), Rett syndrome (MECP2), 
Timothy syndrome (CACNA1C), and tuberous sclerosis (TSC1 and TSC2) 
[95,96,97,98,99]. While mutations in these provide a molecular diagnosis of a 
relevant disorder, these conditions nevertheless provided strong hypotheses 
regarding the types of genes, proteins, and pathways that might contribute to 
what we would consider idiopathic autism and that common pathways may be 
affected in autism and these disorders.  
The X-linked neuroligins and SHANK3, the respective proteins which 
interact to guide glutamatergic synapse formation, have recently been shown to 
be associated with autism by virtue of rare deletions or point mutations 
[60,62,100]. Sanger sequencing identified mutations in two neuroligins (NLGN3, 
NLGN4X, and a gene which interacts with the neuroligins, SHANK3, all genes 
involved in the formation of synapses, were early victories in sequencing which 
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indicated that potential failure to form synapses might result in ASDs [60,62]. 
Neurexin 1 (NRXN1) was identified as a deleted gene in a 2007 paper by the 
Autism Genome Project [45]. By extension of these findings, resequencing of 
NRXN1, which also interacts with the neuroligins, identified rare coding variants 
in this gene [101].   
Other genes with autism-associated variants include SLC6A4, the 
serotonin transporter. These variants have been shown to confer one of two 
distinct gains of function on the activity of the protein [88]. CNTNAP2 has been 
shown to have both rare and common variants associated with autism  [90,102]. 
Some genes, such as Engrailed 2 (EN2), have shown to have not just coding 
variants but also a functional intronic variant shown to be associated with autism 
that have been identified by resequencing [92,103].  
One difficult obstacle here is that the rarer the variant and the lower the 
penetrance, the greater is the threshold of samples required to demonstrate 
statistical significance or to evaluate the total contribution to ASD risk. The 
availability of next generation sequencing methods will allow the rapid 
resequencing of entire genes, not just coding regions. 
By contrast to sequencing studies which seek to find more highly 
penetrant rare alleles, association studies typically seek to find more common 
alleles associated with autism typically through case-control analysis or family-
based association tests. A summary of genes with evidence of common alleles 
associated with autism is presented in Table 1-3.  
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Table 1-3 Common variants associated with ASDs. 
Gene Function (position) Type
1 References 
CNTNAP2 Neurexin family, important in potassium 
channel clustering (7q35) 
C/R [85,90] 
EN2 Involved in cerebellar formation(7q36) C [91,92] 
GABRB3 Neurotransmitter receptor (15q12) C [104,105,106,107] 
ITGB3 QTL for blood serotonin levels (17q21) C [94,108] 
MET Proto-oncogene receptor (7q31) C [109,110] 
NLGN3/NLGN4X Neuroligins involved in synapse 
formation (Xq13/Xp22) 
R [62,111] 
NRXN1 Neurexins interact with neuroligins to 
permit cell adhesion (2p16) 
R [101] 
SHANK3 Synaptic adaptor which interacts with 
neuroligins 
R [60,61] 
SLC6A4 Transports serotonin into cells (17q11) C/R [88,112,113,114] 
UBE3A Angelman syndrome gene and ubiquitin 
ligase important for synapse formation 
(15q11) 
C/R [115,116] 
1 C = common variants, R = rare variants 
 
Association studies have become increasingly frequent in the past ten 
years as the cost of genotyping has decreased and both more samples can be 
genotyped for a single or small number of SNPS (e.g. Taqman, Sequenom) or a 
single sample can be genotyped for multiple SNPs (e.g. Affymetrix 5.0 and 6.0, 
Illumina 610S and1M chips). This in combination with awareness of the 
haplotype structure of the genome, made possible most notably by the 
International HapMap Project, has made it possible to more thoroughly index 
most common alleles of various human populations. As the 1000 Genomes 
project races toward its completion, our awareness of rare and common SNPs 
and their corresponding haplotypes will continue to increase.  
In contrast to the findings of most sequencing efforts, most associated 
SNPs appear to be intronic, with MET and ITGB3 being notable exceptions 
18 
[93,109]. Most of these genes do not have any functional variants in linkage 
disequilibrium to explain the observed association. Frequently groups find 
association in the same gene, but in different regions or with different alleles.  
The disconnect between association and apparent functional effects is the 
source of much consternation in the field of autism genetics and other gene or 
genome-wide association studies. One of the more promising avenues for 
explaining variants at great distance from candidate genes is that these variants 
have an impact on gene expression in cis- or in trans-. The tools to investigate 
these possibilities are in early stages of development, but tools such as SCAN 
may allow us to investigate the possibility that associated SNPs (and those in 
strong LD) may act as quantitative trait loci which influence gene expression 
[117]. 
Using endophenotypes or specific traits within the autism spectrum to 
select more homogenous populations or to define quantitative traits for analysis 
of allelic association may offer greater sensitivity and specificity in detecting loci 
or specific alleles in some cases. But the lesson from recent studies is that both 
common and rare variant studies should be pursued in parallel.  
One more point that emerges from the study of candidate genes is the 
importance of genes involved in synapse formation (see Table 1-3). This notion 
of autism, posited by Zoghbi 2003, as potentially a synaptopathology, or disorder 
of the synapse, seems supported in many ways by these studies and others 
described below [118]. 
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Molecular Genetics: Copy Number Variation  
Maternal interstitial duplication of 15q11-q13 was the first CNV (excluding 
the clinically well-defined Fragile X disorder) found to be frequently associated in 
autism [119]. It remains today the most frequent recurrent CNV in autism.  
Since this time, copy number variation (CNV) has been identified to be an 
important source of variation in the genome. Copy number variation frequently 
arises through non-allelic homologous recombination events where there is 
unequal crossing over and joining between chromosomal regions with high levels 
of homology. Typically, the greater the homology, the greater is the likelihood of 
non-allelic homologous recombination. Two major papers in late 2004 one by 
Sebat et al. and another by Iafrate et al. indicated that copy number variation was 
a common element in human genomes [120,121]. It was later shown by Conrad 
et al., in the HapMap samples, that genotyped SNPs could be mined for tracks of 
Mendelian inconsistencies or homozygosity to determine if CNVs existed [122]. 
However, it was not until 2007 when the Affymetrix 500K chips became available 
that measures of intensity, homozygosity, and Mendelian inconsistency could be 
used together to map common copy number variation in the human genome. By 
the estimate of one influential paper by Redon et al., there were over 1,400 copy 
number variable regions (CNVRs) in the 270 HapMap samples [123]. These 
CNVRs spanned over 360Mb or 12% the human genome and notably 
encompass a greater number of total bases than are estimated to be SNPs in the 
genome. 
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Vorstman et al. showed in 2006 that novel structural variation observed in 
previously published reports, often overlapping with regions demonstrating 
linkage with autism, were associated with autism [124]. A new confirmation of the 
importance of CNVs in autism was reported by Sebat et al. in which the authors 
document a highly significant association of de novo CNVs in 10% of 118 
patients with sporadic autism vs. 1% of controls [125].  The finding is striking 
since those with syndromic forms of autism (severe MR, dysmorphologies, or 
known cytogenetic abnormalities) were excluded from the study, highlighting the 
importance of CNVs in the genomic architecture of autism.  
A number of studies since this time have increased resolution and now the 
importance of CNVs in causing autism is known to be greater than previously 
expected. Estimates range between 6%-44% of all cases which bear potentially 
pathogenic CNVs [3,45,125,126,127,128]. The highest estimates are for cases 
where all syndromic forms of autism are included (i.e. non-idiopathic cases). The 
most notable of these CNVs include 15q11-q13 duplication, 16p11.2 deletion and 
duplication, and 22q11.2 (SHANK3) deletions [127]. These and other major 
CNVs are shown in Table 1-4. 
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Table 1-4 CNVs known to be associated with autism. 
Region (loss/gain) Genes 
(candidate) 
Size 
(kb) 
Transmitted/ 
De novo References 
2q37.3 (loss) >40 >2000 De novo > 
Trans 
 
[124,129,130] 
5p15.2 
(loss>gain) 
 
>50 <15000 Both [124,131,132] 
15q11-q13  
(gain) 
8-35 
(UBE3A, 
GABRB3, 
others) 
 
2000-
6000 
Both [119,133] 
16p11.2 (both) 24-31 >750 De novo > 
Trans 
 
[128,134,135] 
22q11.2 (loss) 8-61 
(SHANK3) 
750-
4500 
De novo > 
Trans 
 
[60,124,136,137] 
Xp22 (loss>gain) >20 >5000 Both [100,124] 
1 C = common variants, R = rare variants 
 
Smaller structural variation, in the form of CNVs, is the next logical step in 
the progression from macroscale to microscale detection of genomic variation. 
Even the most common CNV known to cause autism, 15q11-q13, is difficult to 
see by G-banding and often requires FISH or a specific focus on this region with 
high quality metaphase spreads [138]. As resolution has improved in the past 
several years, a number of microdeletions and microduplications within or 
flanking 15q11-q13 have been identified and shown associated with autism, 
schizophrenia, and epilepsy among other disorders [139,140,141,142]. The 
march from G-banding to array-based methods and SNP chips with increased 
coverage dramatically increases our ability to detect duplication and deletion, 
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though not necessarily inversion events. Since mutations ranging from point 
mutation to megabase deletions have been shown to often cause the same 
phenotype, the line between calling one syndromic and the other idiopathic is 
increasingly blurred. SHANK3 or the X-linked neuroligins, are examples of genes 
where both copy number variations or point mutations can result in autism. As 
technology moves from arrays to sequence level data, our ability to detect single 
base pair changes and rare potentially pathogenic changes will likely be the next 
frontier [143].  
Generally speaking, CNVs are many are also seen in controls suggesting 
they are not significant risk factors (see table 1-4), as many are transmitted from 
non-autistic parents. This incomplete penetrance suggests a model where other 
factors (environment, modifier genes, sex, parent-of-origin, etc) may modify 
whether or not the autism phenotype is expressed in events of these CNVs.  
These de novo events may be more common in simplex ASD families (7-
10%) than in multiplex ASD families (2-3%) [58,128]. However, it is important to 
note that given emerging estimates of sibling recurrence risk as high as 20% and 
the tendency of families with an autistic child to stop reproducing, a significant 
fraction of “simplex” families are multiplex families that are not realized because 
of limited sibling number. Nevertheless, if you accept the simplex vs. multiplex 
trend and if you consider common variant findings two models may be 
suggested: one where new highly penetrant mutations are occur, and another 
where multiple risk alleles act in conjunction with one another to increase risk. 
These models are not mutually exclusive and typical autism may present as the 
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result of a collection of both lower penetrance and higher penetrance variants. By 
this model, first degree relatives of probands in multiplex families would be more 
likely to harbor traits of the broader autism phenotype, as has been reported 
[144]. Indeed, it appears that in multiplex families, parents are more likely to 
display elements of the broader autism phenotype where in simplex or “sporadic 
autism” families the rates of the broader autism phenotype are nearer that 
observed in the population [144]. 
 
Maternal Duplication of 15q11-q13 in Autism 
As mentioned above, the first and most common CNV seen in autism is 
duplication of 15q11-q13, which is estimated to occur in 1%-3% of all individuals 
with autism [145]. This genomic region contains a large number of low copy 
repeats with high levels of homology which allow for non-allelic homologous 
recombination at its breakpoints, thus making the region subject to a number of 
genomic disorders including  Angelman syndrome/Prader-Willi syndrome and 
autism. The region on which my studies focus has been refined by the mapping 
of these breakpoints. Duplication of the region (dup(15)) can take two major 
forms, which include the more common isodicentric chromosomes (idic(15)) and 
the less common interstitial duplications spanning 4-5 Mb of the region (int 
dup(15)) (Figure 1-1). It now appears that the major forms of the interstitial 
duplication and the idic(15) have recurrent breakpoints, the with a common 
interval spanning BP2-BP3 (see Figure 1-1, panel B) [146]. The recurrent nature 
of the most common breakpoints (i.e. BP1, BP2; see Figure 1-1) has helped to 
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identify the genes between BP2 and BP3 as the most commonly duplicated 
genes in this genomic interval [147]. Typically, duplications of greater size (i.e. 
idic(15) or larger interstitial CNVs) are associated with more severe phenotypes. 
 
 
FIGURE 1-1 Genomic disorders of 15q11-q13 and genes of the interval. 
A. Deletions and duplication disorders of 15q11-q13. 
Genomic disorders resulting from deletion or duplication of 15q11-q13 are shown. 
In this figure, P indicates chromosomes of paternal origin, and M indicates 
chromosomes of maternal origin. From left to right can be seen (1) karyotypically 
normal individual with two copies of chromosome 15; (2) paternal deletion of 
15q11-q13 resulting in Prader-Willi syndrome (PWS); (3) maternal deletion of the 
15q11-q13 interval resulting in Angelman syndrome (AS); (4) paternal interstitial 
duplication of the region which confers much lower risk for ASD phenotypes; (5) 
maternal interstitial duplication of the region which typically results in autism; and 
(6) the isodicentric chromosome containing four copies of 15q11-q13 is typically 
associated with the most severe autistic phenotypes. 
B. Chromosome 15q11-q13 and the autism candidate region.  
The chromosomal region indicated in panel A that is subject to duplication and 
deletion is shown here. Genes involved in Prader-Willi syndrome and Angelman 
syndrome are indicated (PWS / AS). The autism candidate region is identified 
and contains the genes central to the studies reported here: UBE3A and 
GABRB3.  Jagged lines indicate the recurrent deletion/duplication breakpoints 
(BPs). All forms of the duplication contain, at a minimum, the BP2-BP3 region. 
The region contains maternally and paternally expressed genes (PWS / AS 
respectively) under epigenetic control of the imprinting center (IC).  
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Mutation Spectrum and Phenotypic Overlap Between Autism, PWS, and AS 
The 15q11-q13 interval is subject to genomic imprinting with paternal 
deletion of the region resulting in Prader-Willi syndrome (PWS) (OMIM 176270) 
and maternal deletion resulting in Angelman syndrome (AS) (OMIM 105830) 
[95,148]. The influence of epigenetics in the etiology of the disorder is evident in 
the broad array of disorders which can result from such these structural 
variations (Figure 1-1). Several genes including SNRPN, NDN, and many smaller 
snoRNAs are transcriptionally silenced on the maternal allele [149,150]. UBE3A 
is subject to maternal-specific expression in selected regions of the brain and 
such gene regulation is essential to normal neuronal development [151]. More 
recent work has shown allele specific expression or allelic exclusion is more 
common than previously thought [152].  
AS is caused by both maternal deletion of 15q11-q13 (70%), or point 
mutations in UBE3A (10%), defects in the IC (i.e. “imprinting mutations”) (5%), 
and paternal UPD (2%), with the remaining patients with a clinical diagnosis not 
having any identifiable molecular defects in 15q11-q13 [95,153]. Since the vast 
majority of dup(15) forms which result in autism are of maternal origin, this 
makes UBE3A of particular interest. PWS cases are caused by paternal 
deletions of the 15q11-q13 interval (70%), maternal uniparental disomy (UPD) 
(25%), and imprinting mutations caused by small deletions in the IC (5%) [154].  
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While these conditions are very distinct, it is worth comparing them as 
there is some phenotypic overlap between autism, PWS, and AS, with the 
genomic disorders sharing some unique and some common characteristics.  
PWS presents neonatally with hypotonia, failure to thrive and a poor suck 
reflex. As patients grow older, the most prominent symptom is hyperphagia and 
resulting obesity. Most patients show intellectual disability and various behavioral 
problems [155]. One study reported that 10 out of 56 PWS cases had a history of 
seizures [156]. One report suggests that individuals with an extra maternal 
chromosome, but without a paternal chromosome (maternal UPD) may be more 
likely to express symptoms of autism compared to those with the paternal 
deletion [157]. This is intriguing particularly since those with maternal 
duplications of 15q11-q13 are very likely to manifest autism and such patients 
have increased expression of maternally-expressed genes [158]. Individuals with 
PWS often have compulsive, repetitive, or ritualistic behaviors analogous to 
those seen in autism cases [159]. It is also appears that those with the maternal 
UPD form of PWS have social deficits similar to those in autism [160]. Veltman et 
al found elevated scores on the Autism Screening Questionnaire and their review 
of the literature shows that those with UPD show overexpression of the 
maternally-expressed genes increasing the risk of having an ASD diagnosis 
[161,162].  
AS is a severe neurological disorder that presents with profound 
intellectual disability, absent speech, epilepsy, ataxia, hand-flapping, and 
inappropriate laughter [163]. Many of these features are seen (though typically 
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with less severity) in those with maternal duplication of 15q11-q13. Deletion AS 
patients tend to have more profound abnormalities than those with UPD and 
imprinting defects [164,165]. Those with point mutations in UBE3A have 
characteristic seizures, absent speech, and microcephaly, but they still tend to 
develop better motor skills and the ability to follow simple commands, unlike most 
with the typical deletion [165]. Mutations in 3′ exons of UBE3A tend not to be 
associated with autistic traits, while those in 5′ exons are more often associated 
with ASD traits [153].  
Approximately 50% of individuals with maternal interstitial duplications (int 
dup(15)) and 88% of individuals with the isodicentric chromosome idic(15) meet 
criteria for autism [146][166]. For those meeting criteria for autism, ADI-R domain 
scores are indistinguishable from apparently chromosomally normal individuals 
with idiopathic autism. That 50% of individuals with the interstitial deletion do not 
meet criteria for autism (though they may have other problems) suggests that 
other factors may modulate the expression of the phenotype in those with the 
duplication. Idic(15) cases are more profoundly affected and accompanied by 
frequent physical findings (hypotonia, cleft palate, etc.) All show delay in physical 
developmental milestones, mental retardation, with epilepsy a virtually constant 
finding [167,168,169].  
 
Selection of Candidate Genes UBE3A and GABRB3 
The region most commonly duplicated or deleted in 15q11-q13 is the BP2-
BP3 interval (Figure 1-1). I hypothesized that the two best candidate genes in the 
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interval are UBE3A and GABRB3. The former shows maternal-specific 
expression and the latter is a developmentally critical subunit of the GABAA 
receptor. The major reasons for selection of candidates centered on these two 
genes are as follows: (1) Maternal bias (or maternal-specificity) of dup(15) 
association with autism directly implicates UBE3A.  (2) UBE3A localizes to the 
synapse and nucleus and causes alterations in synapse formation (3) Multiple 
genetic studies have implicated GABRB3, in particular, as being associated with 
non-dup(15) autism.  (4) GABA is he major inhibitory neurotransmitter in the 
brain. (5) Elevated blood plasma levels and reduced numbers of GABA receptors 
are observed in those with autism. (6) GABRB3 is developmentally critical and 
abundantly expressed in the embryonic and neonatal brains. (7) The Gabrb3 
knockout mouse has many features of autism. For all these reasons I 
hypothesize that UBE3A and GABRB3  harbor common and/or rare alleles that 
confer increased risk of autism.  
In this dissertation, I report on my studies of these genes and genes 
encoding proteins regulated by UBE3A as well as MECP2 which may regulate 
gene expression for both UBE3A and GABRB3. The motivation for studying the 
substrates of the UBE3A protein are (1) Action of UBE3A on these substrates is 
likely the major means by which AS (and possibly some cases of autism) are 
caused and (2) The substrates of UBE3A and how this gene causes AS are 
poorly understood. MECP2 is (1) known to cause Rett syndrome, (2) expressed 
at lower levels in autism brains, and (3) correlated with expression of UBE3A and 
GABRB3. The complete list of genes studied includes: MECP2, (chapter 3); 
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UBE3A, ECT2, and GCH1 (chapter 4), and GABRB3 (chapter 5). The model 
illustrating the relationship between the genes proposed for study is shown below 
in Figure 1-2. 
 
Figure 1-2. Schematic of the relationship between genes proposed for 
study. Mutations in MECP2 cause Rett syndrome and studies have suggested 
that MECP2 deficiency results in reduced UBE3A and GABRB3 expression. It 
may do this by acting directly on UBE3A and GABRB3 or at the imprinting center 
locus, which controls the imprinting status of the genes of 15q11-q13. Maternal 
deletions of UBE3A cause AS, which exhibits some phenotypic similarities to 
autism. Since UBE3A is maternally-expressed, and maternal duplications of 
15q11-q13 are associated with autism, UBE3A is a strong candidate. ECT2, 
involved in cell motility and migration, is downregulated by UBE3A.  GCH1, which 
is involved in catecholamine production, is upregulated by increased UBE3A and 
the dysregulation of these proteins by UBE3A may lead to synaptic phenotypes 
such as those seen in autism. GABRB3 has been observed to be dysregulated in 
autism, critical in development, and a number of genetic studies have shown it to 
be associated with ASDs. 
 
UBE3A and related loci ECT2 and GCH1: selection and studies  
The UBE3A protein acts as an E3 ubiquitin-ligase which adds a ubiquitin 
molecule to proteins, tagging them for regulation or, more commonly, 
degradation by the ubiquitin-proteasome system. The widely-held view is that 
UBE3A will mediate the phenotypic effects seen in AS (and potentially autism) by 
virtue of its abnormal gene expression and subsequent action on its substrates. 
In addition to its role in protein degradation, UBE3A also may function as a 
transcriptional activator in the nucleus [170]. It is known to stimulate transcription 
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of steroid hormone receptors in the nucleus among other genes and so 
dysregulation of its expression could lead more broadly to additional changes in 
gene expression [171].  
In addition, our group previously published evidence supporting 
association to the imprinted UBE3A gene at a peak marker, D15S122, located at 
the 5′ end of the UBE3A gene [115]. A recent autism genome-wide association 
study has provided strong evidence supporting a role for the ubiquitin pathway in 
the pathogenesis of ASDs [172].  
Additionally, we and other have hypothesized that the effect of loss of 
UBE3A in causing AS and dup(15) autism is a function of UBE3A acting on other 
loci/proteins. A major limitation of other studies of UBE3A and its role in AS and 
potentially autism, is that no one has studied the protein substrates that are 
regulated by UBE3A and which may underlie these phenotypes.  
My hypothesis (and one generally accepted in the field) is that over-
expression of UBE3A in maternal dup(15) cases and corresponding excess 
protein contributes to the ASD phenotype as a result of altered regulation of 
UBE3A substrates. Thus, the crux of the hypothesis is that genes encoding 
UBE3A substrates and/or genes regulated by transcriptional co-activation of 
UBE3A are candidate loci for harboring autism susceptibility alleles. 
Our collaborator, Dr. Lawrence Reiter, has used a proteomic strategy to 
identify two UBE3A-regulated candidates: ECT2 and GCH1, which, following the 
logic above, I proposed may be good candidates for autism [173][174]. Briefly, 
their approach involves over-expressing UBE3A in Drosophila melanogaster, 
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extracting total protein from heads, separating the protein by 2D gel, and 
identifying proteins as up- or down-regulated in response to increased levels of 
UBE3A in experimental vs. wild-type flies(Figure 1-3).  
 
 
 
FIGURE 1-3. UBE3A and its relationship with ECT2 and GCH1. Since 
maternal duplication of the region including UBE3A puts a carrier at high risk for 
autism, UBE3A and related loci are attractive candidates for investigation. 
UBE3A downregulates ECT2 and upregulates GCH1. Drosophila synaptic 
boutons are shown stained for ECT2 ortholog pbl in wild-type and UBE3A 
overexpressing flies in A and B. Notice the loss of signal from synaptic boutons. 
Mutations in the GCH1 ortholog, Punch, enhance a Dube3A over-expression 
rough eye phenotype as shown in C-E. The wild type eye in C does not result in 
a rough eye phenotype while it does when overexpressing the Drosophila 
UBE3A ortholog, D. When expressed with a mutation to the GCH1 ortholog as in 
E, offspring have a more dramatically affected rough eye phenotype with fewer 
bristles. 
 
Dr. Reiter’s group previously reported that pebble the Drosophila ortholog 
of ECT2 exhibits extensive down-regulation concurrent with the over-expression 
of UBE3A [173]. They also showed that loss of Ube3a protein in the brains of 
Ube3a knockout animals caused an increase in Ect2 protein expression and 
distribution in the hippocampus and cerebellum [173]. Both regions of the brain 
have been implicated in the pathogenesis of autism and Angelman syndrome 
[175]. UBE3A is imprinted and expressed preferentially from the maternal allele 
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in central neurons in most regions of the brain with strong evidence for its 
expression in the cerebellum [176,177]. The cerebellar findings may explain the 
motor stereotypies common to Angelman Syndrome and autism [153]. There is 
also evidence that cerebellar defects may explain some emotion recognition and 
language problems observed in individuals with ASDs [178]. In light of this and 
other findings on ECT2, I hypothesized that the control of levels of ECT2 by 
UBE3A has a role in synapse formation, as mutations in ECT2’s Drosophila 
homolog upset outgrowth in post-mitotic cells as well as GABAergic cell 
differentiation in C. elegans [179,180]. Dysregulation of ubiquitin pathways has 
also been shown to have consequences for synapse formation [181]. 
The Drosophila protein punch, corresponding to human GTP 
cyclohydrolase 1, or GCH1, is a second UBE3A-regulated locus and protein that 
is also currently under investigation.  GCH1 is neuronally expressed and was 
identified as a significantly upregulated protein in response to UBE3A 
overexpression. Mutations of Drosophila ortholog punch enhance a rough eye 
phenotype, a marker of neuronal development, when Drosophila UBE3A is 
overexpressed (Figure 1-3). GCH1 catalyzes the hydrolysis reaction of GTP and 
H2O, forming a precursor of tetrahydrobiopterin (THB), which is involved in the 
production of serotonin and other catecholamine neurotransmitters.  It is 
interesting to note that serotonin is often present at increased levels in people 
with autism [182].  
Only modest association results have been demonstrated near this locus 
known to be critical in Angelman syndrome, and a prime suspect in autism. To 
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this end, the novel proteomic strategy above has uncovered the first known 
UBE3A substrates whose dysregulation results in a clear neurological 
phenotype. In the simplest model of UBE3A dysregulation, it would be expected 
that proteins such as ECT2 will be present at reduced levels and GCH1 at 
increased levels due to an overexpression of UBE3A. It should be noted that this 
would only be of importance in cells where dosage regulation is abnormal. 
Chapter 4 reports on studies of the relationship between UBE3A, ECT2, and 
GCH1. 
 
GABRB3: Role in Development and Guilt by Association 
While the strong maternal bias in dup(15) association with autism make 
UBE3A perhaps the most attractive candidate for contributing to the phenotype, 
genetic studies within the autism candidate region most strongly implicate the 
cluster of GABA receptor subunit genes and, in particular, GABRB3. A number of 
reports (though not all positive) have documented association of common alleles 
at GABRB3 with autism [104,105,107,183,184,185,186,187,188,189].  Few 
association studies have implicated the other subunits of the GABA receptor 
cluster at 15q11-q13. The repeated findings at GABRB3 suggest this subunit 
harbors alleles that increase autism risk. McCauley et al. proposed that multiple 
regions of GABRB3 could harbor susceptibility alleles, thus complicating 
consistent detection of association. 
The GABAA receptor subunit genes represent very attractive functional 
candidate genes. GABAA receptors are ligand-gated chloride channels that 
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mediate the majority of fast synaptic inhibition in the brain. Mutations in GABAA 
receptor subunits have been linked to generalized epilepsies, common in autism. 
Neuropathological studies have shown that GABAA receptor expression is 
significantly reduced in the brains of children with autism [190,191]. Elevated 
plasma levels of GABA have been observed in autistic subjects [192]. GABRB3 
is expressed extensively during the late embryonic to early postnatal period of 
brain development. A deficiency in this subunit during this critical period could 
have significant effects on synaptogenesis. 
The imprinting status of and potential epigenetic dysregulation ofGABRB3, 
particularly in autism, is not clear. Studies by Hogart et al. have shown that while 
expression of GABRB3 is biallelic in normal brain samples, a subset of autism 
samples show monoallelic expression or allelic bias, suggesting that epigenetic 
control of may also extend to this gene [193,194].  
Despite the abundance of functional, genetic, and epigenetic evidence 
implicating GABRB3, a thorough indexing of all major alleles and potential rare 
variants of this gene has not yet been carried out. Chapter 5 covers my analysis 
of common and rare variants of GABRB3 in autism. 
 
MECP2 a Potential Regulator of UBE3A and GABRB3 
Finally, I propose that MECP2, encoding the methyl CpG binding protein, 
responsible for virtually all Rett syndrome (OMIM 312750), shows sufficient 
evidence to warrant investigation. The major reasons for this are as follows: (1) 
Mutations in MECP2 are associated with Rett syndrome and  in some cases 
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autism [195]. (2) Rett syndrome shares a number of phenotypic features with 
autism including deficits in language, social skills, and repetitive and restricted 
behavior [196]. (3) MECP2 expression levels have been shown to be lower in 
autism (and AS) and to potentially regulate gene expression of UBE3A and 
GABRB3.  
Since females carry two X-chromosomes, females who carry disease-
causing mutations in MECP2 typically have a normal copy of the gene on the 
other chromosome. As a result, females often make it to term and present with 
Rett syndrome. By contrast, males who carry only one X-chromosome are 
thought to not survive if carrying equal or less pathological mutations.  
So similar are the two disorders and so common is the misdiagnosis of 
autism in young females that girls with a suspected diagnosis of autism are 
routinely referred for Rett syndrome testing [197].  A number of documented 
cases of rare polymorphisms are located in the Rettbase database 
(http://mecp2.chw.edu.au/mecp2/) and indicate that in many cases these patients 
meet criteria for autism, but not Rett syndrome. 
Samaco et al. showed reduced expression of MECP2 in the brains of 4 of 
5 autistic individuals without MECP2 mutations, suggesting that more modest 
effects on gene expression in MECP2 may be a feature of autism and contribute 
to the presentation of the phenotype [198]. The study by Samaco et al. suggests 
that MECP2, UBE3A, and GABRB3 dysregulation may exist in autism, 
Angelman, and Rett syndrome and interaction between these genes is borne out 
by animal models and patient samples [198].  
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Finally, in the course of the work reported, another group has published 
evidence supporting an association of common alleles of MECP2 with autism 
[199]. 
Given the above, it is plausible that common allelic forms of MECP2 may 
predispose some individuals to the development of autism and may be more 
broadly involved in the disorder.   
 
Summary 
In short, functional relevance, linkage, association, and CNV analysis all 
support the study of the 15q11-q13 region and specifically the UBE3A and 
GABRB3 genes. The selection of the Rett syndrome gene, MECP2, is supported 
given the evidence for its regulation of UBE3A and GABRB3. Finally, study of 
two of the genes, ECT2 and GCH1, dysregulated by overexpression of the 
Angelman syndrome gene UBE3A may yield new genetic targets important in 
synapse formation and relevant to the pathogenesis of both Angelman syndrome 
and autism. 
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CHAPTER II 
 
HYPOTHESIS AND SPECIFIC AIMS 
 
The purpose of this project was to identify both common and rare alleles in 
chromosome 15q11-q13 that predispose chromosomally normal individuals to 
developing autism or autistic traits by investigating selected loci within 15q11-q13 
as well as loci that may regulate or be regulated by the products of these genes 
(see Figure 1-2). To clarify the latter point, I hypothesized that alleles for two 
recently discovered UBE3A substrates, ECT2 and GCH1, may increase 
susceptibility to autism and that common alleles of MECP2 may lead to 
increased risk for autism. 
This dissertation describes the detailed molecular and genetic analyses 
focused around two candidate genes of the 15q11-q13 region, UBE3A and 
GABRB3. In addition, it also sought to study the role of MECP2, ECT2, and 
GCH1 in idiopathic autism.  
The genetic analysis included here focus on common variants and their 
potential role in autism, rare variants with potential function in autism, and an 
investigation of the region using genotype data and other methods to assess the 
possibility of smaller genomic deletions or duplications in UBE3A and GABRB3 
which could potentially perturb cellular homeostasis and lead to an autism 
phenotype. In addition, biochemistry and gene expression studies are used to 
assess the nature of the relationship between UBE3A and ECT2 and GCH1. 
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Hypotheses 
Specifically, I hypothesized the following: 
1. Common and/or rare alleles of GABRB3 and/or UBE3A may contribute 
to autism susceptibility.  
 
2. Upstream or downstream loci which regulate or are regulated by 
GABRB3 and UBE3A, namely MECP2, ECT2, and GCH1, may act to 
increase autism susceptibility. 
 
Toward this end, the following aims were undertaken: 
 
Specific Aim 1: Common Variant Association in Autism 
This aim seeks to undertake association studies of SNPs in selected 15q11-13 
loci (GABRB3, UBE3A) as well as upstream (MECP2) and downstream (ECT2 
and GCH1) interacting loci to identify common autism risk alleles that may act 
alone or in concert to increase disease risk.  
Rationale: This approach attempts to capture common variants in 
chromosomally normal individuals, and to examine potential association of 
selected common variants and haplotypes with autism or autistic traits. For the 
loci of interest, it seeks to localize the source and particular alleles that contribute 
to autism susceptibility.  
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These results are presented in chapter 3 (MECP2), chapter 4 (UBE3A, 
ECT2, and GCH1), and chapter 5 (GABRB3).  
 
Specific Aim 2: Rare Variant Association in Autism  
This aim involves sequencing and functional analysis of GABRB3 and UBE3A for 
potentially functional variants which may predispose individuals to autism. 
Rationale: This aim sought to find rare variants that the I hypothesized 
would act to increase risk for autism or autistic traits. This is done since GABRB3 
point mutations may cause epilepsies and UBE3A mutations early exons are 
sufficient to cause Angelman syndrome with autistic features [153].  
I identified and functionally characterized one GABRB3 variant, P11S , 
covered in the first part of chapter 5.  
 
Specific Aim 3: 15q11-q13 Small CNVs in Autism 
This aim seeks to evaluate sites within UBE3A and GABRB3 for potential copy 
number variation and association with disease. 
Rationale: The 15q11-q13 region has a large number segmental copy 
number gains, typically resulting in recurrent duplication/deletion events. The 
clinical features of idic(15) are distinct enough and the level of developmental 
delay profound enough that it is unlikely many of these individuals exist in our 
sample. However, dysmorphologies and developmental delay is less striking in 
the (int dup(15)) patients and some are known to exist in out sample.  CNV 
analysis is expected to uncover interstitial duplications as well as potentially 
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novel submicroscopic CNVs (microdeletions/microduplications) or association 
with known CNVs within 15q11-q13 potentially further refining the susceptibility 
loci within 15q11-q13.  
Phenotype and genotype information were used together in chapter 6 to 
evaluate the possibility of smaller deletions and duplications in UBE3A and 
GABRB3. 
Chapter 3 covers the studies documenting association of a common allelic 
form of MECP2 with idiopathic autism. Chapter 4 explores the association of 
UBE3A, ECT2, and GCH1 loci with autism and relationship between UBE3A and 
its interacting proteins in autism. Chapter 5 is a study of GABRB3 and 
association of common alleles in autism and epilepsy as well as a detailed 
functional study of one of the major variants identified in GABRB3. Chapter 6 
leverages genotype data and phenotype data in a group of autism samples to 
determine if small previously undetected CNVs might exist in the exons of 
UBE3A or GABRB3. Chapter 7 closes with a summary of findings and suggested 
future analysis based on this work and the evolution of autism genetics over the 
course of this project. 
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CHAPTER III 
 
STUDIES OF MECP2 IN IDIOPATHIC AUTISM 
 
Introduction 
Autism (OMIM 209850) is a neurodevelopmental disorder in which 
individuals present with deficits in social reciprocity and language, and 
additionally exhibit features of repetitive behaviors and restricted interests. When 
narrowly defined, the prevalence of autism is estimated to be approximately 
1/500, but as high as 1/150 when all autism spectrum disorders (ASDs) are 
included [1]. Rett syndrome (OMIM 312750) is a severe neurodevelopmental 
disorder with features of autism, but which also includes deceleration of head 
growth, ataxia, and stereotypical hand movements. Autism and Rett syndrome 
are both classified as pervasive developmental disorders, but considered distinct 
conditions based on clinical and etiological differences. While the features of Rett 
often make the disease clinically distinct from autism, a number of overlapping 
traits are common to both disorders [196]. 
The genetic architecture of autism is comparatively complex, with strong 
evidence for both locus and allelic heterogeneity [24,52]. The genetic etiology of 
Rett syndrome, by contrast, is more straightforward. Approximately 95% of cases 
are caused by loss-of-function mutations of the X-linked MECP2 gene, which 
leads to defective forms or reduced levels of the Methyl CpG binding protein 
2(MeCP2) [97,200] .  
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MeCP2 encodes the Methyl CpG binding protein, which selectively binds 
to methylated DNA altering gene expression across genomic loci, including the 
autism associated 15q11-q13 cluster. Depletion of MeCP2 is associated with 
changes in the histone modification profile to a more active conformation and 
reduced promoter methylation and thus increased gene expression [201,202]. 
Other work indicates that MeCP2 has a more complicated affect on gene 
expression binding to non-methylated promoters or in active regions of 
expression [203]. MeCP2 may act as a chromatin organizer in genes such as 
GABRB3 allowing optimal expression of such genes and absence or reduction of 
MeCP2 thus leads to misexpression and possibly the phenotypic consequences 
of Rett syndrome and related disorders [194]. These and a number of other 
studies point to the importance of the MECP2 gene in proper brain development 
and synapse formation [204,205].  
The sex difference in for Rett syndrome and autism is notable. In autism, 
males are affected four times as frequently as females and epidemiology 
indicates a risk ratio (sibling recurrence risk / population prevalence) of 25-67 
[44,45]. All PDDs are expressed at a higher rate in males with the possible 
exception of Rett syndrome. As such, the potential involvement of X-
chromosome loci is tantalizing and though few linkage studies support 
involvement of the X-chromosome, though there is evidence that mutations of X-
chromosome genes (including NLGN3 and NLGN4X) often segregates with 
autism [62,87,100,206]. Rett syndrome, by contrast to other PDDs, is almost 
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exclusively present in females and is the second most frequent cause of female 
mental retardation [195].  
Rett syndrome is typically lethal in males, while female mutation carriers 
may not express features of Rett syndrome due random X-linked inactivation 
leading to mosaic expression of mutant copies X-linked MECP2 transcript. The 
stochastic nature of X-inactivation may result in silencing of the mutant allele thus 
avoiding the neurological consequences of Rett syndrome. In this manner, 
female mosaicism is probably often protective in that it ameliorates expression of 
deleterious alleles for X-linked loci which otherwise might be lethal or present 
with greater severity [207]. Further, it is thought that the reason fewer males 
present with Rett syndrome is that sporadic cases probably have their origin in 
the paternal germline and thus can only be transmitted to females [208]. There 
are reports of MECP2 mutations in male patients, but severity is typically greater 
with patients presenting phenotypes including fatal encephalopathy , non-specific 
X-linked mental retardation, and autism [209,210,211].  
Since the original report of MECP2 mutations resulting in Rett syndrome, 
a number of reports have documented MECP2 variants in cases of autism, 
atypical Angelman syndrome, and nonspecific mental retardation 
[55,212,213,214,215,216,217]. While autistic cases harboring MECP2 mutations 
are known to exist, they appear to be very rare [212,215,218]. Cases of Rett 
syndrome previously diagnosed with autism often progress to a less severe Rett 
phenotype without the typical motor difficulties. This misdiagnosis does indicate 
that some MECP2 mutations may be tolerated with fewer consequences than 
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other mutations [197]. In some cases of MECP2 mutations, Rett features were 
not noted until a later age [197]. For this reason, it seems possible that some 
MECP2 mutations are incompletely penetrant or may present with a lesser 
phenotype, such as autism.  
Samaco et al. showed reduced expression of MECP2 in the brains of 4 of 
5 autistic individuals without MECP2 mutations, suggesting that more modest 
effects on gene expression in MECP2 may be a feature in some cases of autism 
[198].  
More recent work in genetic association studies has shown that a common 
allele of MECP2 is associated with ASDs [219]. Loat. et al. reported on a 
common haplotype, accounting for more than 80% of haplotypes in their sample, 
which was overtransmitted to affected individuals in a group of 219 trios [219]. 
More recent work reported that the less common allele, accounting for about 
17% of haplotypes, was associated with decreased cortical surface area in two 
different samples, one with psychiatric disorders and another with Alzheimer’s 
disease and cognitive impairment. This is very provocative given the evidence for 
increased head circumference in many cases of autism [220].   
Given the above evidence, we thought it plausible that common allelic 
forms of MECP2 may predispose some individuals to the development of autism. 
This chapter describes our effort to determine if common allelic forms of MECP2 
are involved in the etiology of autism. 
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Subjects and Methods 
Sample Description and Phenotype Definition 
The study sample consisted of 965 families recruited at Vanderbilt or 
Tufts-New England Medical Center or obtained from the NIMH Center for 
Collaborative Genetic Studies on Mental Health Disorders (Table 3-1). Families 
were excluded if they were found to have a non-idiopathic autism (e.g. fragile-X, 
dysmorphic features, birth trauma) or gross chromosomal abnormalities. To 
determine the ancestry of families genotyped, we examined genome-wide SNP 
data available for the majority of our sample. This data is described in two 
previous studies [45,221]. Ancestry determinations used the software 
STRUCTURE available from http://pritch.bsd.uchicago.edu/structure.html in 
combination with HapMap SNP genotype data for known ancestral groups to 
correctly classify founders (Table 3-1). In cases without genotyping data, self-
report was used. Remaining families were classified as unknown.  Autism 
diagnosis was assigned using the Autism Diagnostic Interview (ADI or ADI-R), 
Autism Diagnostic Observation Schedule (ADOS) or both [25,26,27,28].  
 
Table 3-1. Sample description by ancestry. 
  ALL AA ASIAN CAUC HISP UNK
Families 965 31 26 796 39 104
Individuals 4032 116 133 3308 169 415
Number with autism 1624 49 42 1318 69 158
    Female 306 8 9 246 20 28
    Male 1318 41 46 1072 49 130
Type of Families:       
    Simplex 301 7 1 253 13 27
    Multiplex 664 24 25 543 26 77
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Stratification of Families 
Families were further stratified into two diagnostic categories, spectrum or 
strict, based on ADI and/or ADOS measures according to Table 3-2. These 
classifications are defined as indicated in Table 3-2. NA indicates the instrument 
was not available or not administered.  
 
Table 3-2. Phenotypic categories as defined by ADI-R and ADOS. 
Individual 
category 
Phenotype 
classifications: 
ADI-R ADOS 
(1) Strict Autism Autism 
(2) Spectrum Autism NA 
ASD ASD 
NA Autism 
  
Tag SNP Selection 
SNPs were selected using the HapMap release #22, build 35 Caucasian 
genotypes and inter-marker linkage disequilibrium (LD) was measured in the 
computer package Haploview [222]. The Haploview implementation of Tagger 
facilitates selection of tag SNPs. To capture common alleles, we used settings 
corresponding to a pairwise of r2 > 0.8 and MAF ≥5% were used. Potential tag 
SNPs are selected and analyzed using a BLAT query to control for interfering 
SNPs and repetitive elements. Due to high levels of LD in the region, only two 
tag SNPs were required to capture the common alleles of the 75.9kb MECP2 
gene using these criteria. However, to err on the side of caution and include 
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SNPs flanking exons, 5 SNPs were selected. These SNPs allowed capture of all 
(Caucasian) alleles with a mean max r2 of 0.98.  As Figure 3-1 shows, the 5 
SNPs selected spanned 100.3kb encompassing MECP2 and flanking sequence 
between rs4898375 and rs5945397.  
 
 
Figure 3-1. MECP2 Gene Structure and Tag SNP positions.  
The MECP2 gene spans 75.9kb and the tag SNPs 100.3kb on chromosome X. 
SNPs genotyped are identified with triangles and the three significant SNPs are 
highlighted. All five SNPs appear to be in a single block of linkage disequilibrium 
with a high level of r-squared between the three significant SNPs located near 
the terminal (3′) exons.  
 
Genotyping 
Markers meeting criteria were ordered as Assays-on-Demand (AoDs) from 
Applied Biosystems (Foster City, CA, USA). Genotyping was carried out by ABI 
TaqMan reactions were performed in a 5-µl volume according to the 
manufacturer’s recommendations using 5ng of genomic DNA. Cycling conditions 
included an initial denaturation at 95°C for 7 min, followed by 50 cycles of 92°C 
for 15 s and 60°C for 1 min. Samples were analyzed using an ABI 7900HT 
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Sequence Detection System. Genotypes were automatically called if there was 
95% confidence by the SDS software calling algorithm that the call was correct. 
 
Quality Control 
Inter- and intra-plate genotype controls were included in each 96-well 
plate provide for quality control measure. The Pedcheck script was used to check 
for Mendelian inconsistencies and a modification of this script was used to check 
for heterozygous males for the X-chromosome locus [223]. Five families were 
excluded from analysis due to irresolvable Mendelian inconsistencies or because 
genotyping showed heterozygous males. Genotyping efficiencies for all five of 
the markers genotyped were between 98 and 99 percent. Hardy-Weinberg 
equilibrium (HWE) P-values were calculated for each SNP using Haploview 
[222]. Since appreciable differences in allele frequencies were found to exist 
between HapMap populations, HWE values were checked in the overall sample 
and within ancestral groups.  Without doing so large deviations from HWE may 
exist as an artifact. 
 
LD and Family-based Association Analysis 
Haploview was used to calculate pair-wise LD (r2) for each pair of SNPs in 
our dataset [222]. Analyses of allelic transmission were performed in both 
spectrum and strict using the transmission disequilibrium test (TDT) as 
implemented in PLINK , association was tested in all families and in the spectrum 
and strict subsets [224,225]. In addition, I tested for overtransmission to affected 
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males and females, and the four major ancestral groups which compose the 
sample: African American, Asian, Caucasian, and Hispanic groups.  
 
Factor Score Analysis in Males and Females 
Factor scores based on ADI-R inputs have values from 0-1 and index separate 
components of the autism phenotype including: spoken language, social intent, 
compulsions, developmental milestones, savant skills and sensory aversions. 
These scores are calculated by principal components analysis as described by 
an earlier publication [226]. Males and females, respectively hemizygous or 
homozygous for the major haplotypes, were tested by parametric methods (t-test 
and ANOVA) for factor scores with normal distributions and by nonparametric 
methods for factor scores with non-normal distributions to see if a difference in 
means was observed between genotype groups. 
 
Results 
Hardy-Weinberg Equilibrium 
While violation of HWE was present, as expected, in the overall sample, 
no violation of HWE appeared present within ancestral groups. Minor allele 
frequencies and Hardy-Weinberg P-value for the overall sample and each 
ancestral are shown in Table 3-3. This was sufficient to provide deviation from 
HWE in accordance with Wahlund’s principle [227], which indicates that an 
abundance of homozygotes will be observed in situations of underlying 
subpopulations.   
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Table 3-3. Minor allele frequencies and Hardy Weinberg Equilibrium P-
values in overall sample and ancestral groups. 
SNP Name Position MAF HWpval MAF HWpval MAF HWpval MAF HWpval MAF HWpval
1 RS4898375 152926420 0.199 0.002 0.052 1 0.192 1 0.158 0.5437 0.383 0.9631
2 RS2075596 152950586 0.191 6.0E-04 0.065 1 0.22 0.9324 0.149 0.6085 0.358 0.5276
3 RS3027933 152952068 0.198 0.0034 0.169 1 0.228 0.9841 0.154 0.628 0.36 0.5276
4 RS5945175 153011951 0.044 1 0 1 0 1 0.049 1 0.009 1
5 RS5945397 153026720 0.055 1 0 1 0 1 0.061 1 0.037 1
HispanicAll African American Asian Caucasian
 
 
LD Analysis 
LD analysis of the region showed a pattern of LD in our sample largely consistent 
with HapMap with all 5 of the genotyped SNPs existing in a single block of LD 
with high levels of D´ between all SNPs tested. Further, we tested to see if LD 
patterns were consistent between ancestral groups. Figure 3-2 shows LD 
patterns in the four ancestral groups. For each ancestral group, with the 
exception of the African American, r2 levels between SNPs 1-3 were greater than 
0.8. In African American and Asian groups, SNPs four and five were not 
polymorphic. In all ancestral groups, D´ values were estimated to be equal to 1) 
for all polymorphic SNPs suggesting no recombination of haplotypes within the 
markers genotyped. 
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Figure 3-2. Linkage Disequilibrium Patterns in the Four Major Ancestral 
Groups. LD patterns are shown for African American, Asian, Caucasian, and 
Hispanic families. All five genotyped SNPs lie within one block of LD as 
measured by D´=1 between all polymorphic SNPs in all ancestral groups. Levels 
of r2 were high between the first three SNPs in most groups. In the figure above, 
if r2=1, the blocks are red and there is no numeric value given in the square. If r2 
is less than 1, and confidence in D´ is high, (as measured by a LOD>2), red 
squares will give their value of r2  (times 100). Purple squares indicate D´ of 1, 
but lower confidence in the value of D´ (LOD<2), frequently due to smaller 
sample size and/or low frequency of some alleles within different ancestral 
groups. Only three SNPs are shown for African American and Asian groups as 
SNPs 4 and 5 are not polymorphic in these groups. 
 
Single Marker Association Results 
Single marker analysis testing for over-transmission of alleles to affected 
individuals was done using the TDT implementation in PLINK. The results are 
shown in Table 3-4. The five SNPs genotyped in MECP2 are listed with their 
genomic positions and relative position in the gene. A1 indicates the minor allele 
and A2 the major allele. Transmission counts are given for the minor allele 
(T=Transmitted, U=Untransmitted). P-values, TDT odds ratios (OR) with 95% 
confidence intervals, and TDT chi-square statistics are given only for significant 
SNPs.  In this case it appears the major allele correlates with increased risk. 
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Table 3-4. Single marker association results for the entire 965 family 
dataset. 
SNP Name A1 A2 T U CHISQ OR P
1 RS4898375 A G 162 222 9.375 0.73 (0.6-0.89) 0.0022
2 RS2075596 A G 162 209 5.954 0.78 (0.63-0.95) 0.0147
3 RS3027933 G C 162 217 7.982 0.75 (0.61-0.92) 0.0047
4 RS5945175 C T 57 58
5 RS5945397 A G 70 76  
Since results for SNPs 1-3 produced significant evidence in support of 
association, we wanted to examine the potential effect of disease classification 
(see Table 3-2) on association for these SNPs.  The results of our analysis of 
SNPs 1-3 in considering transmissions to individuals affected under the strict 
model are shown in Table 3-5. SNPs 1-3 were very significant, surviving 
Bonferroni correction. Families with probands that met strict criteria for autism 
(see Table 3-2) showed the greatest support for association. Therefore, this strict 
group, contains probands that meet criteria for classical autism by both ADI and 
ADOS-measures and does not appear to indicate that the association is driven 
by Asperger syndrome or PDD-NOS. 
 
Table 3-5. Single marker association results under the strict phenotype 
model. 
 
SNP Name A1 A2 T U CHISQ OR P
1 RS4898375 A G 88 144 13.52 0.61 (0.47-0.8) 0.0002
2 RS2075596 A G 87 132 9.247 0.66 (0.5-0.86) 0.0024
3 RS3027933 G C 91 140 10.39 0.65 (0.5-0.85) 0.0013  
Since MECP2 is X-linked and might be expected to have differential 
impact depending on whether it was transmitted to males or females, we sought 
to examine transmissions to only affected males and to females independently. 
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Analysis of transmissions to-males-only (TMO) and to-females-only (TFO) are 
shown for these three SNPs in the strict disease classification in Table 3-6.   
While transmissions TMO was significant for all SNPs and TFO for only SNP 3, 
the direction of transmission bias and estimated OR were comparable suggesting 
that this is most likely the impact of a smaller number of transmissions to 
consider for affected females since the ratio of males to females in our sample is 
nearly 4:1.  
Table 3-6.Transmission to Affected Males and Females under strict model. 
SNP Name A1 A2 T U CHISQ OR P T U CHISQ OR P
1 RS4898375 A G 70 114 10.52 0.61 (0.46-0.83) 0.0012 18 30 3.00 0.60 (0.33-1.08)0.0833
2 RS2075596 A G 71 107 7.28 0.66 (0.49-0.9) 0.0070 16 25 1.98 0.64 (0.34-1.20)0.1599
3 RS3027933 G C 76 112 6.89 0.68 (0.51-0.91) 0.0087 15 28 3.93 0.54 (0.29-1.00)0.0474
TMO TFO
 
 
Multimarker Haplotype Analysis 
The PLINK program allows haplotype-based TDT association tests. The 
only major haplotypes with frequencies greater than 0.05, h1 (GGCTG) and h2 
(AAGTG), were tested. As table 3-7 indicates, both showed the major haplotype 
significantly overtransmitted to affected individuals in each of the disease strata. 
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Table 3-7. Haplotype-based TDT association test. 
Model Halotype Afreq T U CHISQ P
h1 0.79 230.70 171.40 8.74 0.00311
h2 0.13 90.02 145.40 13.02 0.00031
h1 0.79 148.60 94.47 12.06 0.00002
h2 0.14 47.02 97.77 17.79 0.00051
SPEC
STRICT
 
 
Factor Scores in Associated and Unassociated Males and Females 
Spoken Language, Social Intent, Developmental Milestones, Savant 
Skills, Rigid-Compulsive Behavior, and Sensory Aversions factor scores were 
calculated based on ADI-R items. Depending on the normality of the data 
distribution, either ANOVA or the Kruskall-Wallis test to determine if those 
homozygous (or hemizygous in the case of males) for the risk haplotype were 
significantly different to those with the protective haplotype. The tests were 
carried out controlling for sex and ancestry. Ancestry and sex were predictive of 
Spoken Language score, but genotype was not. Sex, but not ancestry or 
genotype, was significantly associated with Social Intent scores, with males 
having scores indicating less severe dysfunction in social domains. Milestones 
did not appear to be impacted. Rigid-compulsive behavior, as measured by the 
ADI, was significantly impacted by sex, but not by ancestry or genotype.  
Only the Savant Skills factor score appeared impacted by genotype. Using 
Kruskall-Wallis, savant skills was significant by both ancestry and genotype 
group, with those bearing the risk variant having lower scores on measures of 
Savant Skills. This indicates that these individuals are less likely to show high 
function in savant domains which include visuospatial ability, computational 
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ability, and memory skill (p<0.0001) [226]. To the extent that genotype group is 
accounted for by ancestry, we repeated the test within ancestral groups using the 
non-parametric two sample Wilcoxon rank sum test to determine if genotype was 
significantly associated with Savant Scores within each group. We found that for 
within Asian (p=0.038), Caucasian (p=0.002), and Hispanic (p=0.016) groups that 
genotype was associated with savant score, but not in African American group. 
For those three groups, the savant score was significantly lower with the 
associated haplotype (h1) than for the unassociated haplotype (h2) p=0.0009.  
 
Discussion 
Mutations in MECP2 have been observed in subjects clinically diagnosed 
with Rett syndrome, autism, and atypical Angelman syndrome among other 
conditions [55,212,213,214,215,216,217]. However, mutations in MECP2 are 
also present in phenotypically normal female individuals which may be due to the 
mosaic nature of X-inactivation in females or preferential inactivation of mutant 
alleles [228,229]. By extension, we have hypothesized that common alleles may 
contribute to the risk profile in the development of idiopathic autism. The 
mechanism I propose is minor differences in MECP2 expression levels as a 
function of the major haplotypes which thereby impact other gene and protein 
networks though to lesser extent than in cases of Rett syndrome. 
One other report by Loat et al. has also shown common alleles of MECP2 
to be associated with autism [219]. Preliminary evidence in this large sample of 
families with autism is a replication of this earlier finding. SNPs genotyped and 
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shown associated are in high LD as indicated by levels of r2 indicating that the 
same effect is being observed. The same risk haplotype (though different SNPs 
were genotyped) appears to be overtransmitted in both studies. Incidentally, 
SNPs 1-3 also show strong r2 with SNP rs2239464, the rare allele that has been 
shown associated with reduced cortical surface area [230]. This is notable since 
the common allele is in strong r2 with our SNPs 1-3 and macrocephally is a 
common finding in a number of autism cases [220]. In this case, the major allele 
is overtransmitted to those with autism in our study, and in the Joyner et al. study 
the minor allele is associated with reduced cortical surface area. 
Given these findings, it is possible that MECP2 may be a QTL for brain 
size and potentially IQ as well as a risk variant for autism. This is supported by 
the finding of the transmission bias of the major allele to those with classical 
autism and the minor allele of their SNP (which is on the less common 
unassociated haplotype, h2) with reduced cortical surface area. Impact on IQ 
might be reflected in part in the Savant Skills factor score findings where those 
with the associated h1 haplotype were less likely to have lower savant skills, 
reflecting lower ability in visuospatial ability, computational ability, memory skill, 
and musical ability. However the absence of finding of impact on developmental 
milestones suggests that the effect might be more subtle, since in the original 
factor score analysis this was the only factor score associated with IQ [226]. 
The association was driven almost completely by those with strict affection 
status. This suggests that those carrying the variant are more likely to manifest 
with classical autism rather than Asperger syndrome or PDD. This was, in part, 
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the motivation for the factor score analysis. Since fewer transmissions are 
considered in “strict” families, (as fewer individuals meet this criteria,) it is 
surprising that both single-marker and haplotype-based TDT tests identified the 
strict disease category as more significantly impacted.  TDT based tests are not 
only valid in the face of population heterogeneity, but can gain power [231]. 
Previously a significant reduction in MeCP2 expression in frontal cortex 
has been shown for cases of Rett syndrome, autism, and Angelman syndrome 
compared to age matched control autopsy specimens [202,232]. A study by 
Samaco et al. suggests that a MECP2-UBE3A-GABRB3 axis of dysregulation 
may exist in autism, Angelman, and Rett syndrome and this is supported by 
animal models and subject samples [198].  It has been suggested that patients 
clinically diagnosed with Angelman syndrome, but without identifiable 15q11-q13 
molecular be screened for MECP2 mutations as such mutations have been 
observed in these cases [233,234].  Brain architecture in MeCP2 null mice shows 
a slight decrease in neuron size and an increase in packing density in the 
hippocampus, cerebral cortex, and cerebellum [235]. 
It has previously been established that MECP2 is subject to X-inactivation 
and that not all mutations are equally damaging [236,237,238]. This may explain 
the variability of the phenotype observed in those mutation carriers with clinical 
diagnoses as diverse as encephalopathy, Rett syndrome, autism, and Angelman 
as well as phenotypically normal carriers. There does appear to be a trend or 
potential mechanism whereby the mutant MECP2 alleles are selectively 
inactivated [239,240]. The MeCP2 protein has been shown to bind to and repress 
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or activate transcription by binding tightly to methylated DNA sequence which it 
does so at many sites in the genome [241].  
Localization of the MECP2 protein has been shown to be dependent on 
DNA methylation where MECP2 and others can be recruited to neurologically 
important genes such as FMR1 and BDNF and cause their repression 
[242,243,244]. In the case of BDNF, it has been shown that neuronal membrane 
depolarization and calcium increases may lead to phosphorylation and release of 
MeCP2 from the BDNF promoter [244]. In this manner, MeCP2 is involved in 
activity-dependent gene regulation [245]. 
During development Mecp2 levels are high in adult mouse brain though 
there is not a strong correlation between protein levels and RNA levels, 
suggesting translation may be regulated at a post-transcriptional level and its 
levels may correlate with neurological maturity [246]. Restoration of expression of 
a functional copy of MECP2 has been shown to completely rescue the phenotype 
in mice, while overexpression can be lethal [247,248]. 
There are two major splice isoforms for the MECP2 transcript (MECP2A 
and the more abundant MECP2B) with exon 2 occasionally excluded so the two 
isoforms differ only in their N-terminus[249,250]. MECP2B is more abundant in 
ES cells and MECP2A increases as differentiation proceeds [249].  It remains 
unknown whether or not the two different isoforms have different function. If h1 
and h2 haplotypes are associated with differential isoform expression, this might 
be another means by which the association could be explained. 
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MeCP2-mediated modulation of local chromatin structure might 
paradoxically facilitate rather than suppress expression of UBE3A or GABRB3, 
so that null alleles cause concordant reduction in these transcripts [198].  
Cheadle et al. found that most mutations in Rett syndrome patients were 
in the methyl-CpG-binding domain or the transcription repression domain of 
MeCP2 [251]. The group also characterized nine recurrent mutations in 33 
unrelated cases (73% of all cases with MECP2 mutations). Milder disease was a 
characteristic of patients with missense mutations compared to those with 
nonsense mutations. Disease was also milder the later the truncating mutation. 
Bienvenu found 30 mutations in 46 RTT patients including 12 novel mutations 
most of which were in exon 3 [252]. R270Xand frameshift deletions in a 
(CCACC)n-rich region were found with multiple recurrences [252]. Hupke et al. 
found mutations in 24/31 Rett patients with 20/24 being de novo.  Most mutations 
were truncating and some females having the same mutation manifesting with 
varying phenotypes, suggesting other factors may influence phenotype [253]. 
Amano et al. identified 12 different mutations in the MECP2 gene, 8 of which 
were novel [254]. De Bona et al. noted 2 hotspots in Rett patients R270X and 
R294X [255].  
My data represents a second report of association of common alleles at 
MECP2 with autism probands. We have shown that this association is strongest 
in families with probands that meet strict criteria for autism, and that it is the 
major allele of MECP2 which is overtransmitted to those with autism. Given the 
vast number of genes with transcription impacted by MECP2 and the relative 
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frequency of the two major haplotypes, determining the molecular action by 
which risk alleles of MECP2 impact gene expression leading to autism is a 
tractable, though complex, problem. 
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CHAPTER IV 
 
ASSOCIATION, GENE AND PROTEIN EXPRESSION STUDIES OF TWO 
UBE3A NETWORK GENES IN AUTISM 
 
Introduction 
The most common chromosomal abnormality observed in ASD is maternal 
duplication of chromosome 15q11-q13 which accounts by some estimates for as 
many as 3% of all autism cases. This duplication region contains a number of 
genes including UBE3A, maternal deficiency of which results in the mental 
retardation disorder Angelman syndrome (AS) [116,256]. The relatively high 
frequency of maternal 15q duplications resulting in an ASD phenotype implicate 
the genes that exhibit maternal-specific expression in this region (ATP10 and 
UBE3A) as the most likely contributors to the ASD phenotype in individuals with 
15q duplications.   
UBE3A is subject to epigenetic control and shows maternal-biased 
(maternal > paternal) and maternal-specific expression in some brain regions. I 
hypothesize that alleles at UBE3A that act to alter gene expression, imprinting 
regulation, or protein function could increase risk for autism. UBE3A encodes the 
E6-AP ubiquitin protein ligase, an E3 ubiquitin ligase. I hypothesized that dup(15) 
and AS phenotypes result in part or entirely as a result of UBE3A dysregulation. 
As such, both AS and autism may could result from the action of too much or too 
little UBE3A and its protein on target protein substrates or by defects directly in 
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those genes and proteins regulated by, or known to regulate UBE3A, (e.g. 
MECP2). Both of these phenotypes may be a direct result of the dysregulation of 
a number of UBE3A protein substrates or transcriptionally regulated genes. I 
hypothesized that changes in gene expression or protein stability of UBE3A 
targets may also result in an autism phenotype on their own. Dr. Lawrence 
Reiter, identified two proteins that are affected by increased UBE3A expression: 
epithelial cell transforming sequence 2 oncogene (ECT2), a Rho-GTPase 
involved in actin cytoskeletal remodeling and axon guidance and GTP 
cyclohydrolase I (GCH1), the rate limiting enzyme in the synthesis of a variety of 
neurotransmitters [257,258]. 
As an E3 ubiquitin ligase, the primary function of UBE3A is to tag proteins 
with ubiquitin for subsequent degradation or cellular re-localization [259]. UBE3A 
has also been shown to be a potent transcriptional activator for estrogen and 
androgen receptors among others [170]. In addition, it may act indirectly to 
increase or decrease levels of proteins by ubiquitinating and thus degrading 
transcriptional regulatory proteins for these genes. Reiter and colleagues showed 
that ECT2, which remodels the actin cytoskeleton physically interacts with Ube3a 
in cultured cells and is down-regulated by increased expression of Ube3a in 
Drosophila [173]. Likewise, loss of Ube3a protein in the brains of Ube3a null mice 
has a profound effect on ECT2 protein expression in both the hippocampus and 
cerebellum, two regions of the brain implicated in the pathogenesis of both AS 
and autism [175]. ECT2 is important in the creation of the cleavage furrow during 
cytokinesis [260]. However, it also plays a critical role later in development where 
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it is involved in the migration of neuronal P-cells, the progenitors of GABAergic 
interneurons in C. elegans [180].  
Another protein identified in the screen for UBE3A regulated 
proteins/genes is GTP cyclohydrolase 1 (GCH1), which appears to be up-
regulated by the over-expression of UBE3A in both fly and human (manuscript in 
preparation). Mutations (typically loss-of-function) in GCH1 cause dopa-
responsive dystonia and Parkinson’s disease since this protein is the rate limiting 
enzyme in tetrahydrobiopterin (BH4) biosynthesis [261,262]. With ECT2 involved 
in synaptic plasticity and GCH1 in monoamine synthesis, both are excellent 
candidate genes for autism since they regulate synaptic stability and function.  
Here I show that in addition to UBE3A, both ECT2 and GCH1 genes are 
strong candidates for harboring susceptibility alleles for idiopathic autism as 
anticipated above. To test this hypothesis, I conducted an association study in 
694 combined autism families using tag SNPs to index all major alleles for these 
three genes: ECT2, GCH1, and UBE3A. In addition, I analyzed gene expression 
and protein levels in lymphoblastoid cell lines from patients with both AS and 
dup(15q) autism patients to determine if the levels of ECT2 and GCH1 were 
correlated with UBE3A dosage. I then used lymphoblastoid cell lines from 
patients that carry associated alleles and unassociated alleles for ECT2 and 
GCH1 in our analysis to test for differences in gene expression as a result of the 
specific SNP haplotypes. To test the response of these genes to changes in 
UBE3A protein expression, I transfected UBE3A and UBE3A-siRNA constructs 
into mammalian cells to evaluate changes in ECT2 and GCH1 expression and 
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stability. Finally, I attempted to validate our findings by examining gene 
expression for the HapMap CEPH trio offspring. Our findings support the need 
for further study of UBE3A and associated loci ECT2 and GCH1 as candidates 
for involvement in the pathogenesis of autism and AS. 
 
Subjects and Methods 
Subjects 
The cohort used for the association studies contained 694 families with 
one or more ASD affected offspring. Families were ascertained through 5 
different centers shown in Table 4-1. These included families recruited at 
Vanderbilt (VAN) or Tufts-New England Medical Center (TUF). Samples for the 
Autism Genetic Resource Exchange (AGRE), Iowa, and Stanford samples were 
obtained from the NIMH Center for Collaborative Genetic Studies on Mental 
Health Disorders. Families were excluded if they were found to have a non-
idiopathic autism (e.g. fragile-X, dysmorphic features, birth trauma) or gross 
chromosomal abnormalities. Autism was assessed using the Autism Diagnostic 
Interview (ADI or ADI-R), Autism Diagnostic Observation Schedule (ADOS) or 
both. For the purposes of this study, those who met criteria for autism or ASD by 
either or both of these measures were considered “affected” in the association 
study. In terms of ethnicity, 4% percent of the families were of African-American 
origin, 7% of Latino origin, 4% of Asian origin, 83% of Caucasian origin, and 2% 
of unknown ethnic background.  78% of those with autism in our cohort were 
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male. Several individuals for whom cell lines were available were chosen for 
additional gene and protein expression studies. 
 
Table 4-1 – Characteristics of genotyped families with autism stratified by 
center 
ALL AGR IOW STA TUF VAN
Families 694 327 85 131 98 53
Individuals 2823 1420 361 522 353 167
Number with autism 1256 623 162 259 153 59
    Female 268 147 26 52 34 9
    Male 988 476 136 207 119 50
Family type
Simplex 143 36 19 16 27 45
Multiplex 551 291 66 115 71 8
ADI version
ADI / 
ADI-R
ADI ADI* ADI
ADI / 
ADI-R
 
*Short form ADI 
 
Genotyping and Association Analysis 
The ECT2, GCH1, and UBE3A genes span 67kb, 61kb, and 102kb, 
respectively. ECT2, GCH1, and UBE3A contain 24, 7, and 17 exons respectively. 
HapMap data and Haploview’s implementation of the Tagger application, was 
used to select tag SNPs with minor allele frequencies (MAFs) greater than 0.05 
(http://www.broad.mit.edu/mpg/haploview/). Given the predominantly Caucasian 
makeup of our sample, 30 CEPH parent-offspring trios were used for the 
estimation of haplotype blocks and tag SNPs were selected so that each had a 
minimum pairwise r2 of 0.8 with other HapMap genotyped SNPs with MAF>0.05. 
Genotyping was done using TaqMan-MGB probes designed by the Assay-
on-Demand service of Applied Biosystems (Applied Biosystems, Foster City, CA, 
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USA). All PCR was carried out in 384-well plates in a 5µl volume containing 2.5µl 
2x TaqMan Universal PCR Mastermix with 0.125µl 20x Assay-on-Demand probe 
and 5ng of genomic DNA according to manufacturer’s recommendations. Post-
PCR scanning was done on the ABI 7900HT apparatus. Genotyping quality 
control measures included 95% genotyping efficiency for all SNPs, test of Hardy-
Weinberg Equilibrium, and inter-plate and intra-plate QC replicate samples, as 
well as checks for within-family Mendelian inconsistency using Pedcheck  [223]. 
The Family-based Association Test (FBAT) was used to test the 
transmission bias of alleles from heterozygous parents to affected offspring [263]. 
Empirical analysis of LD in our cohort was carried out on genotype data using the 
Haploview program [222]. The HBAT implementation of the FBAT program was 
used to measure overtransmission of haplotypes from parents to affected 
offspring [264]. I examined the results from these analyses to identify associated 
and unassociated alleles and haplotypes of ECT2 and GCH1 for selection of 
patient cells for gene expression analysis described below. 
 
Cell culture 
Lymphoblastoid cell lines (LCLs) for subjects diagnosed with idiopathic 
autism were previously made from Epstein Barr virus-immortalized patient 
lymphocytes. Samples for affected subjects identified as homozygous for ECT2 
and GCH1 associated or unassociated alleles were selected from these cell lines 
to determine if gene expression changes existed between different allelic forms 
of ECT2 and GCH1. Lymphoblastoid cell lines for AS, CEPH, and maternal 
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dup(15q) samples were acquired from the Coriell Cell Repository 
(http://ccr.coriell.org/). AS lines were all known deletions of the 15q11-q13 
interval and dup(15q) cell lines were known to be isodicentric (idic) duplications, 
containing four copies of the 15q11-q13 region. Cell cultures were maintained in 
RPMI-1640 with 15% BCS, 5% L-glutamine, and 5% pen-strep, at a density of 
200,000-500,000 cells/ml at 37۫ C with 5% CO2.  
 
RNA isolation 
RNA was isolated from 5x105 cells in 1ml of Trizol (Invitrogen, Carlsbad, 
CA, USA) according to manufacturer instructions for using suspended cells. RNA 
was quantified by measuring absorbance at 260nm with an ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). 
Concentrations were adjusted to 200ng/µl for preparation of cDNA. 
 
Preparation of cDNA 
cDNA was prepared using Applied Biosystems TaqMan Reverse 
Transcription Reagents (cat #N808-0234, Applied Biosystems, Foster City, CA, 
USA). Reagent volumes were adjusted from manufacturer specifications 
appropriate for 10µl samples each with 400ng of RNA added. One duplicate 
sample and one blank (no RNA) were used as controls.  
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Expression analysis by Quantitative Real-time PCR 
From each sample, I diluted cDNA 1:50 and then transferred triplicate 2µl  
samples to 384-well plates along with 2.5µl Applied Biosystems Universal 
Mastermix (cat no. 4305719) and 0.25µl VIC-conjugated RNase P (cat no. 
4316844), and 0.25µl FAM-conjugated ECT2, GCH1, or UBE3A real time PCR 
assays (cat # Hs00978168_m1, Hs00609198_m1, and Hs00963668_g1, 
respectively). Gene expression was assessed in triplicate for each sample in 5µl 
reactions normalizing the target genes to RNase P expression and using the     
2– Ct method with a relative quantification (RQ)min/RQmax confidence set at 95% 
[265]. Amplification efficiency for each gene product was calculated by serial 
dilutions for each assay.   
 
Transfection with UBE3A and siRNA constructs 
Since expression profiles might be cell-type dependent, I used both 
immortalized CEPH lymphoblastoid cell lines and HEK-293T cells for transfection 
of UBE3A and UBE3A-siRNA constructs. A pcDNA3 vector (Invitrogen) 
containing the UBE3A cDNA was used for transfection of UBE3A into cells. A 
substitution in the same vector at nucleotide 833 (C to A) formed a catalytically 
inactive form of UBE3A which cannot tag substrates, including itself, for 
degradation was also used for transfection [266]. In addition, empty pcDNA3 
vector was used. An siRNA construct against UBE3A was used (cat # AM16706, 
Ambion, Austin, TX) and transfected using Oligofectamine (Invitrogen). All other 
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constructs named above were transfected using Fugene (Invitrogen), in 
accordance with the manufacturer’s recommendations. 
 
Protein extraction, antibodies and Western blot 
To harvest protein, I collected 5mL of cells with a density of ~5x105 
cells/mL. Cells were washed with PBS, then combined with 200µl RIPA buffer 
(50mM Tris-HCL, pH 7.4, 150mM NaCl, 1% NP-40, 0.25% Na-Deoxycholate, 
1mM EDTA) per sample.  Cells were lysed by shaking the tubes at 4°C for 30 
min, before collecting the lysates into 1.5ml Eppendorf tubes. Tubes were rotated 
for another 20 min, centrifuged at maximum speed for 5 min and the supernatant 
taken. Protein concentrations were determined using a Bicinchoninic Acid (BCA) 
assay measuring samples in triplicate with a BMG Labtech, PolarStar Optima 
and Omega software (FLUOstar 403; BMG LabTechnologies, Durham, NC). 
Primary antibodies used for Western blot analysis were α-ECT2 (cat #sc-
25637, Santa Cruz, CA); a chicken polyclonal α-GCH1 generated against a 
mixture of two C-terminal peptide fragments (Nterm-CFSRRLQVQERLTK-Cterm 
and Nterm-HDLELDHKPPTREC-Cterm); α-UBE3A (cat #611416 BD 
Biosciences, San Jose, CA); and for a loading control, α-GAPDH was used (cat 
2-RGM2, Advanced ImmunoChemical Inc, Long Beach, CA). Secondary 
antibodies were as follows: Goat Anti-Mouse IgG, Donkey Anti-Chicken IgG, and 
Goat Anti-Rabbit IgG (cat #115-035-062, cat #703-035-155, and cat #111-035-
003, Jackson Immuno Research, West Grove, PA). 
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A molecular weight standard, SeeBlue Plus2, pre-stained molecular mass 
standard (Invitrogen) was loaded in adjacent lanes for protein size determination. 
After adding 4X SDS sample buffer, samples containing equal protein 
concentration were heated for 5 min at 100 °C and resolved on a 10% Tris-HCl 
denaturing ready-gel (Bio-Rad, Hercules, CA) for detection of UBE3A, ECT2, 
GCH1, and GAPDH. Proteins were transferred to Amersham nitrocellulose 
membrane at 4°C for 1 hour at 0.20uA, blocked with Tris Buffered Saline Tween 
(TBST) + 5% milk, followed by incubation with primary antibodies at 4°C 
overnight.  The following day membranes were washed with TBST followed by a 
1 hour treatment with secondary antibodies, and additional washes with TBST. 
Western blots were developed with ECL reagents (Detection reagent 1 and 2, 
Product #1859701 and #1859698, Thermo Scientific, Rockford, IL). 
Chemiluminescence was recorded on an Omega 12iC Molecular Imaging 
System and was quantified using UltraQuant software (UltraLum, Claremont, CA, 
USA). 
 
Analysis of HapMap genotype and gene expression 
Genotypes were downloaded from the HapMap’s Hapmart website 
(http://hapmart.hapmap.org/BioMart/martview) for all SNPs shown in table 4-2 for 
the CEPH trio offspring. Gene expression data for these samples was 
downloaded from GENEVAR (http://www.sanger.ac.uk/humgen/genevar/) and 
the data was imported into Stata (version 9.0; Stata Corp, College Station, Tex) 
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for analysis of differences in gene expression differences in UBE3A, ECT2, and 
GCH1 genes by genotype and expression level of each gene.  
 
Statistical Analysis 
Comparison of gene and protein expression levels was performed by 
ANOVA or Student’s t-test, where appropriate. The distribution of expression 
data across samples was checked for normality. Where appropriate, adjustments 
were made to control for sex and genotype. Linear regression was used to 
assess the degree to which gene and/or protein expression levels were 
correlated and the strength of that correlation. 
 
Results 
Association Studies 
Tag SNPs designed to index all common alleles with frequency greater 
than 0.05 were identified for ECT2, GCH1, and UBE3A using Haploview and 
Tagger with an r2 >0.8. Tag SNPs covered 109.3kb, 67.4kb, and 143kb, 
respectively for ECT2, GCH1, and UBE3A. The respective transcriptional units 
for these loci are 67kb (ECT2), 60.8kb (GCH1), and 99.4kb (UBE3A). Since the 
majority of our sample is of European ancestry, the CEPH HapMap phase II data 
provided the basis for defining LD relationships for tag SNP selection. In all, six 
informative SNPs were selected for ECT2, eight for GCH1, and eight for UBE3A. 
I genotyped these SNPs using Taqman AoD assays in a sample of 694 ASD 
families described above in Table 4-1 and shown below in Figure 4-1. 
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Figure 4-1- Association results for ECT2, GCH1, and UBE3A in the 694 
autism family sample. Intron/exon gene structure for each of the three genes is 
shown. Tag SNPs (triangles) were selected using Tagger and the HapMap 
CEPH samples to select SNPs which would index the common alleles of each 
gene with frequency of greater than 0.05. SNPs significantly associated by the 
FBAT statistic are shown in red.  These SNPs formed the basis for the 
“associated” (+) and “unassociated” (-) selection of samples used for gene and 
protein expression studies in Figures 4-2 through 4-5. 
 
Results from association analysis are shown in Table 4-2. The Family 
Based Association Test (FBAT) was used to test allelic transmission from 
heterozygous parents to affected offspring and to generate a statistic based on 
what would be observed under the null hypothesis of no association. As shown in 
Table 4-2, both UBE3A substrates ECT2 and GCH1, showed nominal evidence 
for allelic association; ECT2 for two SNPs (P=0.029 and P=0.022) and GCH1 for 
one SNP (P=0.022). In addition UBE3A showed association with one SNP 
(P=0.005). An additive model of affection is assumed.   
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Table 4-2. Association results for ECT2, GCH1, and UBE3A*.  
 
SNP Position Relative position Major 
Allele
Minor 
Allele
MAF T NT P (-e) RR
rs4894585 173931157 -23.8kb 5' exon 1 G T 0.22 284 264 0.32
rs10936737 173954018 -981bp 5' exon 1 C T 0.44 428 390 0.19
rs7644191 174003520 intron 18 C G 0.08 144 134 0.40
rs4485744 174014362 intron 20 G A 0.40 459 397 0.028 1.15 (1.05-1.27)
rs4331694 174021052 3'UTR exon 23 T C 0.44 440 375 0.022 1.17 (1.06-1.29)
rs7374229 174040526 18.6kb 3' exon 23 C T 0.26 349 345 0.65
rs752688 54381319 intron 5 C T 0.19 162 148 0.56
rs4411417 54390313 intron 3 T C 0.2 164 142 0.41
rs2878169 54395743 intron 3 G T 0.08 51 49 0.54
rs998259 54424781 intron 1 C T 0.24 205 180 0.18
rs3783641 54429889 intron 1 T A 0.2 165 141 0.14
rs3783642 54429953 intron 1 T C 0.4 228 186 0.022 1.22 (1.06-1.40)
rs8017210 54431586 intron 1 G A 0.19 154 144 0.51
rs8007267 54448741 9.4kb 5' exon 1 C T 0.18 93 121 0.07
rs12906610 23120693 14.6kb 3' exon 15 T C 0.13 186 148 0.10
rs757439 23123915 11.4kb 3' exon 15 T C 0.29 345 306 0.14
rs10162823 23157263 intron 8 G A 0.14 189 153 0.12
rs2340625 23190278 intron 6 C G 0.23 281 256 0.28
rs8179187 23203419 exon 5 T G 0.08 134 91 0.005 1.47 (1.21-1.78)
rs1041933 23205842 intron 1 A G 0.26 289 272 0.70
rs11161180 23260682 25.9 kb 5' exon 1 G A 0.24 290 264 0.40
rs714900 23263676 28.9 kb. 5' exon 1 C T 0.06 93 80 0.22
E
C
T
2
G
C
H
1
U
B
E
3
A
 
* SNPs listed are given for the forward strand of each chromosome. 
 
Selection of Associated and Unassociated Haplotypes 
The haplotypes were tested, using the haplotype-based association test 
(HBAT) program. The HBAT -p option (haplotype permutation test) was used to 
compute the "exact" P-value via a Monte Carlo method. The HBAT -e option was 
used to compute the empirical P-value for association in the presence of linkage. 
The option "–e" of HBAT was used because it is a test of association given 
linkage. 
In order to determine the nature of the association in the ECT2 and GCH1 
genes, I used associated (and flanking) SNPs in both genes to identify the most 
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common associated haplotype and most common unassociated haplotype for 
each gene. For example, in the ECT2 gene the minor alleles A and C for SNPs 
rs4485744 and rs4331694, respectively, are over-transmitted to affected 
individuals. The A and the C are on the same haplotype background and 
therefore the most common haplotype containing A-C was deemed the “ECT2 
associated” (ECT2+) haplotype. By contrast, the G-T alleles for the same two 
SNPs were under-transmitted to affected individuals. Therefore the most 
common haplotype background containing G-T was identified as the “ECT2 
unassociated” (ECT2-) haplotype. The same was done for GCH1 to identify its 
associated and unassociated haplotypes based on the most frequent haplotypes 
bearing the C or T allele. The frequency of all ECT2, GCH1, and UBE3A 
haplotypes with frequency > 5 percent are shown in Table 4-3 along with those 
deemed “associated” and “unassociated”. Major ECT2 and GCH1 haplotypes 
and their frequencies are given below. LD was empirically analyzed using the 
SNPs genotyped in our dataset by Haploview. Associated cell lines were those 
available who were homozygous for the associated and unassociated 
haplotypes, respectively, as determined by the most common haplotype bearing 
the associated and unassociated alleles, respectively. 
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Table 4-3 – Haplotypes selected for ECT2 and GCH1 associated and 
unassociated cell lines.  
ECT2 Haplotypes - rs4485744 rs4331694
Alleles Haplotype freq fam# HaplotypesS-E(S) 
1
Var(S) 
2
Z 
3
P Global P
ECT2 - GT 0.56 370 -25.06 196.68 -1.79 0.07
ECT2+ AC 0.387 366 29.88 188.47 2.18 0.03
GCH1 Haplotypes - rs4331694
GCH1- T 0.58 216 -25.83 127.86 -2.29 0.02
GCH1+ C 0.416 216 25.83 127.86 2.29 0.02
2 0.08
2 0.02
  
1-2 The S statistic in HBAT is calculated using the distribution of offspring 
genotypes conditional on affection status and parental genotype. E(S) and Var(S) 
are calculated under the null hypothesis conditioned on the parental genotypes. 
3 The Z statistic equals (S-E(S)/(Var(S)(1/2)).  
 
 
 
I then identified individuals who were homozygous for the associated and 
unassociated ECT2 and GCH1 haplotypes and cross-referenced them against 
our collection of available cell lines. Four associated individuals were chosen for 
each of four groups: ECT2 associated (ECT2+), ECT2 unassociated (ECT2-), 
GCH1 associated (GCH1+), and GCH1 unassociated (GCH1-).  
In addition to the sixteen cell lines representing the above haplotypes, I 
also acquired lymphoblastoid cell lines from individuals with AS (n=4), dup(15q) 
autism (n=5), and CEPH controls (n=3) from Coriell Cell Repositories (see 
methods). These samples were included in gene and protein expression studies 
to best determine the effect of decreased, normal, and increased UBE3A 
expression on ECT2 and GCH1 expression and protein levels.  
 
Gene Expression Findings 
Comparisons in gene expression levels for multiple group means were 
done by ANOVA or by T-test when only two groups were compared. UBE3A 
transcript levels were did not differ between idiopathic autism groups associated 
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or unassociated for particular ECT2 and GCH1 haplotypes (Figure 4-2). As 
expected, AS samples showed significantly lower levels of UBE3A than all 
idiopathic autism groups (P=0.002), significantly lower levels than CEPH 
(P=0.027), and significantly lower levels than Dup(15q) autism (P<0.0001). In 
addition, UBE3A expression levels were higher in dup(15q) autism than 
idiopathic autism samples (P<0.0001). 
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Figure 4-2 – Expression analysis for UBE3A, ECT2, and GCH1 in control 
and patient cell lines. qRT-PCR was carried out to measure gene expression in 
lymphoblastoid cell lines from individuals with deletions of UBE3A (Angelman) 
and duplications of UBE3A (dup(15)). Expression analysis was also carried out 
on cell lines from individuals with autism who carried the associated (+) or 
unassociated (-) forms of ECT2 and GCH1. While no significant differences were 
observed for the associated vs unassociated alleles of ECT2 and GCH1, a trend 
is seen with GCH1 transcript levels increasing with UBE3A expression as 
predicted by our model. Gene expression analysis was done in triplicate for each 
sample from each group (e.g. Angelman n=4 has triplicates for each for a total of 
12 reactions). Error bars show standard error. 
 
ECT2 gene expression levels did not differ significantly between ECT2+ 
and ECT2- groups. Expression levels showed no sign of difference in all 
idiopathic autism groups and dup(15) autism. This is not surprising given that 
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UBE3A and ECT2 proteins physically interact and that the ECT2 protein is a 
target for UBE3A ubiquitination. In other words, the ECT2 protein and not the 
mRNA transcript would not be expected to be impacted by increased UBE3A 
gene and protein expression. There is no evidence that the ECT2 gene is 
regulated by the UBE3A protein at the transcript level [173].  
As with ECT2, GCH1 transcript levels are similar comparing between 
GCH1+ and GCH1- groups.  However, GCH1 transcript levels were significantly 
different between AS and idiopathic autism groups (P = 0.008) but not between 
dup(15) and idiopathic autism groups (P = 0.1647). GCH1 expression levels thus 
were higher in groups with higher levels of UBE3A (i.e. Dup(15q) and CEPH 
controls to lesser extent) and lower in groups with lower levels of UBE3A (i.e. 
AS).  
Since GCH1 transcript levels did not differ between GCH1+ and GCH- 
groups, but were positively correlated with increasing UBE3A levels, I analyzed 
individual samples (as opposed to groups) to determine how GCH1 transcript 
levels might vary as a function of UBE3A gene expression levels. I found that 
across samples as there was a strong positive correlation between UBE3A and 
GCH1 expression levels (p = 0.001). In order to rule out a phenomenon of global 
gene over-expression, I tested to see if there were also a relationship between 
UBE3A and ECT2 gene expression and found that the two were not correlated (p 
= 0.294).  
Although transcript levels in the associated and unassociated haplotype 
groups for GCH1 were similar, I wanted to examine UBE3A levels within these 
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groups to explore any differences. I found that for the GCH1 associated group, 
GCH1 levels increased with UBE3A levels (p = 0.016). In the GCH1 
unassociated group, GCH1 levels appeared to show a trend to decrease with 
increasing UBE3A levels, though the correlation was not significant (p = 0.581). 
To exclude the possibility that this provocative difference in correlation was the 
result of artifact, three independent technical replicates for RNA extraction were 
performed and gene expression analyzed for UBE3A and GCH1 for both GCH1+ 
and GCH1- groups. The results were consistent with the trend that GCH1 
transcript expression increases as  UBE3A levels increase in GCH1+ groups 
(P=0.003) with GCH1- apparently uncorrelated to UBE3A levels (P=0.447). In the 
larger experiment, the slope of the GCH1- group was not negative. I adjusted 
UBE3A levels for group and regression indicating no overall effect for groups on 
the response of GCH1 to UBE3A (i.e. there was no significant difference in slope 
between groups.) The relationship between UBE3A and GCH1 expression in the 
associated and unassociated groups is plotted in Figure 4-3.  
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Figure 4-3 – GCH1 levels as a function of UBE3A between GCH1+ and 
GCH1- groups. 
 
Since GCH1 transcript levels (in the GCH1+ group) were positively 
correlated with UBE3A expression, I further probed this relationship by 
manipulating UBE3A expression levels in two different cell types (HEK 293T and 
immortalized human lymphoblasts) to validate that this relationship was 
consistent. I transfected two different cell types, HEK 293T cells and a CEPH 
lymphoblastoid cell line with either (1) siRNA against UBE3A (2) empty pcDNA 
vector, (3) mutant UBE3A-Cys833Ala, or (4) wild type UBE3A. The UBE3A-
C833A construct encodes an enzymatically inactive form of UBE3A which cannot 
catalyze the addition of ubiquitin to its substrate proteins [259]. 
UBE3A transcript levels were appropriately elevated in mutant and wild-
type transfectants. In both cell lines, UBE3A and GCH1 expression levels were 
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positively correlated. The strength of this correlation appeared high in both CEPH 
cells (p = 0.042, R-squared = 0.4692) and HEK-293T cells (p = 0.043, R-squared 
= 0.3803). Further, t-test of GCH1 showed GCH1 significantly higher in the 
UBE3A group than the siRNA group for the overall group (P=0.0049) and for both 
cell groups (HEK293-T, P=0.0266; CEPH, P=0.0262).   
 
Protein Expression Studies   
In order to verify that UBE3A protein levels were different between patient 
groups (AS, CEPH, and dup(15)), I performed Western blots on the three patient 
groups, shown in Figure 4-4, panel A. Quantification of UBE3A signal between 
groups was carried out and significant difference in UBE3A expression was 
found between groups by ANOVA (P=0.0005).  
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Figure 4-4 A- Western blot of UBE3A and GCH1 in AS deletion, CEPH, and 
autism families. As expected, UBE3A protein expression is lower in AS than 
either CEPH or dup(15q) autism samples. GCH1 levels also vary with AS 
samples showing the lowest levels of GCH1 protein bands at 28 kDa and 22kDa 
and dup(15q) samples showing greater levels of GCH1 protein expression. 
GAPDH was used as a loading control and did not change significantly among 
the cell lines.  4B- GCH1 protein levels increase with increasing levels of 
UBE3A in patient lymphoblasts.  Relative expression levels measured by X on 
Western blots from patients with AS deletion, CEPH controls and interstitial 
duplication 15q.  Note that although the levels of UBE3A and the GCH1 isoforms 
are approximately equal in any given group they also increase together as the 
copy number for UBE3A increases, with the exception of the 28 kDa GCH1 band 
in dup15q samples.  The 22 kDa band for GCH1 does increase in the dup15q 
samples, however. 
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I initially examined both ECT2 and GCH1 protein levels and found ECT2 
levels to be surprisingly unchanged across all groups (data not shown). For 
GCH1, however, I noticed small differences between subject groups. Protein 
quantification was done for both GCH1 isoforms (Figure 4-4) and showed a 
significant difference between groups for both the larger isoform (28kDa, 
P=0.0496) and the smaller isoform (20kDa, P=0.0112). Quantification of protein 
is shown in Figure 4-4 panel B. To determine if there was a relationship between 
UBE3A and GCH1 protein levels, Linear regression was carried out.  This 
showed a positive correlation between UBE3A protein levels and GCH1 28 kDa 
isoform (P=0.003) and 20 kDa isoform (P=0.001).  
To determine whether the UBE3A-GCH1 correlation would persist for 
protein in an over-expression transfection mode, I transfected HEK293-T cells 
with (1) an siRNA against UBE3A, (2)empty vector, (3) UBE3A-C833A, and (4) 
wild type UBE3A and then measured UBE3A and GCH1 protein levels in 
samples from these four groups (Figure 4-5). UBE3A levels differed significantly 
among groups by ANOVA (P=0.0067) as predicted from the lymphoblast studies.  
In particular, the UBE3A-C833A form shows a much higher level of stable protein 
compared with wild type UBE3A. The UBE3A protein can self-ubiquitinate and 
the higher molecular weight smear may reflect some poly-ubiquitinated protein 
on the blot (Figure 4-5).  GCH1 levels were significantly different for the 28kDa 
isoform (P=0.0045), but not 22 kDa isoform (0.1383) between the siRNA and 
UBE3A groups. 
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Figure 4-5A – Transfection of UBE3A constructs do not change GCH1 
protein levels in HEK cells. HEK 293T cells were transfected with either siRNA 
against UBE3A, empty vector, enzymatically defective UBE3A-C833A, or wild 
type UBE3A.  Although changes in UBE3A protein levels were clear, they did not 
correspond to analogous changes in the amount of GCH1 protein detected.  
5B- Quantification of banding patterns. 
 
Linear regression on protein levels indicated that the linear relationship 
between UBE3A and GCH1 transcript levels observed in lymphoblastoid cell 
lines was not recapitulated in this system, since neither isoform proved to 
significantly correlate with UBE3A levels. Between three replicate experiments 
(n=3 measurements for each treatment), the 28kDa isoform in GCH1 did appear 
to be significantly stronger in the UBE3A group than in the siRNA group 
(P=0.0146). This was not true for the 22 kDa isoform (P=0.6985). Protein level 
quantification between experiments is shown in Figure 4-5. 
To determine if gene expression levels by UBE3A were mirrored by 
protein levels, I looked at gene expression levels from mRNA and protein drawn 
from the same cell harvests between our patient groups (AS, CEPH, and 
dup(15)). Regression showed a positive correlation between all gene expression 
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and protein levels for UBE3A (P<0.0001) and GCH1 (22 kDa isoform, P=0.012; 
28 kDa isoform, P=0.043. 
 
Gene Expression in HapMap Samples 
To further test the co-directionality in expression levels of UBE3A and 
GCH1 using an alternative strategy, I used HapMap genotypes and gene 
expression data from HapMap CEPH lymphoblastoid cell lines (available from 
GeneVar: http://www.sanger.ac.uk/humgen/genevar/) as the majority of our 
sample is Caucasian. We chose the 30 offspring of the HapMap trios. UBE3A 
and GCH1 gene expression levels were evaluated for gender effects on 
transcription. There were no differences in GCH1 transcript levels by association 
group in 8 GCH1- and 6 GCH1+ homozygous individuals (P=0.7409) However, 
there was again a relationship between the GCH1+ group and increasing levels 
of UBE3A, but there was no significant difference in the slopes between GCH1+ 
and GCH1- groups.  There was, however, a strong correlation in the samples 
between UBE3A and GCH1 expression levels, consistent with our earlier data 
(P=0.0007). This relationship is shown in Figure 4-6. To be sure that this might 
not be a common phenomenon, ten random gene expression probes were 
evaluated for correlation with UBE3A and none of these showed significant 
correlation, increasing the confidence in the UBE3A-GCH1 relationship. 
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Figure 4-6 – HapMap CEPH trio offspring relative expression levels of 
UBE3A and GCH1 in associated (GCH1+) and unassociated (GCH1-) 
groups.  
 
 
Discussion 
 
Maternal duplications of chromosome 15q11-q13 are the most common 
chromosomal abnormalities found in autism. I postulated that disruption or 
dysregulation of the UBE3A network confers risk for autism. In Drosophila 
melanogaster, over-expression of human UBE3A leads to dramatic down-
regulation of the ECT2 ortholog and up-regulation of the GCH1 ortholog at the 
protein level.  Here I have shown that there are particular alleles in this gene 
network associated with increased autism risk. Additionally, I validated the 
relationship between UBE3A and GCH1. It is possible that ECT2 may be more 
involved in the AS phenotype than inherited autism [173]. 
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A number of studies have indicated that maternal deficiency for UBE3A is 
necessary and sufficient to cause AS [95,116,256]. In addition, maternally 
inherited duplications of the chromosome 15q11-q13 region containing UBE3A 
are typically associated with an autism phenotype [119,267,268]. Although there 
are two genes in the autism candidate region, UBE3A and ATP10A, that exhibit 
maternal-specific expression, our data support the hypothesis that UBE3A 
regulated genes are promising autism candidate genes. Several studies in both 
animal models and autopsy brain samples have indicated reduced expression of 
UBE3A in Rett syndrome and idiopathic autism  [194,198]. }. In fact, I did observe 
lower levels of UBE3A gene expression in idiopathic autism groups (non-
dup(15)) relative to CEPH controls (P=0.0178). Given the significant phenotypic 
overlap between autism and Rett syndrome there is further support for the idea 
too little or too much UBE3A causes a synaptic phenotype by its action on other 
proteins in the brain.  
It has been proposed that autism may be a disorder of synaptic 
modulation and maintenance, possibly through the maintenance of synaptic 
partners (e.g. SHANK3 and the neuroligins) by UBE3A [118]. Recent studies 
have shown that UBE3A may also localize to the nucleus and the synapse [177]. 
In fact, the premise that subtle changes in synaptic plasticity and function may 
play a significant role in autism is bolstered by the observation that otherwise 
normal appearing neurons from Ube3a deficient mice have a reduced number of 
dendritic spines [177]. The protein product of UBE3A not only enhances the 
degradation of p53 but also regulates neuronal cell growth [259,266]. This 
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suggests that UBE3A, as with a growing list of other autism associated genes 
that regulate synaptic plasticity (e.g. neuroligins and neurexins), may function 
locally to regulate spine development or synaptic function. Individuals with the 
autism associated disorders such as fragile X and Rett syndrome have also been 
shown to exhibit altered spine morphology [269,270,271]. 
Transfection of UBE3A constructs into mammalian cells causes significant 
(though non-linear) increases in GCH1 protein levels with over-expression of 
either wild type UBE3A or the catalytically inactive UBE3A-C833A.  These data 
are consistent with recent findings in Drosophila that indicate an increase in the 
GCH1 product tetrahydrobiopterin when either Dube3a or Dube3a-C/A is over-
expressed in neurons (L. Reiter manuscript in preparation).  The finding that 
UBE3A may regulate transcription of GCH1 in the nucleus is not unprecedented, 
since it has been known for some time that this particular E3 ligase also has a 
transcriptional co-activation function during the regulation of steroid hormone 
receptors [272]. 
Previous work by Nurmi et al. has shown association of a microsatellite in 
the UBE3A gene with idiopathic autism [273]. Some studies have shown no 
associations with functional variants in UBE3A [274]. Most studies have found 
associations of only nominal significance either in UBE3A or the imprinting center 
and maternal expression domain and replication of identical associations in 
independent datasets is lacking [185,275,276]. The most recent genome-wide 
screens for association has indicated UBE3A among the top candidates by virtue 
of its frequent duplication status in autism patients [127,172]. Here I have 
89 
undertaken to capture all major allelic forms of UBE3A therefore more 
comprehensively indexing its common alleles than in earlier studies. More 
importantly, the association findings, while nominal, are provocative in that they 
show significant association in a large family dataset in UBE3A regulated genes 
(Table 4-2). The finding that both ECT2 and GCH1 show positive association 
suggests that variants within these genes may potentially increase risk for autism 
and that other UBE3A regulated genes may also represent excellent autism 
candidate genes.  
According to one study, UBE3A mutations occur in 5.4% of cases of 
Angelman syndrome and loss of function mutations in UBE3A are known to be 
sufficient to cause AS [277]. The rate of UBE3A mutations is significantly higher 
in familial compared with sporadic subsets of AS [278]. Individuals with UBE3A 
mutations are typically more severely affected than those with imprinting center 
mutations or subjects with uniparental disomy (UPD), but less severely affected 
than those with 15q11-q13 deletions (UBE3A and surrounding genes) [165].  
Using information from association analysis (Table 4-3) I selected autism 
subject cell lines homozygous for risk haplotypes and then examined gene 
expression. Our studies indicated, comparing associated and unassociated 
groups, there were no significant differences in UBE3A, ECT2 or GCH1 gene 
expression levels. This is not necessarily surprising since gene expression 
patterns may be dependent on cell types and specific factors which could be 
different in our lymphoblastoid cell lines.  
90 
However, when I investigated the relationship between UBE3A and GCH1 
expression, the relationship between these two genes observed in Drosophila 
was confirmed. Also interesting is that there appears to be some modest 
difference in the strength of correlation of GCH1+ compared to GCH1- cells to 
increasing levels of UBE3A with regard to gene expression. That is, the GCH1+ 
cells showed a trend toward increases in GCH1 levels than the GCH1- group. In 
transfection experiments GCH1 levels increased in two cell types as a function of 
increasing UBE3A levels. This includes cells transfected with the UBE3A-C833A 
construct which cannot catalyze ubiquitination, suggesting that the transcriptional 
co-activation function of UBE3A may act to increase GCH1 levels.  
Protein studies mirrored gene expression studies closely in this regard. In 
our patient groups, GCH1 levels increased with UBE3A levels and this was 
largely true in our transfected cells. The exception to this was with transfection of 
the UBE3A-C833A group, which appeared to have lower levels of GCH1 protein 
than the siRNA group. This is a harder phenomenon to explain. Increased 
UBE3A, however, only produced modest increases in GCH1 protein expression 
so it appears at least in these two cell types (HEK-293T and lymphoblastoid cell 
lines) that the relationship between UBE3A is present, but not profound, so 
additional experiments in animal models in the appropriate cell type (neurons) 
will be required to confirm this relationship is relevant to autism. 
ECT2 and GCH1 orthologs were initially identified using proteomic 
profiling in Drosophila head extracts as two proteins up-regulated or down-
regulated, respectively, as a result of UBE3A over-expression [173].  
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The finding of genetic association in both of these genes, as well as with 
UBE3A indicates that the network of UBE3A and its downstream targets (and 
possibly upstream regulators) can individually act as risk factors in autism. I have 
biochemically confirmed the positive correlation between UBE3A and GCH1 
protein expression (but not for UBE3A and ECT2). Some caveats should be 
considered in the interpretation of these data. First, our analysis was performed 
on immortalized lymphoblastoid cell lines, rather than from brain tissue or 
neuronal cell lines; and the relationship among these genes may by depend on 
tissue specific factors. Furthermore, while there is some evidence that elevating 
UBE3A levels increases GCH1 protein levels, this was not the case for over-
expression of UBE3A-C833A (Figure 4-5). It might be that a catalytically inactive 
form of UBE3A increases gene expression of GCH1 (as I observed) but because 
it cannot ubiquitinate targets it may not properly regulate intermediates in the 
regulation of GCH1 protein activity and turnover. 
Given the evidence presented here and published elsewhere, UBE3A and 
genes and proteins it regulates by UBE3A appear to be valid candidate loci for 
harboring alleles that confer risk for autism. We hypothesize that dysregulation of 
these genes in idiopathic autism may lead to a diminished ability to form 
functional synapses.  
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CHAPTER V 
 
STUDIES OF GABRB3 IN AUTISM 
 
Introduction 
The most common chromosomal abnormalities in autism are 15q11-q13 
duplications (OMIM: 608636; a.k.a. AUTS4) that occur as an interstitial gain or 
supernumerary idic(15) marker chromosomes with two additional copies of 
15q11-q13 [3,119,268,279]. While paternal duplications are observed, autistic 
phenotypes are almost always associated with duplications of maternal origin. 
Maternal deletion of this region leads to Angelman syndrome (OMIM: 105830), 
and paternal deletion to Prader-Willi syndrome (OMIM: 176270), both of which 
share features of ASDs [119,154,256,280]. As a consequence, the genes in this 
interval have become candidates for investigation of their potential contribution to 
idiopathic autism susceptibility.  A cluster of GABAA receptor subunit genes lies 
within this interval.  GABAA receptors are ligand-gated chloride channels, which 
mediate the majority of fast synaptic inhibition in the brain.  Functional GABAA 
receptors are composed of five subunits that form a chloride ion channel and are 
typically composed of two α, two β, and a γ or δ subunit. 
Multiple lines of evidence have pointed to the potential involvement of 
GABAergic systems in autism [190,192,281,282]. One gene in the 15q11-q13 
cluster encodes the β3 subunit, GABRB3.  Several reports have documented 
association of common alleles at GABRB3 with autism. Data from autism studies 
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(not all of which are positive) show some evidence for replication, but also 
suggest allelic heterogeneity [104,105,106,187,283,284].  Recent epigenetic 
studies of the 15q GABAA receptor subunit cluster by Hogart and colleagues 
indicate predominantly biallelic expression of these genes in normal brain 
samples [193,194].  A subset of autism samples, however, showed monoallelic 
or allelic bias in expression suggesting epigenetic dysregulation.   
GABRB3 is known to play a significant role in development of the CNS.  
β3 is the major β isoform present in a number of brain regions in the prenatal and 
neonate brain [285,286]. β3-containing receptors are critical for stem cell 
proliferation as knock down of GABRB3 by siRNA has been shown to cause 
blastocyst-stage embryos to develop faster than controls and contain smaller 
cells and a larger blastocoel [287]. In adult brain GABRB3 exhibits a far more 
restricted pattern of expression, indicating a potentially critical role for β3 in early 
brain development [285,288,289]. The importance of GABRB3 in development is 
underscored by work with knockout mice. There is a 90% mortality rate in 
Gabrb3 null animals, but the 5-10% of β3−/− mice that survive to adulthood, 
despite multiple behavioral and physiological abnormalities, achieve normal 
weight and are reproductive by adulthood, though they die prematurely [290]. 
Gabrb3 knockout mice show evidence of seizures, hypersensitive behavior, both 
common to autism [290]. The Gabrb3 knockout mouse also exhibits cleft palate, 
an occasional finding in those with chromosome 15q11-q13 duplications or other 
syndromic ASDs [290]. Gabrb3 null mice also show fewer functional GABAA 
receptors and pharmacological evidence indicates that other β subunits are not 
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adequately replacing the absent β3 subunit [291]. Behavioral findings include 
diminished interest in social activity, reduced exploratory behavior, and fewer 
nurturing tendencies than wild-type littermates [292]. These impairments suggest 
that the Gabrb3 knock-out mouse may be a model for studying ASD behaviors in 
the mouse [292,293]. 
Based on the above evidence for GABRB3 as a candidate gene for the 
idiopathic autism condition, I sought to determine if rare and/or common variants 
and common variants in this gene contributed to susceptibility.  This chapter is 
divided into two parts. In the part 1, I describe our efforts to interrogate GABRB3 
for rare variants and present a detailed report of one of those variants, P11S. In 
part 2, I describe our use of genotyping tag SNPs to index all common alleles of 
GABRB3.  
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Chapter V - Part 1: Analysis of a Rare Variant P11S in Autism  
 
Subjects and Methods 
Subjects 
Families included in this study were recruited at Vanderbilt University, the 
University of Chicago, the University of California at San Diego, or they were 
obtained from the NIMH Repository (http://nimhgenetics.org).  Affected 
individuals were subject to a research diagnosis based on scoring of assessment 
using the Autism Diagnostic Interview – Revised and the Autism Diagnostic 
Observation Schedule.  All subjects provided informed consent and this work 
was conducted under approvals from the Institutional Review Boards at recruiting 
institutions. 
 
Genetics 
Genotyping was conducted using Applied Biosystems (ABI, Foster City, CA, 
USA) TaqMan Assays-on-Demand (AoD). PCR for the P11S variant (rs25409; 
ABI assay C__44811455_10) was carried out in 384-well plates in 5µl reactions 
containing 0.125 µl 20x AoD probe/primer mix, 5ng of genomic DNA and TaqMan 
Universal PCR Mastermix according to manufacturer’s recommendations. 
Products were scanned on the ABI 7900HT instrument to call genotyped. 
Genotyping efficiency was 98% and genotyped conformed to expectations under 
Hardy-Weinberg Equilibrium. Quality control also included inter-plate and intra-
plate replicate samples, as well as checks for within-family Mendelian 
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inconsistency using PEDCHECK [223]. Family-based association tests and 
genotype relative risks were calculated using the GenAssoc module for STATA 
(v9.2) provided by David Clayton (http://www-
gene.cimr.cam.ac.uk/clayton/software/) [294]. Log-linear models were 
constructed using SAS version 9.1. 
 
Phenotype 
Subjects were classified as affected under a “strict” diagnostic 
classification if they met criteria for autism on the ADI-R, while “broad” 
classification also includes individuals who met ASD1 or ASD2 criteria according 
to Risi et al [295].  Items from the ADI-R were the basis for comparing S11 
carriers and P11 homozygotes.  Subjects with missing data were excluded from 
analysis.  Effect of genotype on seizures was conducted using a Fisher’s Exact 
test comparing numbers of subjects with definite seizures (score of 2) to those 
with no history of attacks (score of 0) on the “Faints/Fits/Blackouts” item.  
Individuals with a history of attacks without a diagnosis of epilepsy or suspected 
attacks (score of 1) or febrile seizures only (score of 7) were treated as missing.  
For exploratory analyses, core behavior domain and subdomain scores were 
compared using univariate analysis of variance (ANOVA) with score as the 
dependent variable, genotype group as the independent variable, and age at 
ADI-R as a covariate.  Algorithm item scores were compared using Mahon’s chi-
square test to account for the ordinality of the ADI-R scores which were intended 
to be scored qualitatively (from 0 = “absence of behavior specified” to 2 = 
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“behavior definitely present”).  When present, individual item scores of 3 were 
down-coded to 2 as instructed on the algorithm.  The “ever” or most severe 
scores for the following items were also down-coded and compared when 
available: “Loss of Skills,” “Overall Level of Language,” Sensitivity to Noise,” 
“Difficulties with Minor Changes in Subject’s Own Routines or Personal 
Environment,” “Resistance to Trivial Changes in the Environment,, “Gait,” 
“Coordination,” “Aggression toward Caregivers or Family Members,” “Aggression 
toward Noncaregivers or Nonfamily Members,” “Self-Injury,” “Overactivity,” and 
“Special Isolated Skills.”  Ages for developmental milestones (including 1st steps, 
1st words, 1st phrases, and continence) were also compared between groups 
using ANOVA with age as the dependent variable, genotype group as the 
independent variable, and age at ADI-R as a covariate; when codes rather than 
specific ages were given (e.g., 997 for “not known, but apparently delayed”) the 
subject’s data was treated as missing.  
 
Ancestry Analysis 
Classical multidimensional scaling (MDS) was conducted using PLINK 
[225] for the sample of AGRE parents (founders). MDS dimensions were 
estimated from genome-wide average proportion of alleles shared identical by 
state for each possible pair of founders in the sample.  Graphical representation 
of the first two dimensions were used to identify population substructure and 
ancestry clusters.   
 
98 
Electrophysiology 
Expression of recombinant GABAA receptors and subsequent whole cell 
recordings from lifted cells were conducted as previously described [296]. Human 
embryonic kidney (HEK) 293-T cells were co-transfected with 2 µg of each 
subunit-encoding plasmid and 1 µg of the pHook-1 cDNA  (Invitrogen, Carlsbad, 
CA) using a modified calcium phosphate precipitation method and subsequently 
selected 24 hours after transfection using magnetic hapten-coated beads. 
 
Biotinylation  and Western Blot Analysis 
Cell surface receptor biotinylation and western blot procedures were 
modified from a previous protocol [296]. For cell surface receptor biotinylation, 
live, transfected cells were washed with phosphate buffered saline (PBS) 
containing 0.1 mM CaCl2 and 1 mM MgCl2 (pH 7.4) followed by incubation with 
sulfo-NHS biotin for 1 hour at 4º C.  Sulfo-NHS biotin was quenched with PBS 
containing 0.1 mM glycine.  Cells were lysed in RIPA buffer (10 mM Tris, pH 7.4, 
150 mM NaCl, 1mM EGTA, 0.1% SDS, 1% Triton X-100, 1% sodium 
deoxycholate), supplemented with protein inhibitor (Roche) for 1 hour at 4º C.  
The extracted supernatant was then incubated with immobilized streptavidin 
overnight at 4º C.  Biotinylated proteins were eluted from the streptavidin by 
incubation with 1× NEB glycoprotein protein denaturing buffer (5% SDS, 0.4 M 
DTT) at room temperature for 30 minutes. The supernatant was then either 
undigested or digested with Endo-H or PNGase F prior to fractionation by 10% 
SDS-PAGE.  
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35S radiolabeling Metabolic Pulse-Chase Assays 
35S methionine pulse-chase experiments were conducted with 
modifications from a previously published protocol [297]. Briefly, 48h hours 
following transfection, cells were replenished with starving medium that lacked 
methionine and cysteine (Invitrogen), and incubated at 37°C for 30 min.  Starving 
medium was then replaced by 1.5 ml 35S radionuclide methionine (100-250 
µCi/ml (1 Ci = 37GBq); PerkinElmer, Wellesley, MA) labeling medium for a series 
of different time points at 37°C.  FLAG-tagged human β3 subunits were then 
immunoprecipitated from radio-labeled lysates with an anti-FLAG M2-agarose 
affinity gel by rotating at 4°C overnight.  Immunoprecipitated products were then 
eluted from the beads with FLAG peptide (Sigma-Aldrich)I, and immunopurified 
subunits were then analyzed by 10 % SDS-PAGE and exposed on a digital 
PhosphorImager (GE Healthcare, Piscataway, NJ). 
 
Data analysis 
Macroscopic currents were low pass filtered at 2 kHz, digitized at 10 kHz, 
and analyzed using pClamp9 software suite (Axon Instruments).  Except for the 
pulse-chase assays, proteins were quantified by ChemiImager AlphaEaseFC 
software. Data from pulse-chase experiments were quantified using Quantity 
One software (Bio-Rad, Hercules, CA).  Numerical data were expressed as mean 
± SEM.  When wild-type data were arbitrarily taken as 1, column statistics were 
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used.  Statistical significance, using Student’s unpaired t test (GraphPad Prism), 
was taken as P < 0.05.   
 
Results 
Association of GABRB3 P11S with Autism 
To screen for novel functional variation, GABRB3 exons were sequenced 
in a discovery sample of 100 unrelated probands, and from this effort a single 
nonsynonymous variant (C87T, Pro11Ser) was identified in exon 1a, one of two 
alternative initiating exons for GABRB3 [298]. This variant, deposited into dbSNP 
(rs25409), was determined to be inherited and of maternal origin in two unrelated 
cases in an initial study cohort.  We subsequently genotyped this variant in a 
sample of 1,152 combined simplex and multiplex families to determine its 
frequency and potential association with autism in a larger population (Table 5-
1).  Seventeen families (1.47%) were found to harbor the rare S11 variant (Figure 
5-1), corresponding to an allele frequency of 0.40%.  Given substantial precedent 
for parent-of-origin effects in the region, parental transmissions were examined 
separately, and we observed a maternal (but not paternal) S11 over-transmission 
(P = 0.045; Table 5-2).  Indeed, 12 of 16 maternal transmissions resulted in a 
broad autism phenotype (see Methods), compared with only 3 of 8 paternal 
transmissions.  For the strict autism phenotype the maternal over-transmission 
was more pronounced (P = 0.008), with 12 of 14 transmissions resulting in a 
strict autism phenotype. The S11 variant confers a genotype relative risk (GRR) 
of 3.00 (95% CI: 1.26-7.12, P = 0.013) for the broad autism phenotype when the 
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transmission is maternal in origin. Similarly, the S11 variant confers a GRR of 
6.00 (95% CI: 1.62-22.16, P = 0.007) for the strict autism phenotype when 
transmission is maternal in origin.  Genotyping Caucasian controls identified a 
single S11 carrier from a sample of 584 chromosomes, corresponding to a 0.17% 
allele frequency, compared with 0.40% observed in the overall autism sample.   
Table 5-1. Characteristics of families with autism genotyped for the 
Pro11Ser variant (P11S) stratified by ancestry.  
 
  ALL AA ASIAN CAUC HISP UNK 
Families 1152 40 40 922 49 101 
Individuals 4603 145 168 3719 201 370 
Number with autism 1776 58 68 1433 82 135 
    Female 331 9 11 247 23 41 
    Male 1465 49 57 1186 59 114 
Number without diagnosis 2807 87 100 2266 119 235 
    Female 1419 50 54 1144 64 107 
    Male 1388 37 46 1122 55 128 
Number of Families with:       
    0 affected 38 2 1 19 0 16 
    1 affected 498 18 14 406 22 38 
    2 affected 553 20 22 449 23 39 
    3 affected 56 0 2 43 4 7 
    4 affected 6 0 1 4 0 1 
    5 affected 1 0 0 1 0 0 
AA=African American, CAUC=Caucasian, HISP=Hispanic, OTHER=other, 
UNK=unknown, or more than one ethnicity.  
 
102 
 
 
Figure 5-1 - Pedigree structure of ASD families bearing the P11S variant.  
17 ASD families in total were identified to harbor the variant. Individuals carrying 
the variant are marked with asterisks. Individuals for whom DNA was not 
available are marked N/A. Our strict analyses considered individuals affected if 
they met criteria for autism on the ADI-R diagnostic algorithm (completely filled 
black). Our broad analyses considered these individuals and individuals who met 
the AGP criteria ASD1 or ASD2 as affected (half filled black) (see [295] for 
details); note no individuals met ASD2. Unfilled individuals are considered 
unknown.  For individuals who did not meet broad criteria Social Responsiveness 
Scale (SRS) t-scores from teacher (/parent) report are provided when available.  
SRS scores ranging from 60-75 are considered mild to moderate range for ASD; 
children with high functioning autism may score in the t-score range of 55-59. 
AGR 80-4 had significant language delay and impairment per the ADI-R, but did 
not meet our broad criteria or have a SRS.  Individuals with definite seizures per 
the ADI-R are marked SZ = 2; those with suspected seizures per the ADI-R are 
marked SZ = 1.  
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Table 5-2. Transmission statistics, parental origin and genotype relative 
risk estimates are provided for the Pro11Ser (C87T from NM_021912) 
variant rs25409. 
Affection
Parental 
origin
Fams.
Informative 
Trans.
P11 (C)  
Observed 
Trans. 
P11 (C) 
Expected 
Trans.  
S11 (T) 
Observed 
Trans. 
S11 (T) 
Expected 
Trans. 
χ
2 P
Genotype 
Relative Risk
Both parents 17 24 9 12 15 12 1.5 0.220 1.67 (0.73-3.81)
Maternal 11 16 4 8 12 8 4.0 0.046 3.00 (0.97-9.30)
Paternal 6 8 5 4 3 4 0.5 1.000 0.60 (0.14-2.51)
Both parents 17 21 7 10.5 14 10.5 2.3 0.130 2.57 (1.01-5.86)
Maternal 11 14 2 7 12 7 7.1 0.008 6.00 (1.34-26.81)
Paternal 6 7 5 3.5 2 3.5 1.3 0.250 0.40 (0.08-2.06)
Spectrum
Strict
  
 
Exploratory parent-of-origin tests were also conducted using a log-linear 
model framework allowing for a maternal genetic effect [299]. Application of this 
approach allowed us to exclude the possibility that a simple effect of maternal 
genotype, in which offspring of mothers with the S11 allele were at increased risk 
of developing autism regardless of whether the S11 allele was transmitted to the 
offspring, accounted for our observations, since there was clearly preferential 
transmission of the S11 allele to affected offspring of heterozygous mothers.  
Using either a broad or a strict autism phenotype, this parent-of-origin effect was 
statistically significant (p=0.040 and p=0.004 respectively).  Although it is 
theoretically possible that there could be a direct effect of maternal genotype on 
offspring risk of autism in addition to the parent-of-origin effect that I have 
established, we have little power to test for a maternal effect in the presence of a 
parent-of-origin effect. A fully developed test for such joint effects would require a 
more fully characterized sample with ascertainment of all affected and unaffected 
offspring from both mothers and fathers carrying this risk allele.   
The GABRB3 P11S mutation was recently identified in 2 independent families 
segregating for CAE in a Hispanic/Mexican-American cohort of 48 families [300]. 
Self report data for the families genotyped in our study suggested that the S11 
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variant was on a non-Hispanic Caucasian background.  To resolve uncertainty 
about ancestry, and to ensure that an appropriate control sample was used, we 
examined genome-wide SNP data available for a subset of subjects from the 
Autism Genetics Resource Exchange (AGRE) collection, which was previously 
genotyped using the Affymetrix 5.0 (500k) SNP platform [135].  Multidimensional 
scaling (MDS) of SNP genotype data for all AGRE parents was conducted using 
PLINK to estimate dimensions of population genetic variation [225].  Figure 5-2 
shows a graphical representation of the first two dimensions from this analysis 
that identified population substructure and ancestral clusters for founders 
(parents). Our analysis found that the S11 variant was present in Caucasian 
parents.  The rare S11 variant had a frequency of 0.94% (7/743) and 0% (0/105) 
in Caucasian and Hispanic founders, respectively, though only 75 families 
screened were determined to have Hispanic ancestry.  Given the mixed ancestral 
history of Hispanic populations with Spanish Caucasians and Native Americans, 
it is not surprising that the variant was identified previously in a Hispanic sample.  
The total S11 frequency was 0.48% in the overall sample. 
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Figure 5-2 – MDS plot of all AGRE parents carrying the S11 risk allele  
Black dots represent parents with p11s mutation. Out of 22 AGRE samples with 
rare variation, 7 are founders with AGRE Affy 5.0 genome-wide data available. 
Classical multidimensional scaling (MDS) was conducted in PLINK using the total 
sample of AGRE parents in order to estimate dimensions of population genetic 
variation. These dimensions are estimated from genome-wide average 
proportion of alleles shared by state for each possible pair of individuals in the 
sample. Graphical representation of the first two dimensions is used to identify 
population substructure and ancestry clusters.  
 
Phenotypic Correlates of P11S in Autism 
Given the association of the S11 mutation with CAE, I examined item level 
data from the Autism Diagnostic Interview-Revised (ADI-R)[27] on seizure 
history.  The rate of confirmed non-febrile seizures was 16.7% (2/12) in affected 
probands with the maternal S11 compared to 4.9% (55/973) for those 
homozygous for the P11 allele, but this difference was not significant (P = 0.10; 
Table 5-3). Seizure rates in autism increase with age, however, age did not 
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significantly differ between the maternal S11 (M = 97 mos ± 45) and homozygous 
P11 (M = 94 mos  ± 52) groups, t(1137) = -0.18, P = 0.86.  
 
Table 5-3. Frequency (% within group) of seizures in probands with and 
without S11.  
 
Rs25409 
genotype  
None 
(0)
1
 
Possible 
(1) 
Definite 
(2) 
Febrile 
seizures (7) Total 
Mean age 
(sd) (mos) 
Homozygous P11 973 (86) 76 (7) 55 (5) 23 (2) 1127 94 (52) 
P11/S11 
(maternal) 
9 (75) 1 (8) 2 (17) 0 (0) 
12 
97 (45) 
P11/S11 
(paternal) 
1 (50) 1 (50) 0 (0) 0 (0) 
2 
48 (28) 
1 
Score on ADI-R item “Faints/fits/seizures.”  A score of 7 means “Febrile convulsions only, with 
no continuing daily medication outside the period of fever.”  Individuals with definite seizures with 
S11 were from different families.  Seven sibling pairs homozygous P11 reported definite seizures; 
the remaining 41 individuals homozygous P11 with definite seizures were from different families. 
 
Tables 5-4 and 5-5 provide characteristics of probands with maternally- 
and paternally-derived variants, respectively.  Inspection of S11 pedigrees 
indicates that maternal transmission results in a narrowly-defined autism 
phenotype based on standard diagnostic algorithms including the ADI-R.  To 
further explore P11S phenotypic correlates, I compared ADI-R dimensions 
between the maternal S11 to the homozygous P11 cases.  Individuals with the 
paternal S11 were considered unknown for these analyses and omitted since the 
variant was not significantly over-transmitted from fathers to individuals with 
ASD.  Table 5-6 shows the results for the comparison of groups’ domain and 
subdomain scores.  The maternal S11 and homozygous P11 groups did not 
significantly differ on any domain score.  The maternal S11 group scored more 
severely than the homozygous P11 group on the subdomain “Stereotyped, 
repetitive, or idiosyncratic speech” and less severely on “Preoccupations with 
part of objects or non-functional elements of material.”  There was no significant 
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difference in ADI-R item level data between groups where the maternal S11 
cases were more severe at the P < 0.01 level. 
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Table 5-4. Description of affected individuals with maternally inherited S11. 
(See legend on next page.) 
  AGR 80-3 
AGR 
116-4 
AGR 
285-3 
AGR 
285-4 
AGR 
520-3 
AGR 520-
4 
AGR 
1147-301 
AGR 
1147-
302 
Sex F M F F M M M M 
Epilepsy Possible Possible No No No Confirmed Confirmed No 
Age head 
circumference 
(yrs) 8 -- 12 9 -- -- -- 9 
Head 
circumference 
(%ile) 82 -- 98 98 -- -- -- 90 
Autism 
phenotype Strict Strict Strict Strict Strict Strict Strict Strict 
ADOS 
classification Autism -- Autism Autism -- -- Autism Autism 
Age IQ test 
(yrs) -- -- 12 9 -- -- -- -- 
Verbal IQ -- -- 72 43 -- -- -- -- 
Non-verbal IQ -- -- 83 83 -- -- -- -- 
ADI-R                 
Age ADI-R 
(yrs) 6 17 9 7 11 6 8 6 
Classification Autism Autism Autism Autism Autism Autism Autism Autism 
Social domain 22 28 16 25 28 27 28 26 
Communication 
domain verbal    9 16 26 19   
Communication 
domain non-
verbal 13 14     14 14 
Restricted, 
repetitive 
behavior 
domain 5 8 4 4 11 5 4 4 
Age 1
st
 words  Regression 96 11 14 38 38 16 32 
Age 1
st
 phrases DNA 114 13 33 38 48 18 38 
Any language 
regression SP,W,S,A No No No No No SP,W,A No 
Any regression 
of other skills C,S,P,SH,M No No No No No S No 
Anxiety Absent Absent + + ++ ++ -- -- 
Aggression ++ ++ + ++ ++ -- ++ ++ 
Overactivity ++ +++ Absent Absent ++ Absent -- -- 
Savant skills M MEM,R MEM,C Absent D Absent Absent Absent 
Age 1
st
 steps  18 12 11 11 12 15 12 10 
Odd gait + + No + +++ ++ ++ ++ 
Gross or fine 
motor 
difficulties GF None F None GF GF -- -- 
Age urinary 
continence  -- -- -- -- -- -- DNA DNA 
Age bowel 
continence  DNA DNA 45 45 24 52 DNA DNA 
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Sex (M: male, F: female); Epilepsy designation comes from the ADI-R item “history of seizures” 
and the AGRE physical examination when available; Classification “Autism” met autism cut-offs 
on the ADI-R algorithm; Level of language (NV: non-verbal or fewer than 5 words used/day, V: 
verbal, fluent with daily phrase speech); Language regression (SP: speech, W: 5+ words, S: 
syntax, A: articulation); Regression of other skills (C: communication, S: social, P: physical, SH: 
self-help, M: motor); Anxiety includes social anxiety and fears (+ mild to +++ most severe); 
Aggression includes to family members, others, and self-injury (+ mild to +++ most severe); 
Savant skills (M: music, MEM: memory, R: reading, C: computational, D: drawing); Gait 
abnormality (+ mild to +++ most noticeable); Bowel: age of continence (DNA – did not achieve 
continence at time of interview);  ADOS classification of “Autism” met autism cut-offs on the 
ADOS algorithm. 
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Table 5-4 (continued). Description of affected individuals with maternally 
inherited S11. (See legend on page 109.) 
  
AGR 
911-3 
IOW 
2427-5 
TUF 
5019-1 
VAN 3522-
100 SD2 SD3 
Sex M M M F M M 
Epilepsy No No No No No Yes 
Age head 
circumference 
(yrs) -- -- -- -- 4.5 4.9 
Head 
circumference 
(%ile) -- -- -- -- 99 84 
Autism 
phenotype Strict Strict Strict Strict Strict Strict 
ADOS 
classification -- -- -- Autism 
-- -- 
Age IQ test 
(yrs) -- 
-- -- -- 
8 6 
Verbal IQ -- -- -- -- 89 49 
Non-verbal IQ -- -- -- -- 117 46 
ADI-R             
Age ADI-R 
(yrs) 4 13 7 5 12 6 
Classification Autism Autism Autism Autism Autism Autism 
Social domain 20 20 15 26 24 28 
Communication 
domain verbal   18 20  21 20 
Communication 
domain non-
verbal 11   13   
Restricted, 
repetitive 
behavior 
domain 3 5 7 3 13 9 
Age 1
st
 words  15 12 -- Regression 24 30 
Age 1
st
 phrases DNA 16 -- Regression 36 60 
Any language 
regression No SP,W,S,A No SP,W,S,A -- -- 
Any regression 
of other skills No No No No -- -- 
Anxiety -- -- ++ ++ -- -- 
Aggression ++ ++ ++ Absent -- -- 
Overactivity ++ ++ +++ Absent -- -- 
Savant skills -- Absent M M -- -- 
Age 1
st
 steps  12 Typical 14 13 -- -- 
Odd gait + ++ No + -- -- 
Gross or fine 
motor 
difficulties -- F GF GF 
-- -- 
Age urinary 
continence  -- 54 39 DNA 
-- -- 
Age bowel 
continence  -- 54 51 DNA 
-- -- 
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Table 5-5. Description of affected individuals with paternally inherited S11. 
(See legend page 107.) 
  IOW 
2368-4 AGR 128-4 AGR 210-4 CHI 1 
Sex M F M M 
Epilepsy -- No Possible -- 
Age head circumference 
(yrs) 
-- -- -- -- 
Head circumference (%ile) -- -- -- -- 
Autism Phenotype Strict Unknown Broad Strict 
ADOS classification 
-- Not spectrum or 
autism 
Not spectrum or 
autism 
-- 
Age IQ test (yrs) -- 14 -- 9 
Verbal IQ -- 117 -- 77 
Non-verbal IQ -- 97 -- 95 
ADI-R         
Age ADI-R (yrs) -- 6 2 9 
Classification Autism Broad Spectrum Not Quite Autism Autism 
Social domain -- 3 23 24 
Communication domain 
verbal  
-- 3  
14 
Communication domain 
non-verbal 
--  11 
 
Restricted, repetitive 
behavior domain 
-- 6 2 
5 
Age 1
st
 words -- 18 DNA 15 
Age 1
st
 phrases -- 21 DNA Normal 
Any language regression -- No -- -- 
Any regression of other 
skills 
-- No -- 
-- 
Anxiety -- + Absent -- 
Aggression -- Absent -- -- 
Overactivity -- Absent Absent -- 
Savant skills -- MEM,R,C -- -- 
Age 1
st
 steps -- 11 -- -- 
Odd gait -- No ++ -- 
Gross or fine motor 
difficulties 
-- No No -- 
Age urinary continence -- -- -- -- 
Age bowel continence  -- 36 DNA -- 
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Table 5-6. Comparison of Autism Diagnostic Interview-Revised domain and 
subdomain scores for individuals with maternally inherited S11 and 
homozygous P11. 
  S11 (maternal)/P11   P11/P11   ANOVA
1
 
 Measure Mean SD n   Mean SD n   F df P 
Domain (WPS label
2
)              
Qualitative Impairments in 
Reciprocal Social 
Interaction (A) 
23.4 4.7 12  23.0 5.0 1448  0.08 1, 1457 0.78 
Communication: Verbal (B) 18.0 5.5 6  17.4 3.9 916  0.16 1, 919 0.69 
Communication: Non-
verbal (B) 
13.2 1.2 6  12.6 1.7 532  0.49 1, 535 0.49 
Repetitive Behaviors and 
Stereotyped Patterns (C) 
5.3 2.3 12  6.1 2.2 1448  2.04 1, 1457 0.15 
Subdomain (WPS label)            
Failure to use nonverbal 
behaviors to regulate social 
interaction (A1) 
4.4 1.4 12  4.3 1.6 1448  0.04 1, 1457 0.84 
Failure to develop peer 
relationships (A2) 
6.8 1.5 12  6.5 1.6 1448  0.32 1, 1457 0.57 
Lack of shared enjoyment 
(A3) 
4.8 1.5 12  5.1 1.3 1448  0.35 1, 1457 0.56 
Lack of socioemotional 
reciprocity (A4) 
7.4 2.1 12  7.2 2.1 1448  0.09 1, 1457 0.77 
Lack of, or delay in, spoken 
language and failure to 
compensate through 
gesture (B1) 
6.5 2.1 12  6.1 2.1 1448  0.35 1, 1457 0.56 
Lack of varied spontaneous 
make-believe or social 
imitative play (B4) 
4.8 1.6 12  5.1 1.2 1448  0.78 1, 1457 0.38 
Relative failure to initiate or 
sustain conversational 
interchange (B2V) 
3.7 0.8 7  3.6 0.8 887  0.08 1, 890 0.78 
Stereotyped, repetitive or 
idiosyncratic speech (B3V) 
5.7 1.5 6  4.1 1.9 916  4.13 1, 919 0.04 
Encompassing 
preoccupation or 
circumscribed pattern of 
interest (C1) 
1.0 1.3 12  1.5 1.3 1446  1.93 1, 1455 0.17 
Apparently compulsive 
adherence to nonfunctional 
routines or rituals (C2)
3
 
1.2 1.5 12  1.4 1.3 1352  0.10 1, 1360 0.75 
Stereotyped and repetitive 
motor mannerisms (C3) 
1.7 0.7 12  1.6 0.7 1447  0.27 1, 1456 0.60 
Preoccupations with part of 
objects or non-functional 
elements of material (C4) 
1.4 0.7 12   1.7 0.5 1448   4.52 1, 1457 0.03 
1
 Test statistic for independent variable of genotype group (maternally inherited S11/P11 vs. P11/P11).  Age was included 
in as a covariate in all ANOVAs, and was significant (p<.05) for all but the following domains and subdomains: BV, A2, A4, 
B1, B2V, and B3V.  The maternally inherited S11 group (n = 12, M = 97 mos, SD = 45) did not significantly differ from the 
homozygous P11 group (n = 1448, M = 95, SD = 57) in age, t(1458) = 0.15, P = 0.89. 
2 
WPS label refers to the abbreviation of the domain or subdomain on the scoring algorithm of the Western Psychological 
Services (2003) version of the Autism Diagnostic Interview-Revised. 
3 Some individuals were missing data for this subdomain. 
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Functional Analysis of the P11S Variant 
To identify the molecular defect underlying the genetic association, a P11 and 
S11-encoding human β3 subunit cDNAs were engineered for in vitro studies in 
HEK293T cells. β3 subunits are incorporated into hetero-pentameric complexes 
at the cell surface (e.g. synapses), and the most common combination involves 
co-assembly of β3 with γ2 and α3 subunits during development and/or α1 
subunits in the adult brain.  Therefore, I co-expressed both wild-type and mutant 
β3 subunits with either α1 or α3 and γ2S subunits.  The γ2S subunit was used 
instead of the γ2L subunit since it is much more abundant in the brain.  To mimic 
the heterozygous condition seen in patients, equal amounts of wild-type β3(P11) 
and mutant β3(S11) subunits were co-transfected with α3 and γ2S subunits 
(Figure 5-3a and 5-3b).  Compared with wild-type α3β3γ2S receptors, mutant 
receptors displayed reduced peak current amplitudes with either mixed 
β3(P11)/β3(S11) subunit expression or with only mutant β3(S11) subunit 
expression, and the amplitude reduction was greater with expression of only 
mutant β3(S11) subunits than with the mixed condition.  Reduced receptor 
function in the context of the more developmentally relevant α3β3γ2S subunit 
combination is consistent with recent findings by Tanaka and colleagues [300]. 
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Figure 5-3 - Mutant β3(S11) subunit harboring receptors had reduced 
current and subunit  surface expression. (A) Human GABAA receptor currents 
were obtained from HEK 293T cells co-transfected with α3 and γ2S subunit 
cDNAs and wild-type β3(P11) and the mutant  β3(S11) subunit for wild-type (wt 
α3β3γ2S 1:1:1 cDNA ratio, black), mixed of the wild-type β3(P11) and mutant 
β3(S11) (1:0.5:0.5:1, mix, green) or for mutant (mut α3β3(S11)γ2S) and evoked 
with 1 mM GABA for 6 sec (A).  In A arrows indicates the peak of each actual 
trace.  (B) The mean peak amplitude of each group was plotted (n = 10 for wt, n 
= 15 for mix, n = 13 for mutant from three different transfections).  (C) HEK 293T 
cells co-transfected with α1, β3HA (wt) or β3(P11S) HA (mut) and γ2S subunit 
cDNAs. Equal amounts of membrane-bound protein from live cells cell 
biotinylation, were pulled down with immobilized streptavidin, eluted with 1X NEB 
glycoprotein protein denaturing buffer (5% SDS, 0.4 M DTT) at room temperature 
for 30 min. The eluted products were then incubated in absence (U) or presence 
of PNGAse F (F) for 1hr at 37°C before fractionated by 10% SDS-PAGE and 
probed with monoclonal anti-HA antibody. (D) The relative amount of surface β3 
HA  subunit protein of wild-type and mutant receptors from C was plotted (n  = 4). 
In B and D, the data were plotted as mean ± SEM, *P < 0.05, **P < 0.01, ***P < 
0.001 vs. wild-type).  
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The reduction of mutant receptor channel current could be due to a 
reduced number of functional receptors.  I expressed α1 and γ2S subunits with 
β3(P11)HA and β3(S11)HA subunits and used surface biotinylation to determine 
the relative expression of wild-type and mutant β3 subunits.  Cell surface 
membrane proteins were isolated following biotinylation of live cells expressing 
wild-type α1β3(P11)HAγ2S receptors or mutant α1β3(S11)HAγ2S receptors and 
treated with PNGase F to remove all carbohydrates attached in the ER and 
trans-Golgi.  Products were then fractionated by SDS-PAGE and immunoblotted 
with anti-HA antibody.  Both mutant β3(S11)HA and wild-type β3(P11)HA 
subunits on the cell surface appeared to the same size both before and after 
PNGase treatment, indicating likely signal peptide cleavage for β3(S11) subunits 
(Figure 5-3C) as for wild-type subunits.  Confirmation of signal peptide cleavage, 
however, will require verification by protein sequencing.  While mutant β3(S11) 
subunits were trafficked to the cell surface, when compared to wild-type 
β3(P11)HA subunits, mutant β3(S11)HA subunit levels were reduced both before 
(U) (1 vs. 0.4637 ± 0.062; P < 0.0017) and after PNGase F treatment (F) (1 vs. 
0.3799; P < 0.0092) (Figure 5-3D). 
Our data are consistent with a molecular defect produced by the P11S 
substitution that occurs at a post-translational level, with mutant subunits 
exhibiting abnormal intracellular processing.  Wild-type β3(P11)HA or mutant 
β3(S11)HA subunits were co-expressed in HEK293T cells with α1 and γ2S 
subunits.  Compared to wild-type β3(P11)HA subunits, mutant β3(S11)HA 
subunits had a small but significant reduction in protein intensity (1 vs. 0.7316 ± 
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0.1270; P = 0.0012, N = 7).  Although surface β3(S11) subunits appeared to 
have the same molecular mass as wild-type β3(P11) subunits, it was possible 
that if the signal peptides attached to mutant β3(S11) subunits were not cleaved, 
the subunits might not fold and oligomerize properly, and thus, would be retained 
inside cells instead of trafficking to the surface. I thus determined the molecular 
mass of mutant β3(S11) subunit from total cell lysates.  Total wild-type 
(α1β3(P11)HAγ2S) or mutant (α1β3(S11)HAγ2S) receptors were digested with  
PNGase-F, which removes all carbohydrates attached in both ER and trans-
Golgi regions,  Without treatment (U), both wild-type β3(P11)HA and the mutant 
β3(S11)HA subunits migrated in a main band at ~58-60 kDa, although a faint 
band with a lower molecular mass representing different glycosylation form was 
also observed.  With PNGaseF (F) treatment, both the wild-type β3(P11)HA and 
mutant β3(S11)HA subunits migrated in a single main band with the same 
molecular mass about 52 KDa consistent with previous reports [301,302], 
suggesting that the majority of wild-type and mutant β3 subunits had successful 
signal peptide cleavage (Figure 5-4C).  I also used 35S methionine metabolic 
labeling to characterize biogenesis of wild-type β3FLAG and mutant β3(S11) 
FLAG subunits.  When expressed alone, both wild-type and mutant subunits 
migrated in two bands, with the higher molecular mass band representing a more 
mature form and the lower band representing a less mature form (Figure 5-4D).  
Compared to wild-type subunits, the ratio of the higher molecular mass band to 
the lower band was lower for mutant subunits as soon as 10 min after translation 
(Figure 5-4E).  The same molecular mass of wild-type β3(P11) and the mutant 
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β3(S11) subunits after PNGase F digestion suggested that the signal peptides 
were both cleaved.  The slightly reduced total amount of mutant β3 (S11) subunit 
protein suggested that mutant subunits were not as stable as wild-type subunits. 
Figure 5-4 – (next page) Mutant β3(P11S) subunit protein had impaired 
intracellular processing.   
(A) HEK 293T cells co-transfected with α1 and γ2S subunits with HA tagged 
β3(P11)HA (Wt) or β3(S11) HA (mut) subunit cDNAs. Equal amounts of total 
lysates protein were analyzed by 10% SDS-PAGE and probed with monoclonal 
anti-HA and with monoclonal anti-Na+ K+ ATPase antibody as internal loading 
control. (B) The relative amount of surface β3HA  subunit protein versus loading 
control of wild-type and mutant receptors from A was plotted (n = 7)  (C) Equal 
amount of total cell lysates from A  were undigested (U) or PNGase-F (F) at 37°C 
for 3 hr.  (D-E) HEK 293T cells containing pulse-chase 35S methionine radio-
labeled wild-type β3FLAG (W) and mutant β3(S11)FLAG (M) subunits were pulse-
labeled for  a series of time points.  The cells were lysed and the same amount of 
protein for each sample was used for immunopurification and SDS-PAGE (C).  
The relative ratio of radioactivity of the upper versus lower band is plotted at each 
time point for either the wild-type or mutant subunits (D, n = 4 ).   
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Part 2: Investigation of Common Allelic Association of GABRB3 with 
Autism 
 
 
 
Subjects and Methods 
Subjects 
The sample used for association analysis contained 961 families with 
evidence of ASDs. Families were excluded from analysis if there was a diagnosis 
or significant indicator of non-idiopathic autism (e.g. fragile-X syndrome, 
dysmorphic features, neonatal trauma). The majority of samples were obtained 
from the NIMH Center for Collaborative Genetic Studies on Mental Health 
Disorders. The balance were ascertained through the Tufts-Vanderbilt University 
consortium. In Autism was assessed by the Autism Diagnostic Interview (ADI or 
ADI-R), Autism Diagnostic Observation Schedule (ADOS) or both. For purposes 
of this study, those who met criteria for autism or ASD by either or both of these 
measures were considered “affected” in the association study. Of our families, 
4% percent of families were of African-American origin, 7% of Latino origin, 4% 
of Asian origin, 83% of Caucasian origin, and 2% of unknown origin. In our 
sample, 81% of those with autism were male (Table 5-7).  
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Table 5-7. Characteristics of families genotyped by ascertainment center.  
 
  ALL AGRE IOW STA TUF VAN 
Families 961 538 90 128 113 92 
Individuals 4039 2524 377 515 401 222 
Number with autism 1629 996 158 243 157 75 
    Female 305 207 18 44 25 11 
    Male 1324 789 140 199 132 64 
Type of families:       
    Simplex 298 131 27 22 55 63 
    Multiplex 663 407 63 106 58 29 
AGRE=Autism Genetics Resource Exchange, IOW=Iowa, STA=Stanford, TUF=Tufts, 
VAN=Vanderbilt  
 
 
Tag SNP Selection 
Tag SNPs were selected from markers spanning all 10 exons of GABRB3 
using HapMap data and Haploview’s implementation of Tagger 
(http://www.broad.mit.edu/mpg/haploview/) (Table 5-8 and Figure 5-5). Given the 
primarily Caucasian makeup of our sample, 30 CEPH parent-offspring trios were 
used for the estimation of haplotype blocks, and tag SNPs were selected so that 
each had a minimum pairwise r2 of 0.7 with other HapMap genotyped SNPs with 
MAF greater than 0.05. 
 
Genotyping 
Markers meeting criteria were ordered from Applied Biosystems (Applied 
Biosystem, Foster City, CA, USA) as Taqman Assays-on-Demand (AoDs). 
Taqman genotyping reactions were performed in a 5-µl volume in 384 well plates 
in accordance with manufacturer’s recommendations. Cycling conditions 
included an initial denaturation at 95°C for 7 min, followed by 50 cycles of 92°C 
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for 15 s and 60°C for 1 min. Samples were analyzed using an ABI 7900HT 
(Applied Biosystems) Sequence Detection System. Genotypes were 
automatically called if there was 95% confidence by the software calling 
algorithm that the call was correct. 
 
Quality control 
Pairs of three control samples were included per 96-well sample plate; 
concordant genotypes were required for each of the plates to pass QC. The 
Pedcheck script was used to check for Mendelian inconsistencies [223]. 
Genotyping efficiencies for all 60 markers were between 95 and 99 percent. 
Tests for conformity of the data to expectations under Hardy-Weinberg 
equilibrium (HWE) P-values were conducted for each SNP using Haploview 
[222]. 
 
LD and transmission analysis 
Pair-wise linkage disequilibrium (r2) was calculated for each SNP pair 
using Haploview [222]. FBAT was employed to test for association by 
considering transmissions to probands [263]. We carried out analysis in four 
groupings of our dataset: the overall dataset, the AGRE family dataset, the non-
AGRE family dataset, and a “replication” dataset which consisted of the entire 
dataset with the 189 families previously genotyped by our group in an earlier 
study removed [105].  
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Results 
Association results for GABRB3 SNPs with autism are shown in Table 5-8, 
which also lists the SNPs genotyped, position, alleles and FBAT P values 
detailed. The Family Based Association Test with the –e option was used under 
an additive model. This test measures overtransmission of alleles from 
heterozygous parents to affected offspring and generates a statistic based on 
what would be observed under a null hypothesis of no association. This was 
done on four groups: the overall dataset (ALL), the AGRE sample (AGR), the 
non-AGRE sample (NONAGR) and the independent replication sample 
(REPLICATION). Those SNPs that were previously significant in our previous 
study (McCauley et al.) are highlighted in purple [105]. SNPs significant in recent 
genotyping by Curran et al. are highlighted in light blue [107]. SNPs flanking the 
155CA-2 microsatellite are highlighted in green [106,283]. Since only two SNPs 
(14 and 23) met significance levels of P<0.05 in the overall dataset, eight SNPs 
in the AGR only set (10,12-14,27, 31, 32, and 55), no SNPs in the NONAGR set, 
and one SNP in the ALLEXJAKE set (23), I decided that I would pursue these 
SNPs further. In addition, since four of these nine SNPs fall within the first 
haplotype block (SNPs 2-14) [see Figure 6 for LD),  in the 3´ terminal of GABRB3 
containing all of the GABRB3 terminal exons 4-9, it was decided that the SNPs 
composing this block would be a focus of closer investigation.  
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Table 5-8. GABRB3 association results in ALL families, AGRE, non-AGRE, 
and the Replication dataset. 
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GABRB3 association results
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Figure 5-6 Plot of FBAT –e log10 P values for overtransmitted alleles. 60 
SNPs genotyped in GABRB3 are shown under the FBAT –e test. The –e option 
estimates the empirical variance and is more reliable when linkage has been 
established and provides a more conservative estimate of association.  Results 
here are shown for all SNPs under the additive model. SNPs indicated above 
with numbers (see table 5-8 for marker names) showed nominal evidence of 
transmission ( P < 0.05 ) in one of four subsets of the data. A Haplotype block 
which includes SNPs 1-14 showed prior evidence of transmission bias in an 
earlier study. Only SNPs in this block and those indicated by number outside of 
the block were selected for further analysis. 
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The SNPs in the first block (1-14) and SNPs 23, 27, 31, 32, and 55 listed 
above as significant in one of the four groups were investigated in the same four 
groups more closely under a dominant model. The results are shown below in 
figure 5-7.  
SNP31,
rs878961,
P = 0.00007
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Figure 5-7 Plot of FBAT –e log10 P values under a dominant model.  The 14 
SNPs in the first haplotype block, as well as SNPs 23, 27, 31, 32, and 55 which 
showed evidence of association under the additive model were analyzed for 
transmission disequilibrium using the FBAT –e option under a dominant model.  
As can be seen, one SNP, SNP 31 showed strong evidence of association in the 
overall, AGRE, and replication dataset under the dominant model. 
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Discussion 
Rare Variant P11S and its Role in Autism 
I have shown that a rare coding variant of the GABRB3 gene is associated 
with autism when transmitted maternally.  Statistical association is explained by 
an intracellular processing defect imparted by the N-terminal P11S substitution in 
the signal peptide.  While the S11-encoded signal peptide is cleaved, molecular 
evidence indicates that the S11 signal peptide defect results in reduced surface 
expression and resultant decreased receptor current, probably due to abnormal 
intracellular processing, intracellular retention and fast degradation of the mutant 
subunit.  I suggest that impaired GABAergic signaling during a critical time 
window in brain development could lead to both autism and CAE, and possibly 
other more subtle neurological phenotypes. 
A problem inherent in the study of rare variants is the difficulty in amassing 
a sufficiently large clinical sample to detect risk effects in the absence of full 
penetrance. Such is the case for P11S.  While maternal association is significant, 
it is nevertheless a modestly-significant statistical finding for an allelic 
association.  It is important therefore to consider these results in the context of 
recent and emerging rare variant findings in autism.  By and large, these take the 
form of CNVs, and there is a growing list of genes or regions (e.g. NRXN1, 
SHANK3, 16p11.2) identified as “autism loci”  based upon observed de novo 
variants, but for which other cases show inherited gene disrupting variants 
[61,101,111,128,135].  Such cases reveal incomplete penetrance of such (e.g.) 
loss-of-function mutations for a given gene.  Indeed families may show 
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unexpected segregation patterns with only one of two affected sibs receiving the 
variant or both an affected and unaffected sib inheriting the variant. The pattern 
is much the same for P11S.  The fact that even maternal duplication of the 
GABRB3 containing 15q11-q13 region does not always manifest with autism, 
along with the complex epigenetic regulation of the genes in the region, may 
provide a lens through which to view a potential mechanism [279,290]. 
GABRB3 is known to play a major role in development of the CNS, being 
the major β isoform in a number of regions in prenatal and neonatal brain 
[285,286,289]. The result of Gabrb3 disruption in the mouse is a useful 
comparison, given the effect of P11S substitution in families segregating autism 
and epilepsy.  In the 10% of null animals that survive to maturity, epilepsy and 
hypersensitivity and various other behavioral and physiological  abnormalities are 
noted [290]. Null mice produce fewer functional GABAA receptors, and 
pharmacological evidence indicates that other β subunits do not compensate for 
the absence of β3 [291]. The Gabrb3 knock-out has been proposed as an autism 
model because of reduced social and exploratory behaviors and a tendency for 
diminished nurturing behaviors. 
In light of the epigenetic regulation of 15q11-q13 genes, and that it is 
typically maternal, but not paternal duplication of the interval leads to autism, the 
S11 association is provocative. Maternal bias implicates UBE3A in the dup(15) 
autism phenotype, however, a contiguous gene effect including GABRB3 is very 
likely [303]. Supporting potential contribution of GABRB3 in causing dup(15) 
autism, several genetic and epigenetic studies have independently implicated the 
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GABRB3 gene in autism in the absence of duplication 
[104,105,106,107,194,198,283]. While genetic studies of common allele effects 
are largely positive, the data suggest allelic heterogeneity, with associations seen 
in two or more regions at the GABRB3 locus [105,106,107,283]. Maternal 
inheritance has also been noted in genetic epilepsies [304,305], and given the 
maternal specificity of dup(15) autism [119,279], we speculate that epigenetic 
effects at GABRB3 may tilt the balance to risk for autism when the origin of the 
S11 variant is maternal. Other studies, including one by Nakatani et al. indicate 
that duplication the syntentic region in mouse is associated with traits common in 
autism, though they observe this paternally and acknowledge that some 
epigenetic controls may be different between human and mouse [306]. Further, 
theirs is a contiguous gene duplication effect where he I report a single point 
mutation in just one of the genes of the region. 
I also speculate that the presence of the mutation in both mother and fetus 
may lead to greater impact at some key developmental stage.  To formally test 
for maternal genotypic effects, analytic approaches must assess any increased 
association due to the sex of the non-transmitting parent.  This would be 
consistent with maternal genotype-created environment interacting with fetal 
genotype to increase risk even more in offspring, as opposed to a classic parent-
of-origin effect.  If S11 effects on maternal environment are important, I would 
expect to see increased risk in S11-carrier offspring of carrier mothers, relative to 
offspring of non-carrier mothers (and carrier fathers).  Tests of maternal and 
parent-of-origin effects have been explored in this sample, allowing us to 
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establish a parent-of-origin effect; I were, however, unable to conduct an 
adequately powered test of whether there are effects of maternal genotype on 
offspring risk of autism in addition to established parent-of-origin effects.   
Epigenetic and expression studies of GABRB3 provide some context for 
considering the observed association, although the picture vis-à-vis parent-of-
origin effects on gene expression is far from clear From their analysis of cerebral 
cortex (BA9) brain samples, Samaco and colleagues reported that levels of 
GABRB3 protein were significantly reduced in five of nine autism samples but not 
in controls [198]. Another study by this group revealed monoallelic expression of 
GABRB3 in one of seven autism frontal cortex samples informative for an exon 
1a SNP, and evidence from deletion PWS and AS samples suggesting the allelic 
bias favors paternal expression [194]. These reports cannot tell us, however, 
whether similar effects might occur during fetal development and in other, 
perhaps more phenotypically-relevant, brain regions.  Nevertheless, the 
possibility that imprinting or allelic bias in gene expression might, like with the 
serotonin 2A receptor gene (HTR2A) be a polymorphic trait, leads us to 
speculate that incomplete penetrance of S11 relates to inter-individual 
differences in gene expression and/or epigenetic regulation of the region [307].  
Spatiotemporal expression of GABAA receptor subunits is controlled 
through the use of alternative initiating exons.  The P11S variant is in exon 1a, 
which like exon 1, expresses an alternative signal peptide. In adult, exon 1-
containing transcripts are more abundant than those containing exon 1a.  
However, the relative abundance of exon 1a transcripts is significantly higher in 
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fetal brain than in adult hippocampus [298]. Thus, an exon 1a variant is more 
likely to exert its effects developmentally, prior to the shift in balance of exon 1a 
to exon1 transcripts.  Indeed, age effects are common in epilepsy, with the 
majority of CAE patients having absence seizures that lessen or abate 
completely with age [308].  
In our phenotype analysis, we asked initially whether or not epilepsy was 
associated with the S11 variant, given the observation of S11 segregating in 
families with CAE[300]. The rate was higher in P11S carriers (14.3%) compared 
with P11 homozygotes (5.2%), but not greater than overall estimates of epilepsy 
in autism (5-38.3%) [309].  Aside from ascertainment biases, the broad range of 
epilepsy estimates may reflect the inherent difficulty in identifying more subtle 
epilepsy and/or EEG abnormalities in autism.  The S11 variant displays 
incomplete penetrance in both autism and published CAE families, and thus 
milder phenotypes may be present in S11 carriers  [310]. As functional data 
indicate that S11 reduces, but does not eliminate, functional GABAA receptors, 
this would not be surprising.   
Molecular defects produced by the P11S substitution in GABRB3 likely 
include impaired GABAergic signaling and cellular homeostasis.  The present 
study provides a direct link between GABAA receptor β3 subunit dysfunction and 
autism, and explains the observed association with epilepsy.  Precedent already 
exists for GABAA receptor subunit dysfunction leading to epilepsy, with mutations 
in the γ2 subunit also associated with CAE [296].  Given the nature of its 
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dysfunction, association of this specific, albeit infrequent, allele with autism and 
epilepsy suggests a potential for individualized treatment in these cases. 
In summary, we report (1) the first example of a GABAA receptor subunit 
gene coding variant statistically associated with autism; (2) the first signal peptide 
mutation associated with autism; and (3) the first evidence for maternal over-
transmission of a coding variant within this known imprinted, autism-associated 
region. Since maternal duplication of 15q11-q13 is the most frequent 
chromosomal and copy number abnormality known to cause autism, it is 
provocative that maternal over-transmission of the more discrete GABRB3 S11 
variant may increase risk for autism and epilepsy. These findings complement 
other common-allele linkage and association studies and provide further support 
for involvement of GABRB3 in autism[105,106,107,185,187,283,284]. It appears 
then that allelic heterogeneity at GABRB3, both common and P11S, act as 
genetic risk factors. We predict for autism, as found for other complex diseases, 
that rare variants possessing greater effect sizes will emerge in genes showing 
association of common alleles conferring more modest effects [88,311]. 
 
Common Variant Association with Autism 
Despite the relatively high levels of coverage employed by our tagging 
strategy, we failed to demonstrate significant association in our region of prior 
association at the 3´ end of GABRB3 in SNPs 1-14. Only SNP 7 showed 
evidence of association in the AGRE dataset under the dominant model. SNPs 
10,12, 13, and 14 showed significance in the AGRE dataset under the additive 
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model, but not in the dominant model. The one SNP which appeared associated 
in the AGRE model for which significance dramatically improved under the 
dominant model was SNP 31, rs878961.  
Results for SNP31 were most significant under a dominant model, which 
is of importance since the most significant result, this SNP31, has a minor allele 
frequency of just 5%. This means that a single copy of the SNP significantly 
increases risk for autism.  This SNP was found significant in the overall dataset, 
AGRE dataset, and replication dataset, that is the dataset with the original 
McCauley et al. families removed. The highly significant P-value is the only to 
survive correction for multiple testing. It may be that we have detected a new 
signal in GABRB3.  
The meaning of this finding is hard to interpret. GABRB3 has a very large 
intron which spans over 150kb of the 230kb transcript. RS878961 lies almost 
precisely in the middle of this massive intron in a region of very low levels of 
conservation and linkage disequilibrium. Nearby are repeat structures, but little 
evidence for other functional regions of DNA and the block of linkage 
disequilibrium is quite short. There are no pre-computed siRNA binding sites 
apparent here. Further, this variant is more than 80kb from the 155CA-2 
microsatellite and over 50kb from SNPs found significant in the studies by Curran 
et al. and McCauley et. al [105,106,107]. This is often the case in so many 
association studies where the variant associated is intronic and the biological 
meaning is thus difficult to interpret.  
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Since this variant is in a region that, from review of the literature, appears 
to be untagged by previous association studies, it will be interesting to see if 
other groups replicate this signal in independent samples.  
The finding of modest association in the 3´ haplotype block restricted to 
the AGRE set appears to be the same finding reported by Curran et al. and is 
most likely a phenomenon of multiplex families. The AGRE set, by its very 
nature, is predominantly multiplex families. When our initial sample from the 
McCauley et al. paper is removed, we find four SNPs 2, 7, 13, and 14 in the 3´ 
haplotype block remain significant (dominant not additive model). This seems to 
indicate that the effect in this block is being driven either A) by the AGRE families 
or B) by multiplex families. Whatever the case, the effect size appears to be 
modest.  
Previously Curran et al. showed association of a haplotype consisting of 
our SNPs 7-9-10-11-14 which was overtransmitted to affected offspring with a P-
value of 0.000019 [107]. Our test for overtransmission of the same haplotype 
indicated this was not a significant overtransmission in our own dataset (P = 
0.8097) using the PLINK haplotype TDT test for the same five SNPs. The sample 
used by Curran et al. was highly heterogeneous including only 55% meeting 
criteria for autism and the rest consisting of Asperger syndrome and PDD-NOS. 
In addition, the subjects in their sample had widely varying IQs.  
Here I have undertaken the task of exhaustively indexing all major alleles 
in the GABRB3 locus. It is reasonable to conclude from the above studies that 
there is little evidence for replication of the association in the 3´ haplotype block 
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in which McCauley et al. and Curran et al. observed prior association [105,107]. 
There was no evidence of association near the 5´ end of the gene in the vicinity 
of microsatellite 155CA-2. However, here we have shown an additional SNP, 
rs878961, with a low minor allele frequency and reasonably strong evidence for 
association with GABRB3 under a dominant model. While interpretation of the 
meaning of the association of this intronic SNP is difficult and the finding of a new 
signal in GABRB3 is more frustrating than exciting, it will be interesting to see if 
the association is replicated in other datasets. 
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CHAPTER VI 
 
ANALYSIS OF SMALLER CNVS WITHIN GABRB3 AND UBE3A 
 
Introduction 
As understanding of autism has evolved and the available technology 
matured, it has become increasingly clear that much of the disorder is genomic in 
nature. Copy number variation (CNV) has emerged in the past few years, driven 
largely by technological advances in genotyping methods which capture not only 
SNP genotype, but also intensity information at adjacent SNPs throughout the 
genome.  In 2004, while the vast majority of the genetics world was focused on 
SNPs and ramping up for the coming explosion of genome wide association 
studies, two papers emerged suggesting copy number variation (CNV) may play 
a larger role in the genomic architecture of humans than previously appreciated 
[120,121]. The early HapMap data was mined looking for runs of Mendelian 
inconsistencies or runs of homozygosity, both of which could suggest CNVs 
[312]. And as Illumina and Affymetrix genotyping technologies matured allowing 
not only the collection of more genotypes, but also the analysis of intensity data 
for genotyped SNPs, an entire field quickly began to mature where CNVs now 
began to be more widely appreciated as having a role in a number of diseases 
previously unappreciated. By one estimate, copy number variable regions 
comprise approximately 12% of the genome [313]. 
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(CNV) has emerged as a previously unknown mechanism, which appears 
to explain a minimum of 10% of diagnosed cases of autism [58,126]. One 
analysis of sporadic autism in trios showed a high rate of de-novo CNVs in 10% 
of 118 patients with autism compared to 1% of controls [58]. This was after the 
exclusion of those with severe MR, dysmorphologies, or other known cytogenetic 
abnormalities. Other studies by the Autism Genome Project and others identified 
NRXN1, SHANK3, 16p11, and other CNVs in ASDs [61,101,111,128,135]. 
The largest genome wide association study in autism to-date over 550,000 
SNPs for 780 families consisting of 1204 cases and 6,491 controls showed very 
few SNPs reaching genome-wide significance, but CNV analysis strongly 
implicated the role of ubiquitin pathway genes in the pathogenesis of the disease 
[172,221]. One of the most commonly identified genes identified in the analysis 
was UBE3A [172].  
Since 15q11-q13 contains UBE3A as well as GABRB3, the two candidate 
genes under study, and is the most frequent CNV seen in autism, it seemed 
reasonable to investigate both of these genes for potential submicroscopic CNVs 
that might impact these genes and their respective proteins. The 15q11-q13 
region has very high levels of repetitive sequences and has been subject to a 
large number of genomic disorders, many of which involve new microdeletions 
and microduplications which manifest with autism, epilepsy, and schizophrenia 
and are frequently characterized by incomplete penetrance [140,141,314]. Partial 
duplication of the GABRB3 gene has previously been reported in a patient, as 
well [315].  
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Validation of findings based on inferences made from genotyping intensity 
data, ROH analysis, or Mendelian inconsistencies is often labor intensive and 
can involve cytogenetic approaches, multiplex ligation probe amplification 
(MLPA), or quantitative polymerase chain reaction (Q-PCR).  
The MLPA method was described by Schouten et al. in 2002 and is a 
method to specifically identify copy number in a large set of genomic targets 
[316]. It involves the placement of two probes adjacent to one another on 
genomic target sequence, followed by their ligation and then amplification by Q-
PCR. Since this is done in multiplex and using multiple reference probes (as 
opposed to a single housekeeping gene) the method is an excellent way to test 
multiple sites in the genome for potential CNVs.  
In the present study, we used the MLPA method, in combination with 
genotype data for UBE3A and GABRB3 and phenotype data from the ADI-R 
identifying those with autism and epilepsy, to determine the extent to which small 
CNVs at these loci may be involved in autism or autism with epilepsy. 
 
Subjects and Methods 
Sample Selection 
Samples were selected from a set from the 961 families genotyped for the 
GABRB3 markers listed in chapter 5, table 5-7; and those genotyped for the 
UBE3A markers listed in chapter 4, table 4-2. In total, I chose 48 samples for 
MLPA analysis. I selected samples using three criteria: (1) ROH scores for 
UBE3A and GABRB3, (2) high levels of inconsistent genotypes, (3) epilepsy, (4) 
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IBD2 for SNPs in GABRB3 and UBE3A. I excluded samples for which low 
genotyping efficiency was achieved at unrelated loci in addition to UBE3A and 
GABRB3 loci. 
 
ROH Analysis 
ROH analysis used the –homozyg function of PLINK and examined both 
UBE3A SNPs independently, GABRB3 SNPs independently, and both sets of 
SNPs together [225]. 
In this study, I used Taqman genotype data for the eight SNPs genotyped 
over UBE3A and 60 SNPs genotyped over GABRB3 and subjected that data to 
ROH analysis to identify samples most likely to be homozygous at SNPs across 
one or both of these genes. SNPs that were homozygous across 50 or more 
SNPs (permitting up to two missing genotypes) across 50 or more SNPs in 
UBE3A+GABRB3, all 8 SNPs in UBE3A, or across 50 SNPs in GABRB3 were 
selected. Since UBE3A exists in a single block of LD and hundreds of samples 
were homozygous for all 8 SNPs, this was less useful criteria. The SNPs 
genotyped were those genotyped in chapters 4 and 5.  Table 6-2 lists those 
SNPs in UBE3A and GABRB3 that were genotyped along with their genomic 
position. In total, these SNPs span 1.5Mb. 
 
Genotype Inconsistency 
Dirty flat files with Mendelian inconsistencies identified by the Pedcheck 
program were used to count up the number of Mendelian inconsistencies over 
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GABRB3 and UBE3A loci. This could indicate cases of UPD that might escape 
ROH analysis which tended to look at SNPs over larger distances. 
 
Identification of Epilepsy 
Since dozens of papers have been reported on a number of 15q13 
microdeletions which result in epilepsy, I used samples with potential epilepsy in 
our analysis. Samples with likely diagnosis of epilepsy were identified based on 
available ADI items as described in the previous chapter 5. The two items of the 
ADI-R used were the answers to the following questions: 
    Has the subject ever fainted of had a fit/seizure/convulsion? 
    Has the subject ever had medicine to control fits? 
The answers to both are 0-no attacks, 1-history suggesting epilepsy, 2-
definite diagnosis of epilepsy, 7-febrile convulsions only. Any family with an 
individual who reported 1, 2, or 7 for either question was considered in one set 
with suspected epilepsy while those with 2 for both answers were also assigned 
to confirmed epilepsy. Those individuals in the “confirmed” category took 
precedence over those in the “suspected category”. 
 
Synthesis 
The top 48 samples by (1) ROH scores for UBE3A and GABRB3, (2) high 
levels of inconsistent genotypes, AND (3) epilepsy shown in table 6-1. I tried, 
when possible, to select individuals who met as many of the criteria cutoffs as 
possible and further those affected sib pairs who showed evidence of IBD2 and 
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concordance for diagnoses of autism and epilepsy. The rationale being that 
chromosome 15 is more likely a source of the genetic etiology of said subjects’ 
disease in cases where sibs are identical by phenotype and genotype. I elected, 
but in rare cases, to genotype only one sib per family.  
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Table 6-1. Samples selected for MLPA analysis. 
Combined ID 
GABA+UBE3A 
homozyg 
UBE3A 
homozyg 
GABRB3 
homozyg Incons 
Broad 
Epilepsy 
Narrow 
Epilepsy 
AGR_138_4 X X X 17     
AGR_567_5 X X X   X X 
AGR_922_301 X X X   X X 
AGR_922_302 X X X   X X 
AGR_543_3 X X X   X   
AGR_293_3 X X     X   
AGR_1072_301 X X X       
AGR_1072_303 X X X       
AGR_111_5 X X X       
AGR_1376_301 X X X       
AGR_1376_302 X X X       
AGR_356_3 X X X       
AGR_450_3 X X X       
AGR_835_5 X X X       
IOW_2843_5 X X X       
IOW_3505_3 X X X       
STA_447_7894 X X X       
TUF_1072_8 X X X       
TUF_6028_103 X X X       
VAN_3507_1 X X X       
VAN_3531_1 X X X       
AGR_1038_303 X X         
AGR_1214_302       19 X X 
VAN_3599_101       17     
STA_235_4508       16     
AGR_240_3       15     
TUF_2004_3       15     
TUF_3057_4       13     
TUF_5012_1       13     
AGR_138_3       12     
AGR_959_301       11     
IOW_2836_4       11     
IOW_2836_5       10     
TUF_1092_4       9     
TUF_2004_1       9     
TUF_2010_1       9     
AGR_1270_301       8     
AGR_1323_301       8     
AGR_521_4       7 X   
AGR_862_302       4 X X 
AGR_548_5     X   X X 
AGR_520_4     X   X X 
AGR_939_303     X   X X 
IOW_2806_5     X   X X 
AGR_1249_302     X   X   
AGR_994_301     X   X   
AGR_1312_302     X       
AGR_164_4     X       
143 
MLPA 
Since MLPA is a relatively new method and validating its reliability was 
essential, I used CEPH control samples, Angelman syndrome samples known to 
be deleted for both UBE3A and GABRB3, as well as samples with duplication of 
chromosome 15q11-q13 as controls. All samples used were checked for DNA 
concentration by use of Nanodrop. The MLPA kit was a product TS-047 custom 
manufactured by MRC-Holland (Amsterdam, Netherlands) and contains 13 
probes for 11 exons of UBE3A, 13 probes for 9  exons of GABRB3 (excluding 
exon 1a) as well as 14 independent reference probes which target independent 
genomic loci. These are shown in table 6-2 along with the length of each 
amplicon, the target probe gene, the right probe oligo (RPO), the left probe oligo 
(LPO) the mapview coordinates of the probe junction, relative chromosome 
position, and targeted exon in the case of non-reference loci. The MLPA protocol 
was performed according to the manufacturer’s protocol available in SALSA 
MLPA Kit TS-047. Probe amplification products were run on an ABI 3730 DNA 
Analyzer using the GS500 size standard (Applied Biosystem, Foster City, CA, 
USA). 
144 
Table 6-2. Probes for MLPA analysis of 9 GABRB3 and 11 UBE3A exons as 
well as 14 independent reference probes for unrelated genomic loci. 
length ampl. probe RPO LPO mapview chr. pos. exon
409 GABRB3 M-02038 LIG-02330 15-024.569103 15q12 1
226 GABRB3 M-10865 LIG-11535 15-024.568953 15q11 2
250 GABRB3 M-10866 LIG-11536 15-024.568896 15q11 2
355 GABRB3 M-10867 LIG-11537 15-024.568655 15q11 3
184 GABRB3 M-10868 LIG-11538 15-024.417665 15q11 4
274 GABRB3 M-10869 LIG-11539 15-024.417552 15q11 4
319 GABRB3 M-10870 LIG-11540 15-024.379640 15q11 5
148 GABRB3 M-10872 LIG-11542 15-024.376510 15q11 6
202 GABRB3 M-10873 LIG-11543 15-024.363971 15q11 7
382 GABRB3 M-10874 LIG-11544 15-024.363881 15q11 7
292 GABRB3 M-10875 LIG-11545 15-024.357380 15q11 8
220 GABRB3 M-01315 LIG-09339 15-024.344242 15q12 9
436 GABRB3 M-10876 LIG-11546 15-024.344314 15q11 9
166 UBE3A M-10877 LIG-11547 15-023.204824 15q11 1
283 UBE3A M-10879 LIG-11549 15-023.201527 15q11 2
373 UBE3A M-10878 LIG-11548 15-023.201674 15q11 2
196 UBE3A M-10880 LIG-11550 15-023.171919 15q11 3
160 UBE3A M-04620 LIG-00863 15-023.167740 15q12 4
427 UBE3A M-10881 LIG-11551 15-023.156677 15q11 5
142 UBE3A M-10883 LIG-11553 15-023.152935 15q11 6
178 UBE3A M-10882 LIG-11552 15-023.153027 15q11 6
310 UBE3A M-10884 LIG-11554 15-023.152177 15q11 7
214 UBE3A M-10885 LIG-11555 15-023.150798 15q11 8
244 UBE3A M-10886 LIG-11556 15-023.150555 15q11 9
256 UBE3A M-01317 LIG-00864 15-023.136395 15q12 10
346 UBE3A M-10887 LIG-11557 15-023.135402 15q11 11
264 Reference probe M-10243 LIG-02149 01-247.075309 01q44
328 Reference probe M-05297 LIG-04685 03-095.102326 03q11.2
364 Reference probe M-02601 LIG-02072 05-176.651646 05q35.3
301 Reference probe M-09986 LIG-10445 07-098.341749 07q21
238 Reference probe M-07642 LIG-07327 08-011.651883 08p23.1
337 Reference probe M-09937 LIG-12248 08-071.291427 08q13
154 Reference probe M-09431 LIG-09680 11-066.148469 11q13
136 Reference probe M-09285 LIG-09516 11-067.950073 11q13.4
418 Reference probe M-08682 LIG-08694 13-099.607548 13q32.3
445 Reference probe M-08404 LIG-08258 15-029.149319 15q13.3
400 Reference probe M-02989 LIG-09994 16-016.188508 16p13.1
172 Reference probe M-03087 LIG-02487 16-003.869877 16p13.3
190 Reference probe M-09979 LIG-10438 19-010.998005 19p13.2
391 Reference probe M-09929 LIG-10388 22-039.866992 22q13.2  
MLPA data was analyzed using the GeneMarker software (SoftGenetics, 
State College, PA, USA) for MLPA analysis. After population normalization, data 
were compared to two different controls: 1) a single control sample, representing 
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the sample with the fewest abnormal calls in each experiment; and, 2) a synthetic 
control sample, which represents the median of all normal (CEPH) samples in 
each experiment, though these methods typically produced virtually identical 
results. A threshold of dosage change <0.75 marked samples as potential 
deletions and changes greater than 1.3 marked potential duplications. 
 
Results 
Validation of Target Amplification in Control Samples 
Since amplicon sizes differ between 6bp and 12bp, each sample produce 
peaks representing the molecular weight of the product and an amplitude 
concordant with its amplification, scaled against the control samples as described 
above. The resultant plots appear as those below in figure 6-1. 
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Figure 6-1. MLPA products analysis for a single sample. Amplicons are 
separated by capillary electrophoresis. Each peak represents the amplification 
product of a specific probe. Here the red peaks are those being tested and the 
blue peak is the synthetic control, which is the average of copy number known 
(CEPH) samples. On the X axis above is amplicon size. On the Y axis is relative 
fluorescent units (RFU) intensity values. 
 
The pilot experiment used only samples with Angelman syndrome, 
duplications of 15q11-q13, and CEPH controls. GeneMarker software uses peak 
ratios to determine gains or losses in a sample. Since the first sample used a 
three Angelman and three dup(15) samples, it would be expected to be easy to 
distinguish the two from one another. In the graph below, one can see the clear 
discrimination of Angelman samples from dup(15) autism samples. 
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Angelman syndrome
Dup(15) autism
 
Figure 6-2. MLPA peak ratios for Angelman and Dup(15) samples. Here the 
blue dots between the green lines represent a normal copy number. Blue dots 
represent reference probes located at genomic loci on chromosomes separate 
from 15q. The red dots are the probes for UBE3A and GABRB3 exons. In the top 
panel, those probes all fall below the green line at 0.75, indicating their loss, 
consistent with Angelman syndrome. In The lower panel, those probes are above 
the green line at 1.3, indicating their duplication status for this isodicentric 
duplication. The X-axis shows the amplicon sizes of the amplicons listed in table 
6-2 and the Y axis shows the peak ratio between the measured relative 
fluorescence of the synthetic control sample and the sample being measured. 
 
Absence of Fine Copy Number Variation in ASD Samples 
The success of MLPA in correctly determining the copy number of 
Angelman, CEPH, and dup(15) samples across UBE3A and GABRB3 exons 
gave us confidence to try running those samples listed in table 6.2. The samples 
were selected as described above by their ROH status at UBE3A and GABRB3, 
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abundance of Mendelian inconsistencies, or epilepsy status. To be sure that the 
protocol worked as before, Angelman, dup(15), and CEPH samples were also 
run again. 
Results appeared largely negative for the samples of Table 6.1. Figure 6-3 
shows two representative plots from the MLPA analysis of this group, neither of 
which suggested any exonic losses or gains in the UBE3A or GABRB3 genes. 
 
 
Figure 6-3. MLPA peak ratios for idiopathic autism samples. Here, in both 
panels blue dots represent reference probes and green dots are the probes for 
UBE3A and GABRB3 exons, all within the normal peak ratio range. The X-axis 
shows the amplicon sizes of the amplicons listed in table 6-2 and the Y axis 
shows the peak ratio between the measured relative fluorescence of the 
synthetic control sample and the sample being measured. 
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Discussion 
In this study, I investigated 48 samples with apparently idiopathic autism 
for the presence of microdeletion or microduplication in the UBE3A and GABRB3 
genes. 
MLPA appears to be a powerful and rapid technique for interrogating 
multiple genomic loci for potential copy number variation. Its correct identification 
of duplication or deletion in dup(15) and Angelman samples, respectively, for all 
UBE3A and GABRB3 exons is proof of principle that the method can correctly 
identify small deletions and duplications that may fall beyond the threshold of 
cytogenetics. Further, the built-in independent reference sequences at neutral 
genomic loci offer assurance that the phenomenon of gains or losses at these 
loci is not simply an artifact of a problematic sample.  
Here, I correctly identified the loss of 9 exons of GABRB3 and 11 exons of 
UBE3A from Angelman samples and their respective gains in dup(15) samples. 
Idiopathic autism samples, however, appeared chromosomally normal despite 
our best efforts to enrich for samples I thought would prove most promising for 
deletions or duplications in these genes. There are several reasons this could be 
so. 
ROH analysis is typically performed on genome-wide association 
datasets. Its utility might be still better suited for detecting much larger deletions. 
Since the window of 50 SNPs required meant that it would span most of UBE3A 
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or GABRB3, it would not pick up smaller deletions such as those of single exons. 
As such, it may have lent little or no value in the selection of initial samples.  
Taqman genotyping does not provide intensity data in a manner that 
permits the calling of copy number from genotype plots in an effective manner. 
The absence of this intensity data, a feature of the newer SNP-chip based 
genotyping platforms available from companies such as Illumina or Affymetrix, 
makes inferring gains or losses from Taqman data impractical if not impossible. It 
should be noted, however, that MLPA would be useful in detecting small 
deletions below the threshold of both intensity and ROH algorithms to pick up, 
particularly in regions of poor coverage or within exons. 
The high levels of LD present in the UBE3A gene, which exists in a single 
block of LD, along with the relatively few number of common haplotypes, means 
that hundreds of samples appeared homozygous across UBE3A, giving little 
value to the use of its SNPs in ROH analysis. GABRB3, with its relatively low 
levels of LD, seemed a better target since homozygosity across multiple LD 
blocks becomes increasingly less probable.  
Mendelian inconsistencies are often compatible with a deletion. 
Occasionally, manual inspection of the pedigrees indicated parents homozygous 
for the opposite allele present in homozygous offspring, suggesting hemizygosity 
at the locus. Other times, both parents appeared homozygous over a number of 
loci. It is possible that two parents both chromosomally identical over some 
number of loci could pass on some kind of recessive gene to chromosomally 
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normal children and that this could results in autism. Again, this type of scenario 
would not be detected by MLPA. 
While epilepsy is associated with most of the 15q microdeletion disorders, 
our sample included only relatively small number with potential epilepsy. As this 
sample was ascertained for autism and possible epilepsy, and status was 
garnered just from two questions on the ADI-R, it is difficult to draw inferences 
from no findings of exonic CNVs in GABRB3 and UBE3A for those samples with 
epilepsy. We can conclude, however, that such CNV events are likely to be very 
rare. 
I restricted our analysis to two genes. A broader assay testing exons 
centered in more candidate genes in our sample may have been more likely to 
yield positive findings, but such an experiment is outside of the scope of this 
project.  
Finally, my sample size, while dictated by clinical criteria, may also have 
been an issue. With only 48 samples tested and the apparent infrequency of 
15q11.2 microdeletions and duplications, our power to detect a rare event was 
very low [315].  
In summary, MLPA appears to be a powerful method to rapidly interrogate 
a large number of loci simultaneously. It appears to be accurate and while I 
identified no CNVs in UBE3A and GABRB3, it appears to have correctly and 
reliably detected the presence or absence of these exons in controls. Future use 
of this method should potentially be informed by alternate selection measures, 
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probe spacing calculations, sample size considerations, and cost of alternative 
platforms. 
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CHAPTER VII 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Autism in Context 
The Blessing (and Curse) of Genetic Technology 
The development of the publicly financed genome projects, most notably 
the HapMap, in combination with the parallel maturation of genotyping and 
sequencing technologies has revolutionized genetics. In just the past six years, 
we have gone from a single and now multiple finished genome sequences, to 
having human variation catalogued in several major world populations, now 
being expanded by the 1000 Genomes project. As “next generation sequencing” 
proliferates and improves in cost and performance, investigators will be able to 
capture vast sequences of DNA in single experiments that would have previously 
taken months or years. The explosion in the field mirrors Moore’s law as the cost 
of sequencing and genotyping is reduced by a factor of two or three each year. 
This technology-driven revolution in genetics makes it evident that human 
genetics is approaching an era where complete genome information (structural 
variation, common and rare SNPs, and complete genome sequence,) will be 
available in the future.  
These developments and the maturation of the field of autism genetics 
has meant that researchers have moved from cytogenetics to array based CGH 
studies, from linkage studies and candidate gene studies to much larger scans 
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for genome-wide association and CNVs. But the wealth of information carries 
with it its own problems. Not every discovered functional, disease-associated, or 
even highly penetrant variant is causal in all cases, as CNVs such as 15q11-q13 
and 16p11.2 illustrate. How do we account for this? In genome-wide association 
studies, how will we correct for 1 million tests and sub-significant results? What is 
the meaning of common allelic variants with odds ratios on the order of 1.2-1.6? 
New genome-wide methods for interpreting association results and integrating 
both common and rare risk alleles (see tables 1-3 and 1-4) must be developed.  
 
Overcoming Heterogeneity 
Despite many advances and the high heritability and relative frequency of 
autism and the ASDs, the genetic etiology of the vast majority of cases remains 
unknown. However, the past decade has witnessed major advances in defining 
aspects of the genetic etiology of autism. As indicated in the introduction, a large 
number of genomic disorders and syndromes can be easily identified. Just as the 
declination of intellectual disability (i.e. mental retardation) diagnoses has been 
correlated with increased ASD diagnoses, I would speculate that autism will—at 
least in part—resolve into some distinct genomic disorders as the genetics and 
biology are better understood. 
Many of the samples in existing autism datasets may already have an 
identified molecular defect, such as a highly penetrant CNV, which may be 
sufficient to be causal in a given case. As indicated in the introduction (see table 
1-4), a number of CNVs are now understood to be sufficient to cause an ASD 
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phenotype. Identifying individuals who have causal or highly penetrant defects or 
those whose disorder is caused by a combination of less penetrant alleles will 
likely become key to better understanding the mixed genetic architecture of the 
disease and knowing how to appropriately council families carrying autism-
related variants. If the CNV burden in a family appears high, this might be 
sufficient to warrant meaningful genetic counseling to families facing difficult 
decisions. 
 
Decomposing the Autism Phenotype 
In addition to parsing genetic heterogeneity, it is also important to relate 
the underlying genetics to ASD clinical heterogeneity. ASDs have highly variable 
clinical presentations (see table 1-1) with wide ranging differences in IQ, medical 
co-morbidities, developmental trajectory, and other phenotypic dimensions. We 
must move beyond the categorical diagnostic category of autism to more 
carefully dissect the phenotype.  
In addition to approaches which analyze autism as a whole, understanding 
the genes that may subtly increase risk for individual autistic traits (e.g. language 
deficits, rigid/repetitive behaviors, and impairments in social interaction) may also 
help to unravel the disorder. Such traits have been measured in the general 
population and people who do not meet diagnostic criteria for ASDs may exhibit 
significant impairment for an individual trait  [317,318]. Further, there are low 
correlations between impairments in these three domains in the general 
population [319,320]. Perhaps considering how impaired both autistic individuals 
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and those in the general population are in these domains or studying the tails of 
these distributions may yield insight into the genes which increase risk for each 
of the component traits of autism. 
 
Sporadic vs. Familial Autism 
It will become increasingly important to understand any differences 
between cases of sporadic autism versus familial autism. More importantly, it 
may become important to determine a way to distinguish them from one another. 
Since there is an established risk of increased autism in children born to older 
mothers and to older fathers, this suggests that for sporadic cases there may be 
a strong case for de-novo mutation. However, it is not so straightforward since 
the birth of a single autistic child will often dissuade the parents from having 
additional children, so that a family which may be theoretically “multiplex” in its 
genetic architecture of autism risk alleles may present as a “simplex” family, that 
is, with just one affected child [321]. 
I would posit that most chromosomal forms that are known to be inherited 
are often due to CNVs originating in the mother or to point mutations originating 
in the father. Age is a known risk in mothers for chromosomal abnormalities. It 
seems possible that this could be the case for smaller structural variation. Since 
we do not yet have extensive ability to sequence whole genomes in a cost-
efficient manner, the impact of older fathers and their contribution to de-novo 
point mutation remains to be seen. Nevertheless, parental age at conception is 
one means by which researchers may begin to determine if it is likely that autism 
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cases may be sporadic or familial. The knowledge that there is increased 
likelihood of de-novo events in sporadic vs. familial forms of autism is the 
motivation for the development of the Simons Simplex Collection (SSC) which, 
unlike the Autism Genetics Resource Exchange (AGRE), features simplex 
families whereas AGRE is almost exclusively multiplex families. Perhaps these 
collections will soon help to reveal if this distinction between simplex and 
multiplex families and their supposed genetic architecture of autism risk alleles is 
a meaningful distinction. 
Another means to distinguish sporadic or de novo events from events that 
may be familial or polygenic may be by investigating unaffected family members 
for co-morbid phenotypes (see table 1). Elements of the BAP may be evident in 
“unaffected” siblings or in parents. Identifying families that have either traits that 
are part of the core phenotype or comorbidities common in autism may help to 
separate the sporadic/de novo cases from the familial/polygenic cases and to 
genetically map loci associated with subclinical traits of the BAP. 
 
The Importance of 15q11-q13 to Idiopathic Autism 
In the 1980s and 1990s the chromosome 15q11-q13 region was identified 
to be deleted in Prader-Willi and Angelman syndromes and maternally-duplicated 
in some cases of autism [119,322,323]. Since that time, it is now understood that 
a number of other rare deletions and duplications in or near the 15q11-q13 
region (e.g. 15q13.3) can also dramatically increase risk for autism [324].  Other 
work has shown rare, but recurrent submicroscopic deletions and duplications in 
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and around this region with phenotypes including autism, seizures, 
schizophrenia, and mental retardation [139,141,314,325]. Now that the methods 
for assaying CNVs have matured, it will be possible to quantitate the extent to 
which the collected genomic disorders in and flanking the 15q11-q13 interval 
contribute to total autism risk. The common 15q11-q13 duplications (interstitial 
and idic(15)) alone account for 1-3% of autism cases, so the total fraction of 
autism explained by additional CNVs in and around this region is likely to be 
slightly higher.   
In my study, analysis of genes believed to contribute to the phenotype and 
associated with genomic disorders in this region was restricted to UBE3A and 
GABRB3. While MLPA assay was shown to work correctly in identifying deletion 
and duplications of this region, of the 48 autism samples screened, none 
appeared to have had exonic duplications of UBE3A or GABRB3.  
Several points here are worth re-stating, however. First, since most of our 
overall sample (nearly 1000 families) were karyotyped, they should be largely 
devoid of any gross chromosomal abnormalities including idic(15), the most 
common form of the duplication. This is due largely to the severity presentation 
which often includes dysmorphologies which would be more likely to come to the 
attention of a physician or clinical geneticist. If any duplications were present, it 
would most likely have only been interstitial duplications, because these are 
more likely to be missed by standard karyotyping. Second, given the low 
frequency of “common” interstitial duplications of 15q11-q13, 48 samples is 
certainly a small number to screen and it is unlikely that we would detect smaller 
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CNVs in so few samples.  A clear future direction would include screening more 
samples. Third, while my strategy was to enrich for samples with CNVs by 
selecting those demonstrating of homozygosity, no exon level CNVs were 
detected and this method would be unlikely to enrich for small duplications. I also 
hypothesized that selection of subjects with a history of epilepsy and those 
whose samples showed short runs of Mendelian inconsistency might enrich the 
sample for CNV discovery. Perhaps better methods (e.g. CNV calling using more 
high density SNP or CGH arrays) will identify samples with CNVs in this region 
not detected by the limited MLPA pilot. Also characterization of the phenotype of 
those found to have CNVs in these genes might better help to identify those 
candidates which would merit such screening. Fourth, we were restricted not just 
to UBE3A and GABRB3, but specifically to exons of those genes. CNVs outside 
of exons would thus be missed.  
In this limited pilot experiment, while sensitive to CNV differences 
experimentally, only gives a very limited snapshot of copy number status of a 
narrowly defined portion of the 15q11-q13 interval. Acknowledging that other 
CNVs are being discovered outside of this region this further suggests that CNVs 
involving UBE3A and GABRB3 play an incomplete role in explaining the autism 
risk conferred by all CNVs possible in the 15q11-q13 and surrounding region. 
Turning attention to common variation, GABRB3 has been studied in 
numerous family-based association studies as a potential autism candidate gene. 
While results for GABRB3 studies are mixed, most studies show positive results 
and Curran et. al. replicated association that we published in McCauley et. al.  
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We have speculated that there may be multiple susceptibility alleles which 
have aggregated at GABRB3, since multiple regions—not in LD—show evidence 
for association. It is important to consider that while the single replication of 
association at GABRB3 by McCauley and Curran supports a real risk effect at 
this locus, many explanations exist for failed replication. The simplest is that the 
initial finding was a false positive. It may also be that several risk variants come 
to accumulate in different populations, as is supported by the rare variant, P11S, 
which makes results inconsistent and associations difficult to interpret. 
Fewer studies have been conducted for UBE3A, in part because most 
findings have been negative or mixed. Clearly the positive association I show 
with UBE3A needs to be replicated in independent samples. Our association 
study of UBE3A (chapter 4) showed association with UBE3A and two genes 
which code for proteins that are regulated by UBE3A in an a Drosophila 
experimental system. That genetic association showed association of alleles of 
UBE3A, ECT2, and GCH1 is very encouraging and suggests that model 
organisms and known biology may be able to correctly guide us to additional 
candidate genes. 
While allelic association was modest at UBE3A, ECT2, and GCH1, the 
associated allele for ECT2 as for GCH1 were not good predictors of mRNA or 
protein expression level. Despite this, the positive relationship between UBE3A 
and GCH1 gene expression was consistent with the correlations of protein 
expression observed in Drosophila.  
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Future studies should seek to verify or refute association in UBE3A, 
ECT2, and GCH1. Ideally, functional studies in appropriate cell lines (i.e. 
neuronal) or tissue samples (patient and control brain samples) could help to 
corroborate whether or not the gene and protein expression relationships 
observed in Drosophila extend to humans, and similarly perturbed in autism as 
predicted for Angelman syndrome. Such studies are underway in other labs. 
There is strong evidence that in chromosomally-normal from subjects with autism 
that UBE3A and GABRB3 expression are perturbed [198,326]. This suggests 
that despite the absence of high rates of CNVs or strong association in the 
UBE3A and GABRB3 genes that these genes may be subject to dysregulation in 
idiopathic autism. Determining what proportion of autism cases show such a 
profile could be important for unraveling a major pathway that may result in 
autism. 
Association results were also modest in GABRB3 given the number of 
tests performed. In addition, the site of association for the strongest signal 
observed was not in LD with that observed near the 155CA-2 region by two other 
groups, nor with that in the 3′ region of the gene previously observed by our 
group and Curran et. al [105,106,107,283].  
The top result was identified for a relatively rare SNP in the large intron 3 
region. The dominant model under which this SNP appears significant could 
imply that a single copy is all that is required for increased risk of autism. 
Encouragingly, this SNP does not appear to be in an LD block captured by 
previous association studies. As such, it will be interesting to see if the 
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association replicates in an independent dataset. Even so, there is virtually no 
apparent functional sequence (conserved non-coding regions, miRNA or other 
binding sites) around the variant to explain the observed association. 
GABRB3 is a very attractive functional candidate. Despite these disparate 
results, positive association has been found on several occasions that the 
potential involvement of this gene and others encoding GABAA receptor subunits 
in autism is quite plausible. However, aside from this it is fair to ask what, if 
anything, these collected findings of association are contributing to our 
knowledge of the role of GABRB3 in autism. Such disparate findings suggest 
involvement, but do not offer clear guidance on a single allele of the gene which 
may be associated. Perhaps other studies which identify QTL for GABRB3 (and 
UBE3A) expression may shed light on other genes which may regulate 
expression of these two genes which appear to play an important role in the 
pathology of autism. Until then, it seems unlikely that additional association 
studies in GABRB3 by themselves will yield much useful information. 
While rare, the P11S variant provides more direct evidence for a role  of 
GABRB3  in autism by virtue of the functional evidence implicating its affect on 
receptor function and association with autism. Perhaps more importantly, it 
illustrates two phenomena. First, it shows that a rare coding variant in a gene that 
has hitherto shown only evidence of common allele association with autism may 
also have rare variants of higher penetrance. Such has also been shown for 
CNTNAP2 and SLC6A4 [88,90,102]. Secondly, it demonstrates that maternal 
and not paternal overtransmission of the S11 risk allele is associated with autism. 
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This is extremely interesting in light of the strong maternal bias of 15q11-q13 in 
dup(15) autism. It provides further evidence that parental origin of not just a 
genomic variant, but also a single point mutation, may play a role in disease. 
Such is the case in Angelman syndrome in which maternal deletion of the region 
was first identified to cause the disorder and later point mutations on the 
maternal copy of UBE3A found to be sufficient [256,327]. 
By contrast to the modest case for association of common alleles of 
GABRB3 and UBE3A with autism, the case for common alleles of the X-
chromosome gene MECP2 showing association with autism is more consistent. 
Loat et al. showed association of SNPs in strong LD with SNPs that I genotyped 
in this project [219]. Work not shown here indicates that the same allele is 
associated in yet another independent set of families confirming this pattern of 
association.  
Since the major allele appears associated, it will be interesting to 
determine if the major allele increases risk for any particular subphenotypic trait 
or is associated with other perturbations in gene expression in males or females. 
This gene could hypothetically represent a very attractive QTL which increases 
risk for some autism-related trait. However, given the high frequency of the 
associated form, by itself this will likely give little information about the likelihood 
of developing autism. The new finding of association of MECP2 with idiopathic 
autism is potentially very important in light of the genes role in Rett syndrome 
and strong evidence suggesting involvement in the regulation of UBE3A and 
GABRB3. 
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In addition to MECP2, a number of other X-linked loci including FMR1 
(fragile X), NLGN3, and NLGN4X have shown rare alleles that segregate with 
ASD phenotypes. More than 22 genes on the X-chromosome may give rise to X-
linked forms of mental retardation [328]. X-linked mental retardation is, of course, 
far more common in males than in females. The male:female ratio of X-linked 
mental retardation is 1.4:1 for profound MR and approximately 1.9:1 for moderate 
MR [329]. That a number of other X-linked loci are being shown to contribute to 
autism and emerging data continues to support this trend will make investigation 
of both common and rare alleles on the X-chromosome an exciting avenue for 
research. 
 
Making Sense of the Model 
While specific genomic disorders, point mutations, and common alleles 
may, at first blush, collectively only implicate 15q11-q13 genes in just a small 
fraction of autism, it is important to consider the larger picture (see figure 1-2). 
While such variants in this region may be present in only a small number of those 
ascertained to have idiopathic autism, dysfunction of the genes in this system 
and those regulating this system—most notably MECP2, UBE3A, and 
GABRB3—might contribute in a greater fraction of autism. While genomic and 
coding variants of this region are relatively uncommon and may offer explanation 
of just a small percentage of the phenotype, this network of genes may be 
perturbed in a much wider set of individuals. We still have only a very limited 
knowledge of the extent of this “gene network”. 
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Genes act within networks and multiple genes and proteins (in addition to 
MECP2) are likely to regulate the expression of UBE3A and GABRB3. Moving 
beyond what CNVs and coding mutations are present to understand more 
comprehensively the networks which are perturbed with such dysregulation is 
central to understanding how these genes may collectively contribute to the 
phenotype. 
Work frequently cited in this thesis by Samaco et al. and Hogart et al. is 
perhaps the best indicator of the relationship between UBE3A, GABRB3, and 
MECP2 [194,198,326]. In this thesis I have shown in the case of the GABRB3 
mutation, P11S, evidence that suggests deviation from biallelic expression of 
GABRB3 which supports earlier observations [194]. An alternate explanation, not 
mutually exclusive, is that there is an effect based on maternal genotype. 
I predict that the net effect of dysregulation of UBE3A, GABRB3, and 
MECP2 is to contribute to a disruption of synapse development that may 
contribute to autism. Syndromic conditions with autism phenotypes have 
indicated that autism is often caused by genes important in playing a role in 
synapse formation and/or function. Evidence is accumulating that autism may in 
part be a synaptopathology as Zoghbi proposed in 2003 [118]. SHANK3, 
neuroligins, neurexins, CNTNAP2, UBE3A, SLC6A4, GABRB3, and others all 
have a role in formation of or signaling at the synapse. Examination of other 
genes in these pathways may uncover further candidate genes for which 
dysfunction may lead to autism. 
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This project has sought to bridge and garner evidence to build an 
understanding of the role of two 15q11-q13genes, and two associated network 
genes, in the development of autism. It has sought to further our understanding 
of whether and how two genes in the most commonly-observed CNV in autism, 
maternal duplication of 15q11-q13, play a role in autism. We have found the 
following: (1) We have shown association at MECP2, whose product shows 
evidence for regulating epigenetic control of this region. (2) We have shown 
association with UBE3A, the Angelman syndrome gene; and two loci in the 
UBE3A network, ECT2 and GCH1; (3) weak evidence for association in the 3´ 
region of GABRB3; (4) a new, undocumented region of significance in intron 3; 
and (5) a functional GABRB3 variant (P11S), in the signal peptide that confers 
increased  autism risk when maternally-transmitted. To complete this profile it will 
be essential to understand the depth and extent to which dysregulation of the 
genes in this model contribute to autism susceptibility or even potentially cause 
autism, in the case of highly penetrant alleles. 
 
Concluding Remarks 
The last ten years have been an exciting time in human genetics, 
particularly for autism genetics where our understanding of the underlying 
disease risk has increased by leaps and bounds. As researchers work toward 
more closely dissecting the phenotype and the component rare and common 
variants that contribute to it, new methods will be required to integrate this 
information. The evidence for a synaptic pathology in autism has increased and 
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hopefully emerging clues may also lead us to better understand the types of 
synaptopathologies and other developmental defects that might cause autism. It 
is hoped that understanding the dysregulation of networks that lead to autism—
including those involving UBE3A, GABRB3, and MECP2--may ultimately permit 
early detection and suggest medical treatments. 
 
REFERENCES 
 
 
 
1. (2007) Prevalence of autism spectrum disorders--autism and developmental 
disabilities monitoring network, 14 sites, United States, 2002. MMWR 
Surveill Summ 56: 12-28. 
2. Ganz ML (2007) The lifetime distribution of the incremental societal costs of 
autism. Arch Pediatr Adolesc Med 161: 343-349. 
3. Abrahams BS, Geschwind DH (2008) Advances in autism genetics: on the 
threshold of a new neurobiology. Nat Rev Genet 9: 341-355. 
4. Kuhn R (2004) Eugen Bleuler's concepts of psychopathology. Hist Psychiatry 
15: 361-366. 
5. Asperger H (1944) Die „Autistischen Psychopathen” im Kindesalter. Eur Arch 
Psychiatry Clin Neurosci. 
6. Kanner L (1943) Autistic disturbance of affective contact. Nervous Child 2: 
217-250. 
7. Wolff S (2004) The history of autism. Eur Child Adolesc Psychiatry 13: 201-
208. 
8. Hanson DR, Gottesman, II (1976) The genetics, if any, of infantile autism and 
childhood schizophrenia. J Autism Child Schizophr 6: 209-234. 
9. Folstein S, Rutter M (1977) Infantile autism: a genetic study of 21 twin pairs. J 
Child Psychol Psychiatry 18: 297-321. 
10. Folstein S, Rutter M (1977) Genetic influences and infantile autism. Nature 
265: 726-728. 
168 
11. Ritvo ER, Freeman BJ, Mason-Brothers A, Mo A, Ritvo AM (1985) 
Concordance for the syndrome of autism in 40 pairs of afflicted twins. Am 
J Psychiatry 142: 74-77. 
12. Gillberg C, Wahlstrom J (1985) Chromosome abnormalities in infantile autism 
and other childhood psychoses: a population study of 66 cases. Dev Med 
Child Neurol 27: 293-304. 
13. Wahlstrom J, Gillberg C, Gustavson KH, Holmgren G (1986) Infantile autism 
and the fragile X. A Swedish multicenter study. Am J Med Genet 23: 403-
408. 
14. American Psychiatric Association., American Psychiatric Association. Task 
Force on DSM-IV. (2000) Diagnostic and statistical manual of mental 
disorders : DSM-IV-TR. Washington, DC: American Psychiatric 
Association. xxxvii, 943 p. p. 
15. World Health Organization. (2004) International statistical classification of 
diseases and related health problems. Geneva: World Health 
Organization. 
16. Gillberg C, Coleman M (2000) The biology of the autistic syndromes. 
booksgooglecom. 
17. Richdale AL, Prior MR (1995) The sleep/wake rhythm in children with autism. 
European child & adolescent psychiatry 4: 175-186. 
18. Wiggs L, Stores G (1996) Severe sleep disturbance and daytime challenging 
behaviour in children with severe learning disabilities. Journal of 
intellectual disability research : JIDR 40 ( Pt 6): 518-528. 
19. Wiggs L, Stores G (2004) Sleep patterns and sleep disorders in children with 
autistic spectrum disorders: insights using parent report and actigraphy. 
Developmental medicine and child neurology 46: 372-380. 
20. Tuchman R, Moshé SL, Rapin I (2009) Convulsing toward the 
pathophysiology of autism. Brain Dev 31: 95-103. 
21. Munesue T, Ono Y, Mutoh K, Shimoda K, Nakatani H, et al. (2008) High 
prevalence of bipolar disorder comorbidity in adolescents and young 
adults with high-functioning autism spectrum disorder: a preliminary study 
of 44 outpatients. Journal of affective disorders 111: 170-175. 
22. Folstein SE, Rosen-Sheidley B (2001) Genetics of autism: complex aetiology 
for a heterogeneous disorder. Nature Reviews Genetics 2: 943-955. 
169 
23. Veenstra-VanderWeele J, Christian SL, Cook JEH (2004) Autism as a 
Paradigmatic Complex Genetic Disorder. Annual Review of Genomics and 
Human Genetics 2003 Jan 01;5(1):379 5: 407-441. 
24. Folstein SE, Rosen-Sheidley B (2001) Genetics of autism: complex aetiology 
for a heterogeneous disorder. Nat Rev Genet 2: 943-955. 
25. Le Couteur A, Rutter M, Lord C, Rios P, Robertson S, et al. (1989) Autism 
diagnostic interview: a standardized investigator-based instrument. J 
Autism Dev Disord 19: 363-387. 
26. Gotham K, Risi S, Pickles A, Lord C (2007) The Autism Diagnostic 
Observation Schedule: revised algorithms for improved diagnostic validity. 
J Autism Dev Disord 37: 613-627. 
27. Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: 
a revised version of a diagnostic interview for caregivers of individuals with 
possible pervasive developmental disorders. J Autism Dev Disord 24: 659-
685. 
28. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, et al. (2000) The 
autism diagnostic observation schedule-generic: a standard measure of 
social and communication deficits associated with the spectrum of autism. 
J Autism Dev Disord 30: 205-223. 
29. Lord C, Leventhal BL, Cook EH, Jr. (2001) Quantifying the phenotype in 
autism spectrum disorders. Am J Med Genet 105: 36-38. 
30. Howlin P, Goode S, Hutton J, Rutter M (2004) Adult outcome for children with 
autism. J Child Psychol Psychiatry 45: 212-229. 
31. Kuehn BM (2007) CDC: autism spectrum disorders common. JAMA 297: 
940. 
32. Van Naarden Braun K, Pettygrove S, Daniels J, Miller L, Nicholas J, et al. 
(2007) Evaluation of a methodology for a collaborative multiple source 
surveillance network for autism spectrum disorders--Autism and 
Developmental Disabilities Monitoring Network, 14 sites, United States, 
2002. MMWR Surveill Summ 56: 29-40. 
33. Reichenberg A, Gross R, Weiser M, Bresnahan M, Silverman J, et al. (2006) 
Advancing paternal age and autism. Arch Gen Psychiatry 63: 1026-1032. 
34. Cantor RM, Yoon JL, Furr J, Lajonchere CM (2007) Paternal age and autism 
are associated in a family-based sample. Mol Psychiatry 12: 419-421. 
170 
35. Croen LA, Najjar DV, Fireman B, Grether JK (2007) Maternal and paternal 
age and risk of autism spectrum disorders. Arch Pediatr Adolesc Med 161: 
334-340. 
36. Crow JF (2000) The origins, patterns and implications of human spontaneous 
mutation. Nat Rev Genet 1: 40-47. 
37. Fombonne E (2003) The prevalence of autism. Jama 289: 87-89. 
38. Rutter M (2005) Incidence of autism spectrum disorders: changes over time 
and their meaning. Acta Paediatr 94: 2-15. 
39. Shattuck PT (2006) The contribution of diagnostic substitution to the growing 
administrative prevalence of autism in US special education. Pediatrics 
117: 1028-1037. 
40. Croen LA, Grether JK, Selvin S (2001) The epidemiology of mental 
retardation of unknown cause. Pediatrics 107: E86. 
41. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, et al. (2007) 
The epidemiology of autism spectrum disorders. Annu Rev Public Health 
28: 235-258. 
42. Skuse DH, Mandy WP, Scourfield J (2005) Measuring autistic traits: 
heritability, reliability and validity of the Social and Communication 
Disorders Checklist. The British journal of psychiatry : the journal of 
mental science 187: 568-572. 
43. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, et al. (1995) 
Autism as a strongly genetic disorder: evidence from a British twin study. 
Psychol Med 25: 63-77. 
44. Chakrabarti S, Fombonne E (2005) Pervasive developmental disorders in 
preschool children: confirmation of high prevalence. Am J Psychiatry 162: 
1133-1141. 
45. Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, et al. (2007) 
Mapping autism risk loci using genetic linkage and chromosomal 
rearrangements. Nat Genet 39: 319-328. 
46. Piven J, Palmer P, Jacobi D, Childress D, Arndt S (1997) Broader autism 
phenotype: evidence from a family history study of multiple-incidence 
autism families. The American journal of psychiatry 154: 185-190. 
47. Dawson G, Estes A, Munson J, Schellenberg G, Bernier R, et al. (2007) 
Quantitative assessment of autism symptom-related traits in probands and 
parents: Broader Phenotype Autism Symptom Scale. J Autism Dev Disord 
37: 523-536. 
171 
48. Briskman J, Happe F, Frith U (2001) Exploring the cognitive phenotype of 
autism: weak "central coherence" in parents and siblings of children with 
autism: II. Real-life skills and preferences. J Child Psychol Psychiatry 42: 
309-316. 
49. Piven J, Wzorek M, Landa R, Lainhart J, Bolton P, et al. (1994) Personality 
characteristics of the parents of autistic individuals. Psychol Med 24: 783-
795. 
50. Abramson RK, Ravan SA, Wright HH, Wieduwilt K, Wolpert CM, et al. (2005) 
The relationship between restrictive and repetitive behaviors in individuals 
with autism and obsessive compulsive symptoms in parents. Child 
Psychiatry Hum Dev 36: 155-165. 
51. Constantino JN, Todd RD (2005) Intergenerational transmission of 
subthreshold autistic traits in the general population. Biol Psychiatry 57: 
655-660. 
52. Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, et al. (1999) A genomic 
screen of autism: evidence for a multilocus etiology. Am J Hum Genet 65: 
493-507. 
53. Gutierrez GC, Smalley SL, Tanguay PE (1998) Autism in tuberous sclerosis 
complex. Journal of Autism & Developmental Disorders 28: 97-103. 
54. Williams CA, Angelman H, Clayton-Smith J, Driscoll DJ, Hendrickson JE, et 
al. (1995) Angelman syndrome: consensus for diagnostic 
criteria.Angelman Syndrome Foundation. American Journal of Medical 
Genetics 56: 237-238. 
55. Zappella M, Meloni I, Longo I, Canitano R, Hayek G, et al. (2003) Study of 
MECP2 gene in Rett syndrome variants and autistic girls. Am J Med 
Genet 119B: 102-107. 
56. Pickles A, Bolton P, Macdonald H, Bailey A, Le Couteur A, et al. (1995) 
Latent-class analysis of recurrence risks for complex phenotypes with 
selection and measurement error: a twin and family history study of 
autism. Am J Hum Genet 57: 717-726. 
57. Battaglia A, Carey JC (2006) Etiologic yield of autistic spectrum disorders: a 
prospective study. American journal of medical genetics Part C, Seminars 
in medical genetics 142C: 3-7. 
58. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al. (2007) Strong 
association of de novo copy number mutations with autism. Science 316: 
445-449. 
172 
59. Jacquemont ML, Sanlaville D, Redon R, Raoul O, Cormier-Daire V, et al. 
(2006) Array-based comparative genomic hybridisation identifies high 
frequency of cryptic chromosomal rearrangements in patients with 
syndromic autism spectrum disorders. J Med Genet 43: 843-849. 
60. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, et al. (2007) 
Mutations in the gene encoding the synaptic scaffolding protein SHANK3 
are associated with autism spectrum disorders. Nat Genet 39: 25-27. 
61. Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, et al. (2007) 
Contribution of SHANK3 mutations to autism spectrum disorder. Am J 
Hum Genet 81: 1289-1297. 
62. Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, et al. (2003) 
Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 
are associated with autism. Nat Genet 34: 27-29. 
63. Lander ES, Schork NJ (1994) Genetic dissection of complex traits. Science 
265: 2037-2048. 
64. Yang MS, Gill M (2007) A review of gene linkage, association and expression 
studies in autism and an assessment of convergent evidence. Int J Dev 
Neurosci 25: 69-85. 
65. Goring HH, Terwilliger JD, Blangero J (2001) Large upward bias in estimation 
of locus-specific effects from genomewide scans. Am J Hum Genet 69: 
1357-1369. 
66. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003) Meta-
analysis of genetic association studies supports a contribution of common 
variants to susceptibility to common disease. Nat Genet 33: 177-182. 
67. Freitag CM (2007) The genetics of autistic disorders and its clinical 
relevance: a review of the literature. Mol Psychiatry 12: 2-22. 
68. Buxbaum JD, Silverman JM, Smith CJ, Kilifarski M, Reichert J, et al. (2001) 
Evidence for a susceptibility gene for autism on chromosome 2 and for 
genetic heterogeneity. Am J Hum Genet 68: 1514-1520. 
69. Shao Y, Raiford KL, Wolpert CM, Cope HA, Ravan SA, et al. (2002) 
Phenotypic homogeneity provides increased support for linkage on 
chromosome 2 in autistic disorder. Am J Hum Genet 70: 1058-1061. 
70. (2001) A genomewide screen for autism: strong evidence for linkage to 
chromosomes 2q, 7q, and 16p. Am J Hum Genet 69: 570-581. 
173 
71. Yonan AL, Alarcon M, Cheng R, Magnusson PK, Spence SJ, et al. (2003) A 
genomewide screen of 345 families for autism-susceptibility loci. Am J 
Hum Genet 73: 886-897. 
72. Trikalinos TA, Karvouni A, Zintzaras E, Ylisaukko-oja T, Peltonen L, et al. 
(2006) A heterogeneity-based genome search meta-analysis for autism-
spectrum disorders. Mol Psychiatry 11: 29-36. 
73. (1998) A full genome screen for autism with evidence for linkage to a region 
on chromosome 7q. International Molecular Genetic Study of Autism 
Consortium. Hum Mol Genet 7: 571-578. 
74. (2001) Further characterization of the autism susceptibility locus AUTS1 on 
chromosome 7q. Hum Mol Genet 10: 973-982. 
75. Alarcon M, Cantor RM, Liu J, Gilliam TC, Geschwind DH (2002) Evidence for 
a language quantitative trait locus on chromosome 7q in multiplex autism 
families. Am J Hum Genet 70: 60-71. 
76. Alarcon M, Yonan AL, Gilliam TC, Cantor RM, Geschwind DH (2005) 
Quantitative genome scan and Ordered-Subsets Analysis of autism 
endophenotypes support language QTLs. Mol Psychiatry 10: 747-757. 
77. Schellenberg GD, Dawson G, Sung YJ, Estes A, Munson J, et al. (2006) 
Evidence for multiple loci from a genome scan of autism kindreds. Mol 
Psychiatry 11: 1049-1060, 1979. 
78. Shao Y, Cuccaro ML, Hauser ER, Raiford KL, Menold MM, et al. (2003) Fine 
mapping of autistic disorder to chromosome 15q11-q13 by use of 
phenotypic subtypes. Am J Hum Genet 72: 539-548. 
79. Nurmi EL, Dowd M, Tadevosyan-Leyfer O, Haines JL, Folstein SE, et al. 
(2003) Exploratory subsetting of autism families based on savant skills 
improves evidence of genetic linkage to 15q11-q13. J Am Acad Child 
Adolesc Psychiatry 42: 856-863. 
80. Kilpinen H, Ylisaukko-oja T, Rehnstrom K, Gaal E, Turunen JA, et al. (2009) 
Linkage and linkage disequilibrium scan for autism loci in an extended 
pedigree from Finland. Hum Mol Genet 18: 2912-2921. 
81. Cantor RM, Kono N, Duvall JA, Alvarez-Retuerto A, Stone JL, et al. (2005) 
Replication of autism linkage: fine-mapping peak at 17q21. Am J Hum 
Genet 76: 1050-1056. 
82. Stone JL, Merriman B, Cantor RM, Yonan AL, Gilliam TC, et al. (2004) 
Evidence for sex-specific risk alleles in autism spectrum disorder. Am J 
Hum Genet 75: 1117-1123. 
174 
83. Strom SP, Stone JL, Ten Bosch JR, Merriman B, Cantor RM, et al. (2009) 
High-density SNP association study of the 17q21 chromosomal region 
linked to autism identifies CACNA1G as a novel candidate gene. Mol 
Psychiatry. 
84. McCauley JL, Li C, Jiang L, Olson LM, Crockett G, et al. (2005) Genome-
wide and Ordered-Subset linkage analyses provide support for autism loci 
on 17q and 19p with evidence of phenotypic and interlocus genetic 
correlates. BMC Med Genet 6: 1. 
85. Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, et al. (2008) 
Linkage, association, and gene-expression analyses identify CNTNAP2 as 
an autism-susceptibility gene. Am J Hum Genet 82: 150-159. 
86. Jorde LB, Hasstedt SJ, Ritvo ER, Mason-Brothers A, Freeman BJ, et al. 
(1991) Complex segregation analysis of autism. Am J Hum Genet 49: 
932-938. 
87. Hallmayer J, Pintado E, Lotspeich L, Spiker D, McMahon W, et al. (1994) 
Molecular analysis and test of linkage between the FMR-1 gene and 
infantile autism in multiplex families. Am J Hum Genet 55: 951-959. 
88. Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, et al. (2005) 
Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers 
susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 
77: 265-279. 
89. Zhao X, Leotta A, Kustanovich V, Lajonchere C, Geschwind DH, et al. (2007) 
A unified genetic theory for sporadic and inherited autism. Proc Natl Acad 
Sci U S A 104: 12831-12836. 
90. Arking DE, Cutler DJ, Brune CW, Teslovich TM, West K, et al. (2008) A 
common genetic variant in the neurexin superfamily member CNTNAP2 
increases familial risk of autism. Am J Hum Genet 82: 160-164. 
91. Gharani N, Benayed R, Mancuso V, Brzustowicz LM, Millonig JH (2004) 
Association of the homeobox transcription factor, ENGRAILED 2, 3, with 
autism spectrum disorder. Mol Psychiatry 9: 474-484. 
92. Benayed R, Gharani N, Rossman I, Mancuso V, Lazar G, et al. (2005) 
Support for the homeobox transcription factor gene ENGRAILED 2 as an 
autism spectrum disorder susceptibility locus. Am J Hum Genet 77: 851-
868. 
93. Weiss LA, Kosova G, Delahanty RJ, Jiang L, Cook EH, et al. (2006) Variation 
in ITGB3 is associated with whole-blood serotonin level and autism 
susceptibility. Eur J Hum Genet 14: 923-931. 
175 
94. Coutinho AM, Sousa I, Martins M, Correia C, Morgadinho T, et al. (2007) 
Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and 
in the determination of platelet serotonin levels. Hum Genet 121: 243-256. 
95. Fang P, Lev-Lehman E, Tsai TF, Matsuura T, Benton CS, et al. (1999) The 
spectrum of mutations in UBE3A causing Angelman syndrome. Hum Mol 
Genet 8: 129-135. 
96. Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB, Jr., et al. (2006) 
Autistic behavior in children with fragile X syndrome: prevalence, stability, 
and the impact of FMRP. Am J Med Genet A 140A: 1804-1813. 
97. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, et al. (1999) Rett 
syndrome is caused by mutations in X-linked MECP2, encoding methyl-
CpG-binding protein 2. Nat Genet 23: 185-188. 
98. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, et al. (2004) 
Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder 
including arrhythmia and autism. Cell 119: 19-31. 
99. Baker P, Piven J, Sato Y (1998) Autism and tuberous sclerosis complex: 
prevalence and clinical features. J Autism Dev Disord 28: 279-285. 
100. Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, et al. (2004) 
X-linked mental retardation and autism are associated with a mutation in 
the NLGN4 gene, a member of the neuroligin family. Am J Hum Genet 74: 
552-557. 
101. Feng J, Schroer R, Yan J, Song W, Yang C, et al. (2006) High frequency of 
neurexin 1beta signal peptide structural variants in patients with autism. 
Neurosci Lett 409: 10-13. 
102. Bakkaloglu B, O'Roak BJ, Louvi A, Gupta AR, Abelson JF, et al. (2008) 
Molecular cytogenetic analysis and resequencing of contactin associated 
protein-like 2 in autism spectrum disorders. Am J Hum Genet 82: 165-173. 
103. Benayed R, Choi J, Matteson PG, Gharani N, Kamdar S, et al. (2009) 
Autism-associated haplotype affects the regulation of the homeobox gene, 
ENGRAILED 2. Biol Psychiatry 66: 911-917. 
104. Curran S, Roberts S, Thomas S, Veltman M, Browne J, et al. (2005) An 
association analysis of microsatellite markers across the Prader-
Willi/Angelman critical region on chromosome 15 (q11-13) and autism 
spectrum disorder. Am J Med Genet B Neuropsychiatr Genet 137: 25-28. 
105. McCauley JL, Olson LM, Delahanty R, Amin T, Nurmi EL, et al. (2004) A 
linkage disequilibrium map of the 1-Mb 15q12 GABA(A) receptor subunit 
176 
cluster and association to autism. Am J Med Genet B Neuropsychiatr 
Genet 131: 51-59. 
106. Buxbaum JD, Silverman JM, Smith CJ, Greenberg DA, Kilifarski M, et al. 
(2002) Association between a GABRB3 polymorphism and autism. Mol 
Psychiatry 7: 311-316. 
107. Curran S, Powell J, Neale BM, Dworzynski K, Li T, et al. (2006) An 
association analysis of candidate genes on chromosome 15 q11-13 and 
autism spectrum disorder. Mol Psychiatry 11: 709-713. 
108. Weiss LA, Ober C, Cook EH, Jr. (2006) ITGB3 shows genetic and 
expression interaction with SLC6A4. Hum Genet 120: 93-100. 
109. Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, et al. (2006) A 
genetic variant that disrupts MET transcription is associated with autism. 
Proc Natl Acad Sci U S A 103: 16834-16839. 
110. Sousa I, Clark TG, Toma C, Kobayashi K, Choma M, et al. (2009) MET and 
autism susceptibility: family and case-control studies. Eur J Hum Genet 
17: 749-758. 
111. Yan J, Oliveira G, Coutinho A, Yang C, Feng J, et al. (2005) Analysis of the 
neuroligin 3 and 4 genes in autism and other neuropsychiatric patients. 
Mol Psychiatry 10: 329-332. 
112. Coutinho AM, Oliveira G, Morgadinho T, Fesel C, Macedo TR, et al. (2004) 
Variants of the serotonin transporter gene (SLC6A4) significantly 
contribute to hyperserotonemia in autism. Mol Psychiatry 9: 264-271. 
113. Kim SJ, Cox N, Courchesne R, Lord C, Corsello C, et al. (2002) 
Transmission disequilibrium mapping at the serotonin transporter gene 
(SLC6A4) region in autistic disorder. Mol Psychiatry 7: 278-288. 
114. Anderson GM, Gutknecht L, Cohen DJ, Brailly-Tabard S, Cohen JH, et al. 
(2002) Serotonin transporter promoter variants in autism: functional effects 
and relationship to platelet hyperserotonemia. Mol Psychiatry 7: 831-836. 
115. Nurmi EL, Bradford Y, Chen YH, Hall J, Arnone B, et al. (2001) Linkage 
disequilibrium at the Angelman syndrome gene UBE3A in autism families. 
Genomics 77: 105-113. 
116. Matsuura T, Sutcliffe JS, Fang P, Galjaard RJ, Jiang YH, et al. (1997) De 
novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) 
in Angelman syndrome. Nat Genet 15: 74-77. 
117. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, et al. (2010) 
SCAN: SNP and copy number annotation. Bioinformatics 26: 259-262. 
177 
118. Zoghbi HY (2003) Postnatal neurodevelopmental disorders: meeting at the 
synapse? Science 302: 826-830. 
119. Cook EH, Jr., Lindgren V, Leventhal BL, Courchesne R, Lincoln A, et al. 
(1997) Autism or atypical autism in maternally but not paternally derived 
proximal 15q duplication. Am J Hum Genet 60: 928-934. 
120. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, et al. (2004) 
Detection of large-scale variation in the human genome. Nat Genet 36: 
949-951. 
121. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, et al. (2004) Large-
scale copy number polymorphism in the human genome. Science 305: 
525-528. 
122. Conrad DF, R., Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. (2006) A 
high-resolution survey of deletion polymorphismGlobal variation in copy 
number in the human genome. Nat GenetNature 38444: 75-81444-81454. 
123. Redon R, J. A., Ishikawa SS, W. G., Fitch KRD, E., Feuk L, Perry GvE, H., 
et al. (2006) Global variation in copy number in the human 
genomeIdentification of novel autism candidate regions through analysis 
of reported cytogenetic abnormalities associated with autism. NatureMol 
Psychiatry 44411: 444-541, 418-428. 
124. Vorstman JA, Staal WG, van Daalen E, van Engeland H, Hochstenbach PF, 
et al. (2006) Identification of novel autism candidate regions through 
analysis of reported cytogenetic abnormalities associated with autism. Mol 
Psychiatry 11: 1, 18-28. 
125. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al. (2007) 
Strong association of de novo copy number mutations with autism. 
Science 316: 445-449. 
126. Cook EH, Scherer SW (2008) Copy-number variations associated with 
neuropsychiatric conditions. Nature 455: 919-923. 
127. Bucan M, Abrahams BS, Wang K, Glessner JT, Herman EI, et al. (2009) 
Genome-wide analyses of exonic copy number variants in a family-based 
study point to novel autism susceptibility genes. PLoS Genet 5: e1000536. 
128. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural 
variation of chromosomes in autism spectrum disorder. Am J Hum Genet 
82: 477-488. 
129. Sherr EH, Owen R, Albertson DG, Pinkel D, Cotter PD, et al. (2005) 
Genomic microarray analysis identifies candidate loci in patients with 
corpus callosum anomalies. Neurology 65: 1496-1498. 
178 
130. Burd L, Martsolf JT, Kerbeshian J, Jalal SM (1988) Partial 6p trisomy 
associated with infantile autism. Clin Genet 33: 356-359. 
131. Vostanis P, Harrington R, Prendergast M, Farndon P (1994) Case reports of 
autism with interstitial deletion of chromosome 17 (p11.2 p11.2) and 
monosomy of chromosome 5 (5pter-->5p15.3). Psychiatr Genet 4: 109-
111. 
132. Ylisaukko-oja T, Alarcon M, Cantor RM, Auranen M, Vanhala R, et al. 
(2006) Search for autism loci by combined analysis of Autism Genetic 
Resource Exchange and Finnish families. Ann Neurol 59: 145-155. 
133. Bundey S, Hardy C, Vickers S, Kilpatrick MW, Corbett JA (1994) Duplication 
of the 15q11-13 region in a patient with autism, epilepsy and ataxia. Dev 
Med Child Neurol 36: 736-742. 
134. Barnby G, Abbott A, Sykes N, Morris A, Weeks DE, et al. (2005) Candidate-
gene screening and association analysis at the autism-susceptibility locus 
on chromosome 16p: evidence of association at GRIN2A and ABAT. Am J 
Hum Genet 76: 950-966. 
135. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, et al. (2008) Association 
between microdeletion and microduplication at 16p11.2 and autism. N 
Engl J Med 358: 667-675. 
136. Manning MA, Cassidy SB, Clericuzio C, Cherry AM, Schwartz S, et al. 
(2004) Terminal 22q deletion syndrome: a newly recognized cause of 
speech and language disability in the autism spectrum. Pediatrics 114: 
451-457. 
137. Prasad C, Prasad AN, Chodirker BN, Lee C, Dawson AK, et al. (2000) 
Genetic evaluation of pervasive developmental disorders: the terminal 
22q13 deletion syndrome may represent a recognizable phenotype. Clin 
Genet 57: 103-109. 
138. Sahoo T, Shaw CA, Young AS, Whitehouse NL, Schroer RJ, et al. (2005) 
Array-based comparative genomic hybridization analysis of recurrent 
chromosome 15q rearrangements. Am J Med Genet A 139A: 106-113. 
139. Pagnamenta AT, Wing K, Akha ES, Knight SJ, Bolte S, et al. (2009) A 
15q13.3 microdeletion segregating with autism. Eur J Hum Genet 17: 687-
692. 
140. Miller DT, Shen Y, Weiss LA, Korn J, Anselm I, et al. (2009) 
Microdeletion/duplication at 15q13.2q13.3 among individuals with features 
of autism and other neuropsychiatric disorders. J Med Genet 46: 242-248. 
179 
141. Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, et al. (2009) 
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. 
Nat Genet 41: 160-162. 
142. Dibbens LM, Mullen S, Helbig I, Mefford HC, Bayly MA, et al. (2009) 
Familial and sporadic 15q13.3 microdeletions in Idiopathic Generalized 
Epilepsy: Precedent for Disorders with Complex Inheritance. Hum Mol 
Genet. 
143. Alkan C, Kidd JM, Marques-Bonet T, Aksay G, Antonacci F, et al. (2009) 
Personalized copy number and segmental duplication maps using next-
generation sequencing. Nat Genet. 
144. Losh M, Childress D, Lam K, Piven J (2008) Defining key features of the 
broad autism phenotype: a comparison across parents of multiple- and 
single-incidence autism families. Am J Med Genet B Neuropsychiatr 
Genet 147B: 424-433. 
145. Veenstra-Vanderweele J, Christian SL, Cook EH, Jr. (2004) Autism as a 
paradigmatic complex genetic disorder. Annu Rev Genomics Hum Genet 
5: 379-405. 
146. Wang NJ, Liu D, Parokonny AS, Schanen NC (2004) High-resolution 
molecular characterization of 15q11-q13 rearrangements by array 
comparative genomic hybridization (array CGH) with detection of gene 
dosage. Am J Hum Genet 75: 267-281. 
147. Christian SL, Fantes JA, Mewborn SK, Huang B, Ledbetter DH (1999) Large 
genomic duplicons map to sites of instability in the Prader-Willi/Angelman 
syndrome chromosome region (15q11-q13). Hum Mol Genet 8: 1025-
1037. 
148. Horsthemke B, Buiting K (2006) Imprinting defects on human chromosome 
15. Cytogenet Genome Res 113: 292-299. 
149. Li E, Beard C, Jaenisch R (1993) Role for DNA methylation in genomic 
imprinting. Nature 366: 362-365. 
150. Neumann B, Kubicka P, Barlow DP (1995) Characteristics of imprinted 
genes. Nat Genet 9: 12-13. 
151. Reik W, Walter J (2001) Genomic imprinting: parental influence on the 
genome. Nat Rev Genet 2: 21-32. 
152. Gimelbrant A, Hutchinson JN, Thompson BR, Chess A (2007) Widespread 
monoallelic expression on human autosomes. Science 318: 1136-1140. 
180 
153. Bonati MT, Russo S, Finelli P, Valsecchi MR, Cogliati F, et al. (2007) 
Evaluation of autism traits in Angelman syndrome: a resource to unfold 
autism genes. Neurogenetics. 
154. Dimitropoulos A, Schultz RT (2007) Autistic-like symptomatology in Prader-
Willi syndrome: a review of recent findings. Curr Psychiatry Rep 9: 159-
164. 
155. Borgatti R, Piccinelli P, Passoni D, Dalpra L, Miozzo M, et al. (2001) 
Relationship between clinical and genetic features in "inverted duplicated 
chromosome 15" patients. Pediatr Neurol 24: 111-116. 
156. Fan Z, Greenwood R, Fisher A, Pendyal S, Powell CM (2009) 
Characteristics and frequency of seizure disorder in 56 patients with 
Prader-Willi syndrome. Am J Med Genet A 149A: 1581-1584. 
157. Descheemaeker MJ, Govers V, Vermeulen P, Fryns JP (2006) Pervasive 
developmental disorders in Prader-Willi syndrome: the Leuven experience 
in 59 subjects and controls. Am J Med Genet A 140: 1136-1142. 
158. Herzing LB, Cook EH, Jr., Ledbetter DH (2002) Allele-specific expression 
analysis by RNA-FISH demonstrates preferential maternal expression of 
UBE3A and imprint maintenance within 15q11- q13 duplications. Hum Mol 
Genet 11: 1707-1718. 
159. Milner KM, Craig EE, Thompson RJ, Veltman MW, Thomas NS, et al. 
(2005) Prader-Willi syndrome: intellectual abilities and behavioural 
features by genetic subtype. J Child Psychol Psychiatry 46: 1089-1096. 
160. Koenig K, Klin A, Schultz R (2004) Deficits in social attribution ability in 
Prader-Willi syndrome. J Autism Dev Disord 34: 573-582. 
161. Veltman MW, Craig EE, Bolton PF (2005) Autism spectrum disorders in 
Prader-Willi and Angelman syndromes: a systematic review. Psychiatr 
Genet 15: 243-254. 
162. Veltman MW, Thompson RJ, Roberts SE, Thomas NS, Whittington J, et al. 
(2004) Prader-Willi syndrome--a study comparing deletion and uniparental 
disomy cases with reference to autism spectrum disorders. Eur Child 
Adolesc Psychiatry 13: 42-50. 
163. Clayton-Smith J, Laan L (2003) Angelman syndrome: a review of the clinical 
and genetic aspects. J Med Genet 40: 87-95. 
164. Varela MC, Kok F, Otto PA, Koiffmann CP (2004) Phenotypic variability in 
Angelman syndrome: comparison among different deletion classes and 
between deletion and UPD subjects. Eur J Hum Genet 12: 987-992. 
181 
165. Lossie AC, Whitney MM, Amidon D, Dong HJ, Chen P, et al. (2001) Distinct 
phenotypes distinguish the molecular classes of Angelman syndrome. J 
Med Genet 38: 834-845. 
166. Dr. Carolyn Schanen`, personal communication. 
167. Battaglia A (2005) The inv dup(15) or idic(15) syndrome: a clinically 
recognisable neurogenetic disorder. Brain Dev 27: 365-369. 
168. Crolla JA, Harvey JF, Sitch FL, Dennis NR (1995) Supernumerary marker 
15 chromosomes: a clinical, molecular and FISH approach to diagnosis 
and prognosis. Hum Genet 95: 161-170. 
169. Battaglia A, Gurrieri F, Bertini E, Bellacosa A, Pomponi MG, et al. (1997) 
The inv dup(15) syndrome: a clinically recognizable syndrome with altered 
behavior, mental retardation, and epilepsy. Neurology 48: 1081-1086. 
170. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, et al. (1999) The 
Angelman syndrome-associated protein, E6-AP, is a coactivator for the 
nuclear hormone receptor superfamily. Mol Cell Biol 19: 1182-1189. 
171. Verma S, Ismail A, Gao X, Fu G, Li X, et al. (2004) The ubiquitin-
conjugating enzyme UBCH7 acts as a coactivator for steroid hormone 
receptors. Mol Cell Biol 24: 8716-8726. 
172. Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, et al. (2009) Autism 
genome-wide copy number variation reveals ubiquitin and neuronal 
genes. Nature 459: 569-573. 
173. Reiter LT, Seagroves TN, Bowers M, Bier E (2006) Expression of the Rho-
GEF Pbl/ECT2 is regulated by the UBE3A E3 ubiquitin ligase. Hum Mol 
Genet 15: 2825-2835. 
174. Unpublished data. 
175. Bauman ML, Kemper TL (2005) Neuroanatomic observations of the brain in 
autism: a review and future directions. Int J Dev Neurosci 23: 183-187. 
176. Albrecht U, Sutcliffe JS, Cattanach BM, Beechey CV, Armstrong D, et al. 
(1997) Imprinted expression of the murine Angelman syndrome gene, 
Ube3a, in hippocampal and Purkinje neurons. Nat Genet 17: 75-78. 
177. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL (2008) The 
Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, 
and maternal deficiency results in abnormal dendritic spine morphology. 
Hum Mol Genet 17: 111-118. 
182 
178. Dyck MJ, Piek JP, Hay D, Smith L, Hallmayer J (2006) Are abilities 
abnormally interdependent in children with autism? J Clin Child Adolesc 
Psychol 35: 20-33. 
179. Settleman J (2001) Rac 'n Rho: the music that shapes a developing embryo. 
Dev Cell 1: 321-331. 
180. Morita K, Hirono K, Han M (2005) The Caenorhabditis elegans ect-2 
RhoGEF gene regulates cytokinesis and migration of epidermal P cells. 
EMBO Rep 6: 1163-1168. 
181. DiAntonio A, Haghighi AP, Portman SL, Lee JD, Amaranto AM, et al. (2001) 
Ubiquitination-dependent mechanisms regulate synaptic growth and 
function. Nature 412: 449-452. 
182. Cook EH, Jr., Arora RC, Anderson GM, Berry-Kravis EM, Yan SY, et al. 
(1993) Platelet serotonin studies in hyperserotonemic relatives of children 
with autistic disorder. Life Sci 52: 2005-2015. 
183. Buxbaum JD, Silverman JM, Smith CJ, Greenberg DA, Kilifarski M, et al. 
(2002) Association between a GABRB3 polymorphism and autism. 
Molecular Psychiatry 7: 311-316. 
184. Cook EH, Courchesne RY, Cox NJ, Lord C, Gonen D, et al. (1998) Linkage-
Disequilibrium Mapping of Autistic Disorder, With 15q11-13 Markers. 
American Journal of Human Genetics 62: 1077-1083. 
185. Kim SJ, Brune CW, Kistner EO, Christian SL, Courchesne EH, et al. (2008) 
Transmission disequilibrium testing of the chromosome 15q11-q13 region 
in autism. Am J Med Genet B Neuropsychiatr Genet 147B: 1116-1125. 
186. Salmon B, Hallmayer J, Rogers T, Kalaydjieva L, Petersen PB, et al. (1999) 
Absence of linkage and linkage disequilibrium to chromosome 15q11-q13 
markers in 139 multiplex families with autism. American Journal of Medical 
Genetics 88: 551-556. 
187. Maestrini E, Lai C, Marlow A, Matthews N, Wallace S, et al. (1999) 
Serotonin transporter (5-HTT) and gamma-aminobutyric acid receptor 
subunit beta3 (GABRB3) gene polymorphisms are not associated with 
autism in the IMGSA families. The International Molecular Genetic Study 
of Autism Consortium. American Journal of Medical Genetics 88: 492-496. 
188. Martin ER, Menold MM, Wolpert CM, Bass MP, Donnelly SL, et al. (2000) 
Analysis of linkage disequilibrium in gamma-aminobutyric acid receptor 
subunit genes in autistic disorder. Am J Med Genet 96: 43-48. 
183 
189. Kim SA, Kim JH, Park M, Cho IH, Yoo HJ (2006) Association of GABRB3 
polymorphisms with autism spectrum disorders in Korean trios. 
Neuropsychobiology 54: 160-165. 
190. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, et al. (2001) 
Density and distribution of hippocampal neurotransmitter receptors in 
autism: an autoradiographic study. J Autism Dev Disord 31: 537-543. 
191. Oblak A, Gibbs TT, Blatt GJ (2009) Decreased GABAA receptors and 
benzodiazepine binding sites in the anterior cingulate cortex in autism. 
Autism Res 2: 205-219. 
192. Dhossche D, Applegate H, Abraham A, Maertens P, Bland L, et al. (2002) 
Elevated plasma gamma-aminobutyric acid (GABA) levels in autistic 
youngsters: stimulus for a GABA hypothesis of autism. Med Sci Monit 8: 
PR1-6. 
193. Hogart A, Leung KN, Wang NJ, Wu DJ, Driscoll J, et al. (2008) 
Chromosome 15q11-13 duplication syndrome brain reveals epigenetic 
alterations in gene expression not predicted from copy number. J Med 
Genet. 
194. Hogart A, Nagarajan RP, Patzel KA, Yasui DH, Lasalle JM (2007) 15q11-13 
GABAA receptor genes are normally biallelically expressed in brain yet 
are subject to epigenetic dysregulation in autism-spectrum disorders. Hum 
Mol Genet 16: 691-703. 
195. Ballestar E, Ropero S, Alaminos M, Armstrong J, Setien F, et al. (2005) The 
impact of MECP2 mutations in the expression patterns of Rett syndrome 
patients. Hum Genet 116: 91-104. 
196. Jedele KB (2007) The overlapping spectrum of rett and angelman 
syndromes: a clinical review. Semin Pediatr Neurol 14: 108-117. 
197. Young DJ, Bebbington A, Anderson A, Ravine D, Ellaway C, et al. (2007) 
The diagnosis of autism in a female: could it be Rett syndrome? Eur J 
Pediatr. 
198. Samaco RC, Hogart A, LaSalle JM (2005) Epigenetic overlap in autism-
spectrum neurodevelopmental disorders: MECP2 deficiency causes 
reduced expression of UBE3A and GABRB3. Hum Mol Genet 14: 483-
492. 
199. Loat C, Curran S, Lewis C, Abrahams B, Duvall J, et al. (2008) Methyl - 
CpG - binding protein (MECP2) polymorphisms and vulnerability to 
autism. Genes Brain Behav. 
184 
200. LaSalle JM (2007) The odyssey of MeCP2 and parental imprinting. 
Epigenetics 2: 5-10. 
201. Abuhatzira L, Makedonski K, Kaufman Y, Razin A, Shemer R (2007) 
MeCP2 deficiency in the brain decreases BDNF levels by REST/CoREST-
mediated repression and increases TRKB production. Epigenetics 2: 214-
222. 
202. Nagarajan RP, Hogart AR, Gwye Y, Martin MR, LaSalle JM (2006) Reduced 
MeCP2 expression is frequent in autism frontal cortex and correlates with 
aberrant MECP2 promoter methylation. Epigenetics 1: e1-11. 
203. Yasui DH, Peddada S, Bieda MC, Vallero RO, Hogart A, et al. (2007) 
Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-
range interaction with active genes. Proc Natl Acad Sci U S A 104: 19416-
19421. 
204. Armstrong DD (2005) Can we relate MeCP2 deficiency to the structural and 
chemical abnormalities in the Rett brain? Brain Dev 27 Suppl 1: S72-S76. 
205. Armstrong DD, Deguchi K, Antallfy B (2003) Survey of MeCP2 in the Rett 
syndrome and the non-Rett syndrome brain. J Child Neurol 18: 683-687. 
206. Vincent JB, Melmer G, Bolton PF, Hodgkinson S, Holmes D, et al. (2005) 
Genetic linkage analysis of the X chromosome in autism, with emphasis 
on the fragile X region. Psychiatr Genet 15: 83-90. 
207. Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, et al. (2006) 
Learning and memory and synaptic plasticity are impaired in a mouse 
model of Rett syndrome. J Neurosci 26: 319-327. 
208. Venancio M, Santos M, Pereira SA, Maciel P, Saraiva JM (2007) An 
explanation for another familial case of Rett syndrome: maternal germline 
mosaicism. Eur J Hum Genet 15: 902-904. 
209. Masuyama T, Matsuo M, Jing JJ, Tabara Y, Kitsuki K, et al. (2005) Classic 
Rett syndrome in a boy with R133C mutation of MECP2. Brain Dev 27: 
439-442. 
210. Moog U, Smeets EE, van Roozendaal KE, Schoenmakers S, Herbergs J, et 
al. (2003) Neurodevelopmental disorders in males related to the gene 
causing Rett syndrome in females (MECP2). Eur J Paediatr Neurol 7: 5-
12. 
211. Neul JL, Zoghbi HY (2004) Rett syndrome: a prototypical 
neurodevelopmental disorder. Neuroscientist 10: 118-128. 
185 
212. Beyer KS, Blasi F, Bacchelli E, Klauck SM, Maestrini E, et al. (2002) 
Mutation analysis of the coding sequence of the MECP2 gene in infantile 
autism. Hum Genet 111: 305-309. 
213. Carney RM, Wolpert CM, Ravan SA, Shahbazian M, Ashley-Koch A, et al. 
(2003) Identification of MeCP2 mutations in a series of females with 
autistic disorder. Pediatr Neurol 28: 205-211. 
214. Lam CW, Yeung WL, Ko CH, Poon PM, Tong SF, et al. (2000) Spectrum of 
mutations in the MECP2 gene in patients with infantile autism and Rett 
syndrome. J Med Genet 37: E41. 
215. Lobo-Menendez F, Sossey-Alaoui K, Bell JM, Copeland-Yates SA, Plank 
SM, et al. (2003) Absence of MeCP2 mutations in patients from the South 
Carolina autism project. Am J Med Genet B Neuropsychiatr Genet 117: 
97-101. 
216. van Karnebeek CD, van Gelderen I, Nijhof GJ, Abeling NG, Vreken P, et al. 
(2002) An aetiological study of 25 mentally retarded adults with autism. J 
Med Genet 39: 205-213. 
217. Ylisaukko-Oja T, Rehnstrom K, Vanhala R, Kempas E, von Koskull H, et al. 
(2005) MECP2 mutation analysis in patients with mental retardation. Am J 
Med Genet A 132: 121-124. 
218. Coutinho AM, Oliveira G, Katz C, Feng J, Yan J, et al. (2007) MECP2 
coding sequence and 3'UTR variation in 172 unrelated autistic patients. 
Am J Med Genet B Neuropsychiatr Genet 144: 475-483. 
219. Loat CS, Curran S, Lewis CM, Duvall J, Geschwind D, et al. (2008) Methyl-
CpG-binding protein 2 polymorphisms and vulnerability to autism. Genes 
Brain Behav 7: 754-760. 
220. Courchesne E (2004) Brain development in autism: early overgrowth 
followed by premature arrest of growth. Ment Retard Dev Disabil Res Rev 
10: 106-111. 
221. Wang K, Zhang H, Ma D, Bucan M, Glessner JT, et al. (2009) Common 
genetic variants on 5p14.1 associate with autism spectrum disorders. 
Nature 459: 528-533. 
222. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and 
visualization of LD and haplotype maps. Bioinformatics 21: 263-265. 
223. O'Connell JR, Weeks DE (1998) PedCheck: a program for identification of 
genotype incompatibilities in linkage analysis. Am J Hum Genet 63: 259-
266. 
186 
224. Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission test for linkage 
disequilibrium: the insulin gene region and insulin-dependent diabetes 
mellitus (IDDM). Am J Hum Genet 52: 506-516. 
225. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) 
PLINK: a tool set for whole-genome association and population-based 
linkage analyses. Am J Hum Genet 81: 559-575. 
226. Tadevosyan-Leyfer O, Dowd M, Mankoski R, Winklosky B, Putnam S, et al. 
(2003) A principal components analysis of the Autism Diagnostic 
Interview-Revised. J Am Acad Child Adolesc Psychiatry 42: 864-872. 
227. Hartl DL, Clark AG (2007) Principles of population genetics. Sunderland, 
Mass.: Sinauer Associates. xv, 652 p. p. 
228. Hammer S, Dorrani N, Dragich J, Kudo S, Schanen C (2002) The 
phenotypic consequences of MECP2 mutations extend beyond Rett 
syndrome. Ment Retard Dev Disabil Res Rev 8: 94-98. 
229. Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR, et al. (1999) Rett 
syndrome and beyond: recurrent spontaneous and familial MECP2 
mutations at CpG hotspots. Am J Hum Genet 65: 1520-1529. 
230. Joyner AH, Roddey JC, Bloss CS, Bakken TE, Rimol LM, et al. (2009) A 
common MECP2 haplotype associates with reduced cortical surface area 
in humans in two independent populations. Proc Natl Acad Sci U S A. 
231. Ewens WJ, Spielman RS (1995) The transmission/disequilibrium test: 
history, subdivision, and admixture. Am J Hum Genet 57: 455-464. 
232. Samaco RC, Nagarajan RP, Braunschweig D, LaSalle JM (2004) Multiple 
pathways regulate MeCP2 expression in normal brain development and 
exhibit defects in autism-spectrum disorders. Hum Mol Genet 13: 629-639. 
233. Watson P, Black G, Ramsden S, Barrow M, Super M, et al. (2001) 
Angelman syndrome phenotype associated with mutations in MECP2, a 
gene encoding a methyl CpG binding protein. J Med Genet 38: 224-228. 
234. Milani D, Pantaleoni C, D'Arrigo S, Selicorni A, Riva D (2005) Another 
patient with MECP2 mutation without classic Rett syndrome phenotype. 
Pediatr Neurol 32: 355-357. 
235. Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001) Deficiency of methyl-
CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in 
mice. Nat Genet 27: 327-331. 
187 
236. Adler DA, Quaderi NA, Brown SD, Chapman VM, Moore J, et al. (1995) The 
X-linked methylated DNA binding protein, Mecp2, is subject to X 
inactivation in the mouse. Mamm Genome 6: 491-492. 
237. D'Esposito M, Quaderi NA, Ciccodicola A, Bruni P, Esposito T, et al. (1996) 
Isolation, physical mapping, and northern analysis of the X-linked human 
gene encoding methyl CpG-binding protein, MECP2. Mamm Genome 7: 
533-535. 
238. Tate P, Skarnes W, Bird A (1996) The methyl-CpG binding protein MeCP2 
is essential for embryonic development in the mouse. Nat Genet 12: 205-
208. 
239. Braunschweig D, Simcox T, Samaco RC, LaSalle JM (2004) X-
Chromosome inactivation ratios affect wild-type MeCP2 expression within 
mosaic Rett syndrome and Mecp2-/+ mouse brain. Hum Mol Genet 13: 
1275-1286. 
240. Young JI, Zoghbi HY (2004) X-chromosome inactivation patterns are 
unbalanced and affect the phenotypic outcome in a mouse model of rett 
syndrome. Am J Hum Genet 74: 511-520. 
241. Nan X, Campoy FJ, Bird A (1997) MeCP2 is a transcriptional repressor with 
abundant binding sites in genomic chromatin. Cell 88: 471-481. 
242. Nan X, Tate P, Li E, Bird A (1996) DNA methylation specifies chromosomal 
localization of MeCP2. Mol Cell Biol 16: 414-421. 
243. Harikrishnan KN, Chow MZ, Baker EK, Pal S, Bassal S, et al. (2005) 
Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-
dependent transcriptional silencing. Nat Genet 37: 254-264. 
244. Chen WG, Chang Q, Lin Y, Meissner A, West AE, et al. (2003) 
Derepression of BDNF transcription involves calcium-dependent 
phosphorylation of MeCP2. Science 302: 885-889. 
245. Martinowich K, Hattori D, Wu H, Fouse S, He F, et al. (2003) DNA 
methylation-related chromatin remodeling in activity-dependent BDNF 
gene regulation. Science 302: 890-893. 
246. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY (2002) Insight into 
Rett syndrome: MeCP2 levels display tissue- and cell-specific differences 
and correlate with neuronal maturation. Hum Mol Genet 11: 115-124. 
247. Luikenhuis S, Giacometti E, Beard CF, Jaenisch R (2004) Expression of 
MeCP2 in postmitotic neurons rescues Rett syndrome in mice. Proc Natl 
Acad Sci U S A 101: 6033-6038. 
188 
248. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, et al. 
(2004) Mild overexpression of MeCP2 causes a progressive neurological 
disorder in mice. Hum Mol Genet 13: 2679-2689. 
249. Kriaucionis S, Bird A (2004) The major form of MeCP2 has a novel N-
terminus generated by alternative splicing. Nucleic Acids Res 32: 1818-
1823. 
250. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, et al. (2004) 
A previously unidentified MECP2 open reading frame defines a new 
protein isoform relevant to Rett syndrome. Nat Genet 36: 339-341. 
251. Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, et al. (2000) Long-read 
sequence analysis of the MECP2 gene in Rett syndrome patients: 
correlation of disease severity with mutation type and location. Hum Mol 
Genet 9: 1119-1129. 
252. Bienvenu T, Carrie A, de Roux N, Vinet MC, Jonveaux P, et al. (2000) 
MECP2 mutations account for most cases of typical forms of Rett 
syndrome. Hum Mol Genet 9: 1377-1384. 
253. Huppke P, Laccone F, Kramer N, Engel W, Hanefeld F (2000) Rett 
syndrome: analysis of MECP2 and clinical characterization of 31 patients. 
Hum Mol Genet 9: 1369-1375. 
254. Amano K, Nomura Y, Segawa M, Yamakawa K (2000) Mutational analysis 
of the MECP2 gene in Japanese patients with Rett syndrome. J Hum 
Genet 45: 231-236. 
255. De Bona C, Zappella M, Hayek G, Meloni I, Vitelli F, et al. (2000) Preserved 
speech variant is allelic of classic Rett syndrome. Eur J Hum Genet 8: 
325-330. 
256. Kishino T, Lalande M, Wagstaff J (1997) UBE3A/E6-AP mutations cause 
Angelman syndrome. Nat Genet 15: 70-73. 
257. Tatsumoto T, Xie X, Blumenthal R, Okamoto I, Miki T (1999) Human ECT2 
is an exchange factor for Rho GTPases, phosphorylated in G2/M phases, 
and involved in cytokinesis. J Cell Biol 147: 921-928. 
258. Thony B, Auerbach G, Blau N (2000) Tetrahydrobiopterin biosynthesis, 
regeneration and functions. Biochem J 347 Pt 1: 1-16. 
259. Huibregtse JM, Scheffner M, Howley PM (1993) Localization of the E6-AP 
regions that direct human papillomavirus E6 binding, association with p53, 
and ubiquitination of associated proteins. Mol Cell Biol 13: 4918-4927. 
189 
260. O'Keefe L, Somers WG, Harley A, Saint R (2001) The pebble GTP 
exchange factor and the control of cytokinesis. Cell Struct Funct 26: 619-
626. 
261. Souza CP, Valadares ER, Trindade AL, Rocha VL, Oliveira LR, et al. (2008) 
Mutation in intron 5 of GTP cyclohydrolase 1 gene causes dopa-
responsive dystonia (Segawa syndrome) in a Brazilian family. Genet Mol 
Res 7: 687-694. 
262. Wu ZY, Lin Y, Chen WJ, Zhao GX, Xie H, et al. (2008) Molecular analyses 
of GCH-1, TH and parkin genes in Chinese dopa-responsive dystonia 
families. Clin Genet 74: 513-521. 
263. Horvath S, Xu X, Laird NM (2001) The family based association test 
method: strategies for studying general genotype--phenotype 
associations. Eur J Hum Genet 9: 301-306. 
264. Horvath S, Xu X, Lake SL, Silverman EK, Weiss ST, et al. (2004) Family-
based tests for associating haplotypes with general phenotype data: 
application to asthma genetics. Genet Epidemiol 26: 61-69. 
265. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data 
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. 
Methods 25: 402-408. 
266. Talis AL, Huibregtse JM, Howley PM (1998) The role of E6AP in the 
regulation of p53 protein levels in human papillomavirus (HPV)-positive 
and HPV-negative cells. J Biol Chem 273: 6439-6445. 
267. Jacobsen J, King BH, Leventhal BL, Christian SL, Ledbetter DH, et al. 
(1998) Molecular screening for proximal 15q abnormalities in a mentally 
retarded population. J Med Genet 35: 534-538. 
268. Gurrieri F, Battaglia A, Torrisi L, Tancredi R, Cavallaro C, et al. (1999) 
Pervasive developmental disorder and epilepsy due to maternally derived 
duplication of 15q11-q13. Neurology 52: 1694-1697. 
269. Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, et al. 
(2005) Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, 
enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X 
syndrome. Neuron 47: 339-352. 
270. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, et al. (1997) 
Abnormal dendritic spines in fragile X knockout mice: maturation and 
pruning deficits. Proc Natl Acad Sci U S A 94: 5401-5404. 
271. Armstrong DD (2001) Rett syndrome neuropathology review 2000. Brain 
Dev 23 Suppl 1: S72-76. 
190 
272. Ramamoorthy S, Nawaz Z (2008) E6-associated protein (E6-AP) is a dual 
function coactivator of steroid hormone receptors. Nucl Recept Signal 6: 
e006. 
273. Nurmi EL, Amin T, Olson LM, Jacobs MM, McCauley JL, et al. (2003) 
Dense linkage disequilibrium mapping in the 15q11-q13 maternal 
expression domain yields evidence for association in autism. Mol 
Psychiatry 8: 624-634, 570. 
274. Veenstra-VanderWeele J, Gonen D, Leventhal BL, Cook EH, Jr. (1999) 
Mutation screening of the UBE3A/E6-AP gene in autistic disorder. Mol 
Psychiatry 4: 64-67. 
275. Vourc'h P, Martin I, Bonnet-Brilhault F, Marouillat S, Barthelemy C, et al. 
(2003) Mutation screening and association study of the UBE2H gene on 
chromosome 7q32 in autistic disorder. Psychiatr Genet 13: 221-225. 
276. Kato C, Tochigi M, Ohashi J, Koishi S, Kawakubo Y, et al. (2008) 
Association study of the 15q11-q13 maternal expression domain in 
Japanese autistic patients. Am J Med Genet B Neuropsychiatr Genet 
147B: 1008-1012. 
277. Molfetta GA, Silva-Jr WA, Pina-Neto JM (2003) Clinical, cytogenetical and 
molecular analyses of Angelman syndrome. Genet Couns 14: 45-56. 
278. Hitchins MP, Rickard S, Dhalla F, Fairbrother UL, de Vries BB, et al. (2004) 
Investigation of UBE3A and MECP2 in Angelman syndrome (AS) and 
patients with features of AS. Am J Med Genet A 125A: 167-172. 
279. Schanen NC (2006) Epigenetics of autism spectrum disorders. Hum Mol 
Genet 15 Spec No 2: R138-150. 
280. Buiting K, Dittrich B, Gross S, Greger V, Lalande M, et al. (1993) Molecular 
definition of the Prader-Willi syndrome chromosome region and orientation 
of the SNRPN gene. Hum Mol Genet 2: 1991-1994. 
281. Blatt GJ (2005) GABAergic cerebellar system in autism: a neuropathological 
and developmental perspective. Int Rev Neurobiol 71: 167-178. 
282. Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD (2008) GABA(A) Receptor 
Downregulation in Brains of Subjects with Autism. J Autism Dev Disord. 
283. Cook EH, Jr., Courchesne RY, Cox NJ, Lord C, Gonen D, et al. (1998) 
Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 
markers. Am J Hum Genet 62: 1077-1083. 
284. Salmon B, Hallmayer J, Rogers T, Kalaydjieva L, Petersen PB, et al. (1999) 
Absence of linkage and linkage disequilibrium to chromosome 15q11-q13 
191 
markers in 139 multiplex families with autism. Am J Med Genet 88: 551-
556. 
285. Laurie DJ, Wisden W, Seeburg PH (1992) The distribution of thirteen 
GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and 
postnatal development. J Neurosci 12: 4151-4172. 
286. Wisden W, Laurie DJ, Monyer H, Seeburg PH (1992) The distribution of 13 
GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, 
diencephalon, mesencephalon. J Neurosci 12: 1040-1062. 
287. Andang M, Hjerling-Leffler J, Moliner A, Lundgren TK, Castelo-Branco G, et 
al. (2008) Histone H2AX-dependent GABA(A) receptor regulation of stem 
cell proliferation. Nature 451: 460-464. 
288. Brooks-Kayal AR, Pritchett DB (1993) Developmental changes in human 
gamma-aminobutyric acidA receptor subunit composition. Ann Neurol 34: 
687-693. 
289. Ma W, Saunders PA, Somogyi R, Poulter MO, Barker JL (1993) Ontogeny 
of GABAA receptor subunit mRNAs in rat spinal cord and dorsal root 
ganglia. J Comp Neurol 338: 337-359. 
290. Homanics GE, DeLorey TM, Firestone LL, Quinlan JJ, Handforth A, et al. 
(1997) Mice devoid of gamma-aminobutyrate type A receptor beta3 
subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc Natl 
Acad Sci U S A 94: 4143-4148. 
291. Krasowski MD, Rick CE, Harrison NL, Firestone LL, Homanics GE (1998) A 
deficit of functional GABA(A) receptors in neurons of beta 3 subunit 
knockout mice. Neurosci Lett 240: 81-84. 
292. DeLorey TM, Sahbaie P, Hashemi E, Homanics GE, Clark JD (2008) 
Gabrb3 gene deficient mice exhibit impaired social and exploratory 
behaviors, deficits in non-selective attention and hypoplasia of cerebellar 
vermal lobules: a potential model of autism spectrum disorder. Behav 
Brain Res 187: 207-220. 
293. DeLorey TM (2005) GABRB3 gene deficient mice: a potential model of 
autism spectrum disorder. Int Rev Neurobiol 71: 359-382. 
294. Cordell HJ, Clayton DG (2005) Genetic association studies. Lancet 366: 
1121-1131. 
295. Risi S, Lord C, Gotham K, Corsello C, Chrysler C, et al. (2006) Combining 
information from multiple sources in the diagnosis of autism spectrum 
disorders. J Am Acad Child Adolesc Psychiatry 45: 1094-1103. 
192 
296. Kang JQ, Macdonald RL (2004) The GABAA receptor gamma2 subunit 
R43Q mutation linked to childhood absence epilepsy and febrile seizures 
causes retention of alpha1beta2gamma2S receptors in the endoplasmic 
reticulum. J Neurosci 24: 8672-8677. 
297. Gallagher MJ, Shen W, Song L, Macdonald RL (2005) Endoplasmic 
reticulum retention and associated degradation of a GABAA receptor 
epilepsy mutation that inserts an aspartate in the M3 transmembrane 
segment of the alpha1 subunit. J Biol Chem 280: 37995-38004. 
298. Kirkness EF, Fraser CM (1993) A strong promoter element is located 
between alternative exons of a gene encoding the human gamma-
aminobutyric acid-type A receptor beta 3 subunit (GABRB3). J Biol Chem 
268: 4420-4428. 
299. Weinberg CR (1999) Methods for detection of parent-of-origin effects in 
genetic studies of case-parents triads. Am J Hum Genet 65: 229-235. 
300. Tanaka M, Olsen RW, Medina MT, Schwartz E, Alonso ME, et al. (2008) 
Hyperglycosylation and reduced GABA currents of mutated GABRB3 
polypeptide in remitting childhood absence epilepsy. Am J Hum Genet 82: 
1249-1261. 
301. Taylor PM, Thomas P, Gorrie GH, Connolly CN, Smart TG, et al. (1999) 
Identification of amino acid residues within GABA(A) receptor beta 
subunits that mediate both homomeric and heteromeric receptor 
expression. J Neurosci 19: 6360-6371. 
302. McDonald BJ, Amato A, Connolly CN, Benke D, Moss SJ, et al. (1998) 
Adjacent phosphorylation sites on GABAA receptor beta subunits 
determine regulation by cAMP-dependent protein kinase. Nat Neurosci 1: 
23-28. 
303. Sutcliffe JS, Nurmi EL, Lombroso PJ (2003) Genetics of childhood 
disorders: XLVII. Autism, part 6: duplication and inherited susceptibility of 
chromosome 15q11-q13 genes in autism. J Am Acad Child Adolesc 
Psychiatry 42: 253-256. 
304. Tsuboi T, Endo S (1977) Incidence of seizures and EEG abnormalities 
among offspring of epileptic patients. Hum Genet 36: 173-189. 
305. Ottman R, Annegers JF, Hauser WA, Kurland LT (1988) Higher risk of 
seizures in offspring of mothers than of fathers with epilepsy. Am J Hum 
Genet 43: 257-264. 
306. Nakatani J, Tamada K, Hatanaka F, Ise S, Ohta H, et al. (2009) Abnormal 
behavior in a chromosome-engineered mouse model for human 15q11-13 
duplication seen in autism. Cell 137: 1235-1246. 
193 
307. Bunzel R, Blumcke I, Cichon S, Normann S, Schramm J, et al. (1998) 
Polymorphic imprinting of the serotonin-2A (5-HT2A) receptor gene in 
human adult brain. Brain Res Mol Brain Res 59: 90-92. 
308. Loiseau P, Duche B, Pedespan JM (1995) Absence epilepsies. Epilepsia 
36: 1182-1186. 
309. Tuchman R, Rapin I (2002) Epilepsy in autism. Lancet Neurol 1: 352-358. 
310. Levisohn PM (2007) The autism-epilepsy connection. Epilepsia 48 Suppl 9: 
33-35. 
311. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA (2009) Rare variants 
of IFIH1, a gene implicated in antiviral responses, protect against type 1 
diabetes. Science 324: 387-389. 
312. Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK (2006) A 
high-resolution survey of deletion polymorphism in the human genome. 
Nat Genet 38: 75-81. 
313. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, et al. (2006) Global 
variation in copy number in the human genome. Nature 444: 444-454. 
314. van Bon BW, Mefford HC, Menten B, Koolen DA, Sharp AJ, et al. (2009) 
Further delineation of the 15q13 microdeletion and duplication syndromes: 
a clinical spectrum varying from non-pathogenic to a severe outcome. J 
Med Genet 46: 511-523. 
315. Cai G, Edelmann L, Goldsmith JE, Cohen N, Nakamine A, et al. (2008) 
Multiplex ligation-dependent probe amplification for genetic screening in 
autism spectrum disorders: efficient identification of known 
microduplications and identification of a novel microduplication in ASMT. 
BMC Med Genomics 1: 50. 
316. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, et al. 
(2002) Relative quantification of 40 nucleic acid sequences by multiplex 
ligation-dependent probe amplification. Nucleic Acids Res 30: e57. 
317. Constantino JN, Przybeck T, Friesen D, Todd RD (2000) Reciprocal social 
behavior in children with and without pervasive developmental disorders. J 
Dev Behav Pediatr 21: 2-11. 
318. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E (2001) The 
autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-
functioning autism, males and females, scientists and mathematicians. J 
Autism Dev Disord 31: 5-17. 
194 
319. Ronald A, Happe F, Bolton P, Butcher LM, Price TS, et al. (2006) Genetic 
heterogeneity between the three components of the autism spectrum: a 
twin study. J Am Acad Child Adolesc Psychiatry 45: 691-699. 
320. Happe F, Ronald A (2008) The 'fractionable autism triad': a review of 
evidence from behavioural, genetic, cognitive and neural research. 
Neuropsychol Rev 18: 287-304. 
321. Jones MB, Szatmari P (1988) Stoppage rules and genetic studies of autism. 
J Autism Dev Disord 18: 31-40. 
322. Reish O, King RA (1995) Angelman syndrome at an older age. Am J Med 
Genet 57: 510-511. 
323. (1987) Second Annual Prader-Willi Syndrome Scientific Conference. 
Houston, June 17, 1987. Proceedings and abstracts. Am J Med Genet 28: 
779-924. 
324. Christian SL, Brune CW, Sudi J, Kumar RA, Liu S, et al. (2008) Novel 
submicroscopic chromosomal abnormalities detected in autism spectrum 
disorder. Biol Psychiatry 63: 1111-1117. 
325. Sharp AJ, Mefford HC, Li K, Baker C, Skinner C, et al. (2008) A recurrent 
15q13.3 microdeletion syndrome associated with mental retardation and 
seizures. Nat Genet 40: 322-328. 
326. Hogart A, Leung KN, Wang NJ, Wu DJ, Driscoll J, et al. (2009) 
Chromosome 15q11-13 duplication syndrome brain reveals epigenetic 
alterations in gene expression not predicted from copy number. J Med 
Genet 46: 86-93. 
327. Williams CA, Zori RT, Stone JW, Gray BA, Cantu ES, et al. (1990) Maternal 
origin of 15q11-13 deletions in Angelman syndrome suggests a role for 
genomic imprinting. Am J Med Genet 35: 350-353. 
328. Ropers HH, Hamel BC (2005) X-linked mental retardation. Nat Rev Genet 6: 
46-57. 
329. Leonard H, Wen X (2002) The epidemiology of mental retardation: 
challenges and opportunities in the new millennium. Ment Retard Dev 
Disabil Res Rev 8: 117-134. 
 
 
  
